0001437749-21-004259.txt : 20210226 0001437749-21-004259.hdr.sgml : 20210226 20210226163227 ACCESSION NUMBER: 0001437749-21-004259 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210226 DATE AS OF CHANGE: 20210226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 21689564 BUSINESS ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 BUSINESS PHONE: 852-3107-0800 MAIL ADDRESS: STREET 1: UNITS 1205-07, 12F, MIRA PLACE TOWER A STREET 2: 132 NATHAN ROAD, TSIMSHATSUI, KOWLOON CITY: HONG KONG STATE: K3 ZIP: 00000 10-K 1 nhtc20201231_10k.htm FORM 10-K nhtc20201231_10k.htm
0000912061 Natural Health Trends Corp. false --12-31 FY 2020 0.001 0.001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 50,000,000 50,000,000 12,979,414 12,979,414 1,556,875 1,556,875 0.64 0.80 2 5 3 5 5 7 14 1 5 0 0.20 0.20 0.20 0.20 0.20 0.20 0.20 3 3 5 1 4.5 100 1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. 00009120612020-01-012020-12-31 iso4217:USD 00009120612020-06-30 xbrli:shares 00009120612021-02-22 thunderdome:item 00009120612020-12-31 00009120612019-12-31 iso4217:USDxbrli:shares 00009120612019-01-012019-12-31 0000912061us-gaap:PreferredStockMember2018-12-31 0000912061us-gaap:CommonStockMember2018-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2018-12-31 0000912061us-gaap:RetainedEarningsMember2018-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31 0000912061us-gaap:TreasuryStockMember2018-12-31 00009120612018-12-31 0000912061us-gaap:PreferredStockMember2019-01-012019-12-31 0000912061us-gaap:CommonStockMember2019-01-012019-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-31 0000912061us-gaap:RetainedEarningsMember2019-01-012019-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-31 0000912061us-gaap:TreasuryStockMember2019-01-012019-12-31 0000912061us-gaap:PreferredStockMember2019-12-31 0000912061us-gaap:CommonStockMember2019-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000912061us-gaap:RetainedEarningsMember2019-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000912061us-gaap:TreasuryStockMember2019-12-31 0000912061us-gaap:PreferredStockMember2020-01-012020-12-31 0000912061us-gaap:CommonStockMember2020-01-012020-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000912061us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000912061us-gaap:TreasuryStockMember2020-01-012020-12-31 0000912061us-gaap:PreferredStockMember2020-12-31 0000912061us-gaap:CommonStockMember2020-12-31 0000912061us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000912061us-gaap:RetainedEarningsMember2020-12-31 0000912061us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000912061us-gaap:TreasuryStockMember2020-12-31 utr:D 0000912061srt:MinimumMember2020-01-012020-12-31 0000912061srt:MaximumMember2020-01-012020-12-31 iso4217:CNY 0000912061country:CN2019-12-31 iso4217:VND 0000912061country:VN2019-11-30 0000912061country:VN2020-12-31 0000912061country:VN2019-12-31 xbrli:pure 0000912061country:KP2020-12-31 utr:Y 0000912061nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMembersrt:MinimumMember2020-01-012020-12-31 0000912061nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMembersrt:MaximumMember2020-01-012020-12-31 0000912061us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2020-01-012020-12-31 0000912061us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2020-01-012020-12-31 0000912061us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000912061us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-31 0000912061us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMembercountry:HK2020-03-112020-03-11 0000912061us-gaap:RestrictedStockMember2019-01-012019-12-31 0000912061nhtc:UnshippedProductMember2020-12-31 0000912061nhtc:UnshippedProductMember2019-12-31 0000912061nhtc:AutoShipAdvancesMember2020-12-31 0000912061nhtc:AutoShipAdvancesMember2019-12-31 0000912061us-gaap:ProductAndServiceOtherMember2020-12-31 0000912061us-gaap:ProductAndServiceOtherMember2019-12-31 0000912061country:CN2020-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2019-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-31 0000912061us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-31 utr:sqft 0000912061country:HK2020-12-31 0000912061nhtc:RollingHillsEstatesMember2020-12-31 0000912061nhtc:RollingHillsEstatesMember2020-06-30 0000912061nhtc:RichmondBritishColumbiaMember2020-12-31 0000912061nhtc:MetuchenNewJerseyMember2020-12-31 0000912061nhtc:DepartmentForInternationalTaxCooperationMember2020-01-012020-12-31 0000912061nhtc:DepartmentForInternationalTaxCooperationMember2019-01-012019-12-31 0000912061us-gaap:InlandRevenueHongKongMember2020-01-012020-12-31 0000912061us-gaap:InlandRevenueHongKongMember2019-01-012019-12-31 0000912061us-gaap:StateAdministrationOfTaxationChinaMember2020-01-012020-12-31 0000912061us-gaap:StateAdministrationOfTaxationChinaMember2019-01-012019-12-31 0000912061us-gaap:DomesticCountryMember2020-12-31 0000912061us-gaap:StateAndLocalJurisdictionMember2020-12-31 0000912061us-gaap:ForeignCountryMember2020-12-31 00009120612020-01-012020-03-31 00009120612020-04-012020-06-30 00009120612020-07-012020-09-30 00009120612020-10-012020-12-31 0000912061nhtc:SpecialDividendsDeclaredOctober292019Member2019-01-012019-12-31 0000912061nhtc:SpecialDividendsDeclaredJanuary272019Member2019-01-012019-12-31 0000912061nhtc:DividendsDeclaredJanuary272019Member2019-01-012019-12-31 00009120612015-07-28 00009120612016-01-12 0000912061nhtc:BroadyTrustMember2019-05-16 0000912061srt:DirectorMember2019-05-16 0000912061nhtc:OpenMarketPurchasesMember2019-05-31 00009120612019-05-012019-05-31 00009120612019-08-012019-09-30 00009120612019-12-012019-12-31 0000912061nhtc:EquityIncentivePlan2016Member2020-12-31 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2019-02-012019-02-01 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2019-08-092019-08-09 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2018-12-31 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2019-01-012019-12-31 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2019-12-31 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2020-01-012020-12-31 0000912061us-gaap:RestrictedStockMembernhtc:EquityIncentivePlan2016Member2020-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2019-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-31 0000912061us-gaap:AccumulatedTranslationAdjustmentMember2020-12-31 0000912061us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-31 0000912061srt:DirectorMember2020-03-20 0000912061nhtc:BHSMembernhtc:RoyaltyAgreementAndLicenseMember2020-01-012020-12-31 0000912061nhtc:BHSMembernhtc:RoyaltyAgreementAndLicenseMember2019-01-012019-12-31 0000912061nhtc:RoyaltyAgreementAndLicenseMembernhtc:BHSMember2020-03-202020-03-20 0000912061nhtc:ShipmentOfApparelProductsMembernhtc:AberdeenMember2019-01-012019-03-31 0000912061nhtc:AberdeenMembernhtc:SharngHoldingsMember2020-12-31 0000912061nhtc:AberdeenMembersrt:DirectorMember2020-12-31 0000912061nhtc:UnrelatedThirdPartyMembernhtc:AberdeenMember2020-12-31 0000912061nhtc:AberdeenMember2020-01-012020-12-31 0000912061nhtc:BroadyTrustMember2019-05-172019-05-17 0000912061nhtc:PrimaryReportingSegmentMember2020-01-012020-12-31 0000912061nhtc:PrimaryReportingSegmentMember2019-01-012019-12-31 0000912061country:CN2020-01-012020-12-31 0000912061country:CN2019-01-012019-12-31 0000912061nhtc:RussiaAndKazakhstanMember2020-01-012020-12-31 0000912061nhtc:RussiaAndKazakhstanMember2019-01-012019-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:PrimaryReportingSegmentMember2019-01-012019-12-31 0000912061us-gaap:OperatingSegmentsMembercountry:CN2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembercountry:CN2019-01-012019-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMembernhtc:RussiaAndKazakhstanMember2019-01-012019-12-31 0000912061us-gaap:OperatingSegmentsMember2020-01-012020-12-31 0000912061us-gaap:OperatingSegmentsMember2019-01-012019-12-31 0000912061us-gaap:IntersegmentEliminationMember2020-01-012020-12-31 0000912061us-gaap:IntersegmentEliminationMember2019-01-012019-12-31 0000912061country:US2020-01-012020-12-31 0000912061country:US2019-01-012019-12-31 0000912061country:CA2020-01-012020-12-31 0000912061country:CA2019-01-012019-12-31 0000912061country:PE2020-01-012020-12-31 0000912061country:PE2019-01-012019-12-31 0000912061country:HK2020-01-012020-12-31 0000912061country:HK2019-01-012019-12-31 0000912061country:TW2020-01-012020-12-31 0000912061country:TW2019-01-012019-12-31 0000912061srt:EuropeMember2020-01-012020-12-31 0000912061srt:EuropeMember2019-01-012019-12-31 0000912061nhtc:OtherForeignCountriesMember2020-01-012020-12-31 0000912061nhtc:OtherForeignCountriesMember2019-01-012019-12-31 0000912061us-gaap:ProductMember2020-01-012020-12-31 0000912061us-gaap:ProductMember2019-01-012019-12-31 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2020-01-012020-12-31 0000912061nhtc:AdministrativeFeesFreightAndOtherMember2019-01-012019-12-31 0000912061country:US2020-12-31 0000912061country:US2019-12-31 0000912061country:GB2020-12-31 0000912061country:GB2019-12-31 0000912061nhtc:OtherForeignCountriesMember2020-12-31 0000912061nhtc:OtherForeignCountriesMember2019-12-31 0000912061us-gaap:SubsequentEventMember2021-02-082021-02-08
 

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 10-K

 

(Mark One) 

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2020

or

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                 to                

 

Commission file number: 001-36849

NATURAL HEALTH TRENDS CORP. 

(Exact name of registrant as specified in its charter) 

Delaware

59-2705336

(State or other jurisdiction of

(I.R.S. Employer

incorporation or organization)

Identification No.)

 

Units 1205-07, 12F

Mira Place Tower A

132 Nathan Road, Tsimshatsui

Kowloon, Hong Kong

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: +852-3107-0800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NHTC

The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☑

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☑

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☑

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the closing price of such common equity on June 30, 2020: $39,932,227

 

At February 22, 2021, the number of shares outstanding of the registrant’s common stock was 11,422,539 shares.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

Portions of the registrant’s definitive proxy statement to be filed with the United States Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year end to which this report relates are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.



 

 

 

NATURAL HEALTH TRENDS CORP.

Annual Report on Form 10-K

December 31, 2020

 

TABLE OF CONTENTS

 

 

 

Page

PART I

 

Item 1.

Business

1

Item 1A.

Risk Factors

12

Item 1B.

Unresolved Staff Comments

22

Item 2.

Properties

22

Item 3.

Legal Proceedings

22

Item 4.

Mine Safety Disclosures

22

 

 

 

PART II

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

23

Item 6.

Selected Financial Data

23

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

32

Item 8.

Financial Statements and Supplementary Data

33

Item 9.

Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

56

Item 9A.

Controls and Procedures

56

Item 9B.

Other Information

56

 

 

 

PART III

 

Item 10.

Directors, Executive Officers and Corporate Governance

57

Item 11.

Executive Compensation

57

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

57

Item 13.

Certain Relationships and Related Transactions, and Director Independence

57

Item 14.

Principal Accountant Fees and Services

57

 

 

 

PART IV

 

Item 15.

Exhibits and Financial Statement Schedules

58

Item 16.

Form 10-K Summary

58

 

 

 

Signatures

59

 

 

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K, in particular “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Item 1. Business,” include “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.

 

Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.

 

For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in this report. Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes.

 

Unless otherwise noted, the terms “we,” “our,” “us,” and “Company,” refer to Natural Health Trends Corp. and its subsidiaries. References to “dollars” and “$” are to United States dollars.

 

 

 

Part I

 

Item 1. BUSINESS

 

Overview of Business

 

Natural Health Trends Corp. is an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider.

 

Most of our order volume, particularly in our Hong Kong subsidiary, is for personal consumption through existing members’ referrals. Our objectives are to enrich the lives of the users of our products and enable our members to benefit financially from the sale of our products.

 

We are incorporated in Delaware and maintain our corporate headquarters in Hong Kong.

 

Our common stock is currently traded on the NASDAQ Capital Market under the symbol “NHTC.”

 

Available Information

 

Our website is located at www.naturalhealthtrendscorp.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to such reports are available, free of charge, on our website as soon as reasonably practicable after we file electronically such material with, or furnish it to, the United States Securities and Exchange Commission, or SEC. The information provided on our website should not be considered part of this report. The SEC maintains an internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

Our Principal Products

 

We offer a line of “NHT Global” branded products in seven distinct categories: wellness, herbal, beauty, lifestyle, home, baby, and daily. These product categories, along with the business opportunity we offer in most of our markets, provide our members a platform to further their goal of achieving and maintaining healthy, quality lifestyles complete with product supplementation and the opportunity for financial rewards.

 

The following table summarizes our product offering by category:

 

Product Category

 

Description

 

Products

 

 

 

 

 

 

 

Wellness

 

Products formulated and designed to meet specific wellness goals of our customers. Includes targeted nutrition for joint health, antioxidant support, digestive health, heart health, vision health, immune support and cellular health.

 

Liquid, encapsulated, tableted and powder dietary and nutritional supplements, vitamins, minerals

 

Premium Noni Juice, Triotein™, Cluster X2™, Children’s Chewable Multivitamin, ReStor Silver™, ReStor Vital™, Trifusion Max™, Glucosamine 2200™, FibeRich™, Energin, Enhanced Essential Probiotics, Omega-3 Essential Fatty Acids, StemRenu®, OcuFocus™, CurcuMore™, AdaptoGin™

 

 

 

 

 

 

 

Herbal

 

Products formulated incorporating ingredients commonly found in traditional Chinese medicine.

 

Herbal supplements

 

LivaPro™, Cordyceps Mycelia CS-4™, Purus, RespFactor™

 

 

 

Beauty

 

Products to help improve skin health and bring an appearance of youthful vibrancy. This product line includes age-defying and hydrating cleansers, creams, lotions, serums and toners to moisturize, protect and improve the appearance of skin.

 

Facial skin care and hand and body care

 

Skindulgence™ 30 Minute Firming System, Time Restore™ Eye Cream and Essence, BioCell SC Mask, Renaissance™ Rejuvenation Serum, Valesce™, Floraeda Hydrating Series, Botanical Hand Protector™, Airelle® Exfoliating Cleanser, Airelle® Age-Defying Facial Serum, Airelle® Intense Hydrating Repair Complex, Airelle® Age-Defying Eye & Lip Treatment, Airelle® Hydrating Manuka Mask, Color Awakening Lipstick™, Adamas™ Brightening Series, Moisturizing Cleansing Gel, Micellion Cleansing Water

 

 

 

 

 

 

 

Lifestyle

 

Products uniquely formulated to improve overall quality of life and to support active, physical and healthy lifestyles including weight management, and energy enhancing supplements.

 

Supplements and topical gels for improved vitality

 

Alura Lux™ by NHT Global, Valura Lux, LaVie, TwinSlim™ Probiotics, NaturalGlo

 

 

 

 

 

 

 

Home

 

Products designed to create a clean and natural living environment for the home.

 

Home appliances

 

Air Purifier, AquaPur Desktop Water Purifier

 

 

 

 

 

 

 

Baby

 

Products uniquely formulated with gentle ingredients from nature for infants and babies.

 

Infant and toddler bath and body care

 

Moisturizing Lotion and Bubble Cleanser

 

 

 

 

 

 

 

Daily

 

Daily care products designed to cleanse and protect the body and promote personal hygiene.

 

Oral care, hair care, and body care

 

FE Enzyme Toothpaste™, Bontanesse™ Series, Smart Sonic Toothbrush

 

 

We continuously source unique, proprietary and immediate impact products to offer to our members and customers. Our product development is an ongoing process that is fueled by marketplace trends, new technologies and scientific findings, members’ input, research and vendor proposals.

 

 

Working closely with raw material manufacturers and contract manufacturers, our mission is to co-develop and bring to market the highest quality products. Our manufacturers are primarily located in the United States, as well as a few in South Korea, Hong Kong, Taiwan and China. Our raw materials are sourced from reputable suppliers around the world. All current and new products introduced into the market are tested to ensure country and state regulatory compliance requirements are met where the products are sold. This includes proper handling, shipping, and shelf-life recommendations for our products. In addition, raw material Certificates of Analyses are reviewed to ensure that appropriate testing has been performed and are within required ingredient specifications.

 

Operations of the Business

 

Operating Strategy

 

Our objective is to help our members succeed in achieving their life objectives; be it personal health, beauty, happiness or financial rewards. Our employees focus on assisting our members in attaining their goals.

 

We believe we have a competitive business model applicable to the markets in which we conduct business based on six key competencies:

 

 

Our field leaders are experienced and culturally coherent. They work effectively with our management, implementing our strategies and providing continuous feedback to improve our services.

 

 

A discipline and capability has been established to continue launching high-quality consumer products that are designed to facilitate the accomplishment of our corporate objectives.

 

 

We have developed and rolled out a comprehensive training system that provides a complete career path appropriate for our members. Our training material covers the needs of our members, be they prospects, new recruits, product evangelists, sales leaders or dream builders.

 

 

We have developed a year-round, multi-faceted promotional plan that targets different segments of our membership.

 

 

We have implemented a commission structure that makes it as easy as possible to join our business, while giving existing members a chance to start earning money as quickly as possible in multiple ways.

 

 

The continuously improving mentality and methodology in our customer services have not only distinguished us as an organization, but have also given us a constant flow of information as to how we can do better to service our members.

 

Sourcing of Products

 

Our staff works with research and development personnel of our manufacturers and other prospective vendors to create product concepts and develop the product ideas into actual products. We then may enter into supply agreements with the vendors pursuant to which we obtain rights to sell the products under private labels (or trademarks) that are owned by us. In addition, some of our local markets introduce their own products from time to time and these products are sometimes adopted by our other markets.

 

We generally purchase finished goods from manufacturers and sell them to our members for retail and personal consumption. We believe that in the event we are unable to source products from our current or alternate suppliers, our revenue, income and cash flow could be adversely and materially impacted. We have some contracts with our suppliers with automatic renewal rights.

 

 

Marketing and Distribution

 

We distribute our products internationally primarily through a network marketing system, which is a form of person-to-person direct selling.  Under this system, members primarily refer our products to prospective consumers or they may buy at wholesale prices for personal consumption or for resale to consumers.  The concept of network marketing is based on the strength of personal recommendations that frequently come from friends, neighbors, relatives, and close acquaintances.  We believe that network marketing is an effective way to distribute our products because it allows person-to-person product education and testimonials as well as higher levels of customer service, all of which are not as readily available through other distribution channels. In this document, we generically use the term “member” to refer to members who purchase for their own consumption or for resale, or both, as well as to members who only sign up to consume our products.

 

Each of our products is designated a specified number of bonus volume points. Commissions are paid to members based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price.

 

Virtually all of our members are independent full-time or part-time contractors who purchase products directly from our subsidiaries via the internet for their own personal consumption or for resale to retail consumers. Purchasers of our products in some of our smaller markets and purchasers of our products from our China subsidiary may purchase only for their own personal consumption and not for resale.

 

The following table sets forth the number of active members by market as of the dates indicated. We consider a member “active” if they have placed at least one product order with us during the preceding year. Members may not necessarily reside in the market for which they sign up as a member.

 

   

December 31,

 
   

2020

   

2019

 

Americas1

    4,760       7,150  

Hong Kong (including those members residing in China)2

    41,130       43,930  

Taiwan

    2,550       2,550  

South Korea

    90       120  

Japan

    220       130  

Singapore

    50       60  

Malaysia

    240       170  

Russia and Kazakhstan

    1,340       950  

Europe

    1,300       1,670  

India

    550       680  

Total

    52,230       57,410  

 


1 United States, Canada, Mexico and Peru

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

 

Members must agree to the terms and conditions of our member agreement posted on our website. The member agreement sets forth our policies and procedures, and we may elect to terminate a member for non-compliance.

 

We pay commissions to eligible members based on product purchases by such members’ down-line customers and members during a given commission period. To be eligible to receive commissions, members in some countries may be required to make nominal monthly or other periodic purchases of products. See “Working with Members.

 

Members generally place orders through the internet and pay by credit card prior to shipment. Accordingly, we carry minimal accounts receivable and credit losses are historically negligible.

 

 

We sponsor promotional meetings, product education, motivational and personal development training events for current and potential members. These events are designed to inform prospective and existing members about both existing and new product lines, our latest marketing and promotional plans, and new services improvements. These events also serve as a venue for recognition of member accomplishments. Members typically share their experiences in using our products and developing their business at these events. We are continually developing and updating our marketing strategies and programs to motivate our members.

 

Recent Disruptions to our Business

 

Our normal business operations have recently been disrupted by a series of events, including the Chinese government’s 100-day campaign focused on companies involved in the sale of health products in China, recent political and social developments in Hong Kong, and the COVID-19 pandemic and related measures to control it. See “Item 1A. Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...”, “Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong….”, “Risk Factors - Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorists attacks or acts of war…”, and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Business Overview.”

 

Management Information Systems

 

Our business uses a proprietary web-based system to process orders and to communicate bonus volume activity and commissions to members. We have automated a substantial amount of our financial reporting processes through implementation of Oracle’s E-Business Suite, and have integrated other critical business processes such as inventory management, purchasing and costing in our most significant markets.

 

Employees

 

At December 31, 2020, we employed 145 total full-time employees worldwide, of which 93 were located in Greater China (Hong Kong, China, and Taiwan), 31 in the Americas (United States, Canada, Cayman Islands, and Peru), four in Europe, four in India, four in Malaysia, two in South Korea, three in Russia, two in Japan, one in Singapore, and one in Vietnam.

 

Seasonality

 

From quarter to quarter, we are somewhat impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter. This generally has a significant impact on the services of our third-party providers, and can negatively impact our net sales. We believe that net sales can also be negatively impacted during the third quarter, when many of our members traditionally take time off for vacations. In addition, the national holidays in Hong Kong, China and Taiwan in early October tend to have an adverse effect on sales in those markets.

     

Our spending, as well as to some extent revenue, is affected by the major events planned at different times of the year. A major promotional event could significantly increase the reported expenses during the quarter in which the event actually takes place, while the revenue that might be generated by the event may not occur in the same reporting period.

 

Intellectual Property

 

Most of our products are packaged under a “private label” arrangement. We have obtained or applied for trademark registration for certain names, logos and various product names in several countries in which we are doing business or considering expanding. We also rely on common law trademark rights to protect our unregistered trademarks. These common law trademark rights do not provide us with the same level of protection as afforded by a United States federal trademark. Common law trademark rights are limited to the geographic area in which the trademark is actually utilized, while a United States federal registration of a trademark enables the registrant to discontinue the unauthorized use of the trademark by a third party anywhere in the United States even if the registrant has never used the trademark in the geographic area where the trademark is being used; provided, however, that the unauthorized third party user has not, prior to the registration date, perfected its common law rights in the trademark within that geographic area.

 

We have U.S. and foreign holding and operating company structures for our businesses, which involve the division of our United States and non-United States operations. Under this structure, the foreign holding company retains the economic ownership of the intangible property outside of the United States, including trademarks, trade secrets and other proprietary information.

 

 

Working with Members

 

Sponsorship

 

Enrolling new members creates multiple levels in our direct selling structure. The persons that a member enrolls within the network are referred to as “sponsored” members, who may purchase product solely for their own personal consumption, for resale, or both. Persons newly enrolled are assigned into network positions that can be “under” other members, and thus they can be called “down-line” members. If down-line members also enroll new members, they create additional levels within the structure, but their down-line members remain in the same down-line network as the original member that introduced them to our business.

 

While we provide informational brochures and other sales materials, members are primarily responsible for enrolling and educating their new members with respect to products, the compensation plan and how to build a successful membership network.

 

Members are not required to enroll other members as their down-line, and we do not pay any commissions for enrolling new members. However, because of the financial incentives provided to those who succeed in building a member network that consumes and resells products, we believe that many of our members attempt, with varying degrees of effort and success, to enroll additional members. Because they are seeking new opportunities for income, people are often attracted to become members after using our products or after attending introductory seminars. Once a person becomes a member, he or she is able to purchase products directly from us at wholesale prices via the internet. The member is also entitled to enroll other members in order to build a network of members and product users.

 

Compensation Plans

 

We employ what is commonly referred to as a binary compensation plan, enhanced with certain unilevel features. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to sponsor other members located in other countries. Currently, there are basically two ways in which members can earn income:

 

 

Through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

Through retail profits on sales of products purchased by members at discount and wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands, the member receives higher commissions from purchases made by an expanding down-line network. To be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, some of our commission payout may be limited to a hard cap dollar amount per week or a specific percentage of the total product sales. In some markets, commissions may be further limited.

 

In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time.

 

Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into agreements for business or market development, which could result in additional compensation to specific members.

 

 

Member Support

 

We are committed to providing a high level of support services tailored to the needs of our members in each market we are serving. We attempt to meet the needs and build the loyalty of members by providing personalized member services and by maintaining a generous product return policy (see “Product Warranties and Returns”). We believe that maximizing a member’s efforts by providing effective member support has been, and could continue to be, important to our success.

 

Through product training meetings, regular conventions, web-based messages, member focus groups, regular telephone conference calls and other personal contacts with members, we seek to understand and satisfy the needs of our members. Via our platform, we may provide product fulfillment and tracking services that result in user-friendly and timely product distribution.

 

To help maintain communication with our members, we offer the following support programs:

 

 

Teleconferences – we hold teleconferences with associate field leadership on various subjects such as technical product discussions, member organization building and management techniques.

 

 

Internet – we maintain a website at www.nhtglobal.com. On this website, the user can read company news, learn more about various products, sign up to be a member, place orders, and track the fulfillment and delivery of their orders.

 

 

Product Tools – we offer a variety of marketing tools to members, including product catalogs, videos, informational brochures, pamphlets and posters for individual products, which are both printed and available online.

 

 

Broadcast E-mail and Text Messages – we send announcements via e-mail and/or text messages to members who opt in to receive this form of communication.

 

 

Social Media Tools – in some countries we maintain country-specific social media sites to foster a community environment around our product offering and business opportunity.

 

Technology and Internet Initiatives

 

We believe that the internet is important to our business as more consumers communicate online and purchase products over the internet as opposed to traditional retail and direct sales channels. As a result, we have committed significant resources to our e-commerce capabilities and the abilities of our members to take advantage of the internet. Substantially all of our sales take place via the internet. We offer a global platform that allows a member to have a personalized replicating website through which he or she can sell products in all of the countries in which we do business. Links to these websites can be found at our main website for members at www.nhtglobal.com. The information provided on these websites should not be considered part of this report.

 

Rules Affecting Members

 

Our member policies and procedures establish the rules that members must follow in each market. We also monitor member activity in an attempt to provide our members with a “level playing field” so that one member may not be disadvantaged by the activities of another. We require our members to present products and business opportunities in an ethical and professional manner. Members further agree that their presentations to customers must be consistent with, and limited to, the product claims and representations made in our literature.

 

Our policies and procedures require that we produce or pre-approve all sales aids used by members such as presentations, videos, audio recordings, brochures and promotional clothing. Further, members may not use any form of media advertising to promote products unless it is pre-approved by us. Members are not entitled to use our trademarks or other intellectual property without our prior consent. If we are made aware of unapproved materials being used, we notify and direct the relevant members to cease using such materials. In addition to regularly communicating to our members what is and is not appropriate to say about product or income claims, we have engaged a third-party service provider to assist us in monitoring the internet and various social media to identify potential misconduct or violations of our policies and procedures.

 

Our compliance and member services department reviews reports of alleged member misbehavior. If we determine that a member has violated our member policies or procedures, we may terminate the member’s rights completely. Alternatively, we may impose sanctions, such as warnings, probation, withdrawal or denial of an award, suspension of privileges of the membership, fines, withholding commissions, until specified conditions are satisfied or other appropriate injunctive relief. Virtually all of our members are independent contractors, not employees, and may act independently of us. Further, our members may resign or terminate their membership at any time without notice. See “Item 1A. Risk Factors - Our recent loss of a significant number of members is adversely affecting our business...”.

 

 

Government Regulations

 

Direct Selling Activities

 

Direct selling, or multi-level marketing, activities are regulated by various federal, state and local governmental agencies in the United States and other countries. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes. The laws and regulations in our current markets often:

 

 

impose cancellation/product return, inventory buy-backs and cooling-off rights for consumers and members;

 

 

require us or our members to obtain a license from, or register with, governmental agencies;

 

 

impose reporting requirements; and

 

 

impose upon us requirements, such as requiring members to maintain levels of retail sales to qualify to receive commissions, to avoid pyramid schemes by ensuring that members are being compensated for sales of products and not for recruiting new members.

 

The laws and regulations governing direct selling are modified from time to time, and, like other direct selling companies, we may be subject from time to time to government reviews, examinations or investigations in our various markets related to our direct selling activities. This can require us to make changes to our business model and aspects of our global compensation plan in the markets impacted by such changes and examinations.

 

China has direct selling and anti-pyramiding regulations that are restrictive and contain various limitations, including a restriction on the ability to pay multi-level compensation to independent members and engage in certain member recruitment activities. The regulatory environment in China is complex, and our business in China can receive regulatory and media attention.

 

The Chinese government scrutinizes activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations, and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense in the legality of their conduct. We expect that our business model will continue to evolve, as we work with our professional advisors and regulators to make any changes that need to be made to comply with the direct selling and other regulations.

       

We believe that neither our Hong Kong-based e-commerce direct selling platform nor our e-commerce retail platform in China require a direct selling license in China, which we currently do not hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so.

 

Regulation of Our Products

 

Our products and related promotional and marketing activities are subject to extensive governmental regulation by numerous governmental agencies and authorities in the United States, including the U.S. Food and Drug Administration (the “FDA”), the Federal Trade Commission (the “FTC”), the Consumer Product Safety Commission, the United States Department of Agriculture, State Attorneys General and other state regulatory agencies.  In our foreign markets, the products are generally regulated by similar government agencies.

 

 

Our personal care products are subject to various laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter (OTC) cosmetic. In the United States, regulation of cosmetics is under the jurisdiction of the FDA and the FTC.  The Food, Drug and Cosmetic Act defines cosmetics by their intended use, as “articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body . . . for cleansing, beautifying, promoting attractiveness, or altering the appearance.”  Among the products included in this definition are skin moisturizers, eye and facial makeup preparations, perfumes, lipsticks, fingernail polishes, shampoos, permanent waves, hair colors, toothpastes and deodorants, as well as any material intended for use as a component of a cosmetic product.  Conversely, a product will not be considered a cosmetic, but may be considered a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or any function of the body. A product’s intended use can be surmised from marketing or product claims.  The other markets in which we conduct business have similar regulations.  Additionally, the requirement that claims for products must be truthful and substantiated is enforced by the FTC.

 

In Japan, the Ministry of Health, Labor and Welfare regulates the sale and distribution of cosmetics and requires us to have an import business license and to register each personal care product imported into Japan.  In Taiwan, all “medicated” cosmetic products require registration.  In China, personal care products are placed into one of two categories, “general” and “drug.”  Products in both categories require submission of formulas and other information with the health authorities, and drug products require human clinical studies.  The product registration process in China for these products can take from nine to more than 18 months or longer.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  The sale of cosmetic products is regulated in the European Union under the European Union Cosmetics Directive, which requires a uniform application for foreign companies making personal care product sales. In Peru, this is managed by the governing arm DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) and can take up to three months to fully register as saleable. Similarly, in Mexico, the governing arm is COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) and can also take three to six months to fully register as saleable.

 

The markets in which we conduct business all have varied regulations that distinguish foods and nutritional health supplements from “drugs” or “pharmaceutical products.”  Because of the varied regulations, some products or ingredients that are recognized as a “food” in certain markets may be treated as a “pharmaceutical” in other markets.  These regulations may require us to either modify a product or refrain from selling the product in a given market. As a result, we must regularly modify the ingredients and/or the levels of ingredients in our products to ensure all applicable regulatory restrictions are addressed.  In some circumstances, the regulations in foreign markets may require us to obtain regulatory approval prior to introduction of a new product or limit our uses of certain ingredients altogether. There has been an increased movement in the United States and other markets to expand the regulation of dietary supplements. This could impose additional restrictions or requirements in the future.  Because of this increased regulatory focus, our internal regulatory staff has grown and review efforts have been enhanced in order to comply with our understanding of current regulations.

 

FDA regulations require current good manufacturing practices (cGMP) for dietary supplements.  The regulations seek to ensure personnel are routinely and properly trained, that dietary supplements are produced in a quality manner, do not contain contaminants or impurities, and are accurately labeled. The regulations include requirements for establishing quality control procedures for us and our vendors and suppliers, designing and constructing manufacturing plants, and testing ingredients and finished products.  The regulations also include requirements for record keeping and handling consumer product complaints.  If dietary supplements contain contaminants or do not contain the type or quantity of dietary ingredient they are represented to contain, the FDA would consider those products to be adulterated or misbranded. We seek to ensure compliance with all regulatory requirements through our periodic manufacturer and warehouse audits, as well as our corrective action request (CAR) program, if needed. The cGMP also extend to logistics where we seek to minimize any safety risks associated with product distribution.

 

Our business is subject to additional FDA regulations, such as those implementing an adverse event reporting system (“AER’s”), which requires us to document and track adverse events and report serious adverse events, which are events involving hospitalization or death, associated with consumers’ use of our products.  

 

 

Most of our major markets also regulate advertising and product claims regarding the efficacy of products. This is particularly true with respect to our dietary supplements because we typically market them as foods or health functional foods. For example, in the United States, we are unable to claim that any of our nutritional supplements will diagnose, cure, mitigate, treat or prevent disease. In the United States, the Dietary Supplement Health and Education Act, however, permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well-being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or a function of the body. Most of the other markets in which we conduct business have not adopted similar legislation, so distribution of U.S. products may be subject to more restrictive limitations on the claims we can make about our products in these markets.

 

China’s 100-Day Campaign Focusing on Health Products and Services

 

In January 2019 the Chinese government announced a 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has recently been exacerbated by negative social media sentiment expressed for these types of companies.

 

The 100-day campaign, including its extension and aftermath, has and is expected to continue negatively impacting our business in China in the near-term, but we believe will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market. See “Item 1A. Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...” and “Item 7. - Management’s Discussion and Analysis of Financial Condition and Results of Operations - Business Overview.”

 

Other Regulatory Issues

 

As we operate through many subsidiaries in foreign jurisdictions, we are subject to foreign exchange control, transfer pricing and custom laws that regulate the flow of funds between our entities for product purchases, management services and contractual obligations, such as the payment of member commissions. As is the case with most companies that operate in direct sales, we might receive inquiries or scrutiny from time to time from government regulatory authorities regarding the nature of our business and other issues, such as compliance with local direct selling, pyramid selling, transfer pricing, customs, taxation, foreign exchange control, securities and other laws.

 

Product Warranties and Returns

 

Our refund policies and procedures closely follow industry and country-specific standards, which vary greatly by country. For example, in the United States, the Direct Selling Association recommends that direct sellers permit returns during the twelve-month period following the sale, while in Hong Kong the standard return policy is 14 days following the sale. Our return policies typically conform to local laws or the recommendation of the local direct selling association. In most cases, members who timely return unopened product that is in resalable condition may receive a refund. The amount of the refund may be dependent on the country in which the sale occurred, the timeliness of the return, and any applicable re-stocking fee. NHT Global must be notified of the return in writing and such written requests would be considered a termination notice of the membership. We may alter our return policy in response to special circumstances.

 

 

Significant Customers

 

Sales are made to our members and no single customer accounted for 10% or more of our net sales. However, our business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on our net sales and financial results.

 

Our Industry

 

We are engaged in the direct selling industry, selling wellness, herbal, beauty, lifestyle, home, baby, and daily products. More specifically, we are engaged in what is called network marketing or multi-level marketing. This type of organizational structure and approach to marketing and sales include companies selling lifestyle enhancement products, cosmetics and dietary supplements, or selling other types of consumer products. Generally, direct selling is based upon an organizational structure in which independent members purchasing a company’s products are compensated for sales made directly to consumers.

 

Our members are compensated based on sales generated by members they have enrolled and all subsequent members enrolled by their “down-line” network of members. The experience of the direct selling industry has been that once a sizeable network of members is established, new and alternative products and services can be offered to those members for sale to consumers and additional members.

 

Competition

 

The network marketing industry is very diverse, with giant multinational corporations as well as smaller, local operators, some of which are direct-selling subsidiaries of much larger conglomerates. Big network marketing companies include Nu Skin Enterprises, Inc., USANA Health Sciences, Inc., and Herbalife, Ltd, which have much greater name recognition and financial resources than we do and also have many more members. They are publicly traded and therefore serve as informational benchmarks, but we don’t overlap with them in terms of marketplace or product range. On the other hand, many medium- and small-sized privately held Chinese, Taiwanese and Hong Kong companies are fierce competitors and are much closer to directly competing with us. Also, a number of our former employees and members now work for competitors and sometimes try to use relationships and knowledge obtained to compete with us.

 

Our ability to compete with other network marketing companies depends, in significant part, on our success in attracting and retaining members.  There can be no assurance that our programs for attracting and retaining members will be successful.  The pool of individuals interested in network marketing is limited in each market and is reduced to the extent other network marketing companies successfully attract these individuals into their businesses.  Although we believe that we offer an attractive opportunity for our members, there can be no assurance that other network marketing companies will not be able to recruit our existing members or deplete the pool of potential members in a given market.

 

The direct selling channel tends to sell products at a higher price compared to traditional retailers, which poses a degree of competitive risk. There is no assurance that we would continue to compete effectively against retail stores, internet-based retailers or other direct sellers.

 

 

 

Item 1A. RISK FACTORS

 

We are exposed to a variety of risks that are present in our business and industry. The following are some of the more significant factors that could affect our business, results of operations and financial condition.

 

Business, Product and Market Risks, Including COVID-19 Risks

 

Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business.

 

In 2020 and 2019, approximately 79% and 81% of our revenue, respectively, was generated in Hong Kong. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. This geographic concentration in our business means that events or conditions that could negatively impact this geographic region or our operations in this region, including the current economic challenges facing China and Hong Kong, are having and could in the future have a greater adverse impact upon our overall business and financial results than would be the case with a company having greater geographic diversification.  

 

Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorist attacks or acts of war may seriously harm our business.

 

Epidemics, natural disasters, terrorist attacks or acts of war may cause damage or disruption to us, our employees, our facilities and our members and customers, which could negatively impact our revenues, expenses and financial condition.  For example, in late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world, being declared a global pandemic by the World Health Organization in March 2020. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout areas of China and restricting public gatherings and certain travel within the country. We have significant business in China and in 2020 generated approximately 79% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-19, while the governments of other countries in which we operate are working at various stages to control the virus. The severity of the impact on us of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results throughout 2020, and we expect that our financial results for the near-term may be adversely affected. These disruptions have also adversely affected the operations of our third-party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions.

 

This and other epidemics, such as the avian influenza, or natural disasters have in the past and could in the future adversely affect our business, financial condition and results of operations. Terrorist attacks, the national and international responses to terrorist attacks, and other acts of war or hostility, such as challenges to Chinese sovereignty claims in the South China Sea or Chinese objection to the Taiwan independence movement and the resultant tension in the Taiwan Strait, could materially and adversely affect our business, results of operations, and financial condition in ways that we currently cannot predict.

 

Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong, and the negative impact on our operations and financial performance could continue or intensify.

 

Our headquarters and a significant number of our employees are based in Hong Kong, and our Hong Kong subsidiary generates a substantial portion of our overall business. Hong Kong has in recent years experienced significant political unrest and social strife, including a series of large-scale protests. These developments, along with the impact of the COVID-19 pandemic, recently led us to cease conducting member meetings and events in Hong Kong. Inasmuch as member meetings and events located in Hong Kong have in the past served as an important component of our product marketing and distribution efforts, we believe that this action has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, financial condition and results of operations will be adversely affected.

 

We experienced negative operating cash flows during the year ended December 31, 2019, and only modest positive operating cash flows during the year ended December 31, 2020. Unless our operating cash flows improve, this negative financial performance it could have a material adverse effect on our business and our stock price.

 

We experienced negative operating cash flows during the year ended December 31, 2019, and only modest positive operating cash flows during the year ended December 31, 2020. This cash flow performance was primarily due to declines in our revenues being greater than the decreases in expenditures that we could manage. If we again experience negative operating cash flows or our cash balance is substantially diminished, we may not be able to continuing paying cash dividends to our stockholders, our ability to support our operations could be impaired and we may be required to seek debt or equity financing. However, we may not be able to obtain additional debt or equity financing on satisfactory terms, or at all, and any new financing could have a dilutive effect to our existing stockholders. Negative operating cash flows could have a material adverse effect on our business, results of operations and financial condition, as well as our stock price, and could eventually threaten our solvency. Negative operating cash flows and any related adverse market perception may also negatively affect our ability to attract new members and/or sell our products. There can be no assurance that we will be successful in maintaining an adequate level of cash resources.

 

Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.

 

Adverse publicity concerning any actual or claimed failure by us or our members to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, the regulation of our network marketing program, the licensing and distribution of our products for sale in our target markets or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on our goodwill and could negatively affect our ability to attract, motivate and retain members, which would negatively impact our ability to generate revenue.  There have been several instances where adverse publicity in China has harmed our business. For example, in January 2019 Central China Television (CCTV) aired a segment alleging, among other things, that we conduct an illegal pyramid scheme in China, and we believe that this media coverage had a short-term negative impact on our business. See “Risk Factors - Our business in China is subject to a myriad of applicable laws and regulations…”.

 

 

 

In addition, our members’ and consumers’ perception of the safety and quality of our products and ingredients, as well as similar products and ingredients distributed by other companies, can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning our products or ingredients or similar products and ingredients distributed by other companies.  Adverse publicity, whether or not accurate or resulting from consumers’ use or misuse of our products, that associates consumption of our products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact our reputation or the market demand for our products.

 

We are subject to risks relating to product concentration and lack of revenue diversification.

 

Although we have in recent years expanded our line of products, we derive at least 10% of our total revenue from each of our Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products. Further, we currently source each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, we are unable to adequately source or deliver the products, or we are unable to offer the products for any reason without suitable replacements, our business, financial condition and results of operations could be materially and adversely affected. Our future success will also depend on our ability to reduce our dependence on these few products by developing and introducing new products and product or feature enhancements in a timely manner. Even if we are able to develop and commercially introduce new products and enhancements, they may not achieve market acceptance and the revenue generated from these new products and enhancements may not offset the costs, which could substantially impair our business, financial condition and results of operations.

 

The high level of competition in our industry could adversely affect our business.

 

The business of marketing personal care, cosmetic, nutritional supplements, and lifestyle enhancement products is highly competitive.  This market segment includes numerous manufacturers, members, marketers, and retailers that actively compete for the business of consumers both in the United States and abroad.  The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.  Sales of similar products by competitors may materially and adversely affect our business, financial condition and results of operations.

 

We are subject to significant competition for the recruitment of members from other direct selling organizations, including those that market similar products.  Many of our competitors are substantially larger than we are, offer a wider array of products, have far greater financial resources and many more active members than we have.  Even more numerous are those medium- and small-sized, all privately held Chinese, Taiwanese and Hong Kong companies, some of which are direct-selling subsidiaries of much larger conglomerates, that are fierce competitors and are much closer to directly competing with us. Our ability to remain competitive depends, in significant part, on our success in recruiting and retaining members with our products, attractive compensation plan and other incentives.  We believe that we have an attractive product line and that our compensation and incentive programs provide our members with significant earning potential.  However, we cannot be sure that our programs for recruitment and retention of members will be successful.

 

Some of our competitors have employed or otherwise contracted for the services of our former officers, employees, consultants, and members, who may try to use information and contacts obtained while under contract with us for competitive advantage. While we seek to protect our information through contractual and other means, there can be no assurance that we will timely learn of such activity, have the resources to attempt to stop it, or have adequate remedies available to us.

 

Failure of new products to gain member and market acceptance could harm our business.

 

An important component of our business is our ability to develop new products that create enthusiasm among our member force.  If we fail to introduce new products on a timely basis, our member productivity could be harmed.  In addition, if any new products fail to gain market acceptance, are restricted by regulatory requirements, or have quality problems, this would harm our results of operations.  Factors that could affect our ability to continue to introduce new products include, among others, limited capital and human resources, government regulations, proprietary protections of competitors that may limit our ability to offer comparable products and any failure to anticipate changes in consumer tastes and buying preferences.

 

We rely on a limited number of independent third parties to manufacture and supply our products.

 

All of our products are manufactured by a limited number of independent third parties.  There is no assurance that our current manufacturers will continue to reliably supply products to us at the level of quality we require.  If a key manufacturer suffers liquidity problems or experiences operational or other problems assisting with our products, our results could suffer.  In the event any of our third-party manufacturers become unable or unwilling to continue to provide the products in required volumes and quality levels at acceptable prices, we will be required to identify and obtain acceptable replacement manufacturing sources or replacement products.  There is no assurance that we will be able to obtain alternative manufacturing sources or products or be able to do so on a timely basis.  An extended interruption in the supply of certain of our products may result in a substantial loss of revenue.  In addition, any actual or perceived degradation of product quality as a result of our reliance on third-party manufacturers may have an adverse effect on revenue or result in increased product returns.  

 

Growth may be impeded by the political and economic risks of entering and operating in foreign markets.

 

Our ability to achieve future growth is dependent, in part, on our ability to continue our international expansion efforts.  However, there can be no assurance that we would be able to grow in our existing international markets, enter new international markets on a timely basis, or that new markets would be profitable.  We must overcome significant regulatory and legal barriers before we can begin marketing in any foreign market.

 

 

 

Also, it is difficult to assess the extent to which our products and sales techniques would be accepted or successful in any given country.  In addition to significant regulatory barriers, we may also encounter problems conducting operations in foreign markets with different cultures and legal systems from those elsewhere.  There are substantial uncertainties in many such legal systems around the world, including in China, which could limit our ability to enforce third-party contractual arrangements and have other negative consequences. We may also be required to reformulate certain of our products before commencing sales in a given country.  Once we have entered a market, we seek to adhere to the regulatory and legal requirements of that market.  No assurance can be given that we would be able to successfully reformulate our products in any of our current or potential international markets to meet local regulatory requirements or attract local customers.  The failure to do so could have a material adverse effect on our business, financial condition, and results of operations.  There can be no assurance that we would be able to obtain and retain necessary permits and approvals.

 

In many markets, other direct selling companies already have significant market penetration, the effect of which could be to desensitize the local member population to a new opportunity or to make it more difficult for us to recruit qualified members. There can be no assurance that, even if we are able to commence operations in foreign countries, there would be a sufficiently large population of potential members inclined to participate in a direct selling system offered by us.  We believe our future success could depend in part on our ability to seamlessly integrate our business methods, including member compensation plan, across all markets in which our products are sold.  There can be no assurance that we would be able to further develop and maintain a seamless compensation program.

 

Failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act of 2002 could negatively impact our business and the market price of our stock.

 

We are required by federal securities laws to document and test our internal control procedures in order to satisfy the requirements of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”), which requires annual management assessments of the effectiveness of internal control over financial reporting. Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. The SEC’s Sarbanes-Oxley rules require us to include a report by management on the effectiveness of our internal control over financial reporting in our Annual Reports on Form 10-K. Although we review internal control over financial reporting in order to ensure compliance with the SEC’s Sarbanes-Oxley rules, if we fail to maintain effective internal control over financial reporting, we could be required to take costly and time-consuming corrective measures to remedy any number of deficiencies, significant deficiencies or material weaknesses, be required to restate the affected historical financial statements, be subjected to investigations and/or sanctions by federal and state securities regulators, and be subjected to civil lawsuits by stockholders. For instance, as described in “Item 9A. - Controls and Procedures” in our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2018, we identified a material weakness in our internal control over financial reporting as of December 31, 2018. Management, with oversight from the Audit Committee, implemented a plan to remediate this material weakness and completed remediation during 2019. While the existence of this material weakness did not result in a restatement of previously issued interim or annual consolidated financial statements, we incurred substantial costs and utilized meaningful resources to remediate the material weakness during 2019. Any future failure to maintain effective internal control over financial reporting could result in the foregoing identified consequences and could cause investors to lose confidence in our reported financial information and in our company and could cause a decline in the market price of our stock.

 

Management and Member Network Risks

 

We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants.

 

We incur a low level of overhead and are run by a small number of executives, who rely on a small group of employees. Our future success depends to a significant degree on the skills, experience and efforts of our top management and directors.  We also depend on the ability of our executive officers and other members of senior management to work effectively as a team.  The loss of one or more of our executive officers, members of our senior management or directors could have a material adverse effect on our business, results of operations and financial condition.  Moreover, as our business evolves, we may require additional or different management members, directors or consultants, and there can be no assurance that we will be able to locate, attract and retain them if and when they are needed.

 

Our recent loss of a significant number of members is adversely affecting our business, and if we cannot stabilize or increase the number of members our business could be further negatively impacted.

 

We distribute our products through independent members, and we depend upon them directly for all of our sales in most of our markets. Accordingly, our success depends in significant part upon our ability to attract, retain and motivate a large base of members, as well as a relatively small number of key members.  Our members may terminate their services with us at any time and, like most direct selling organizations, we have a high rate of attrition. We had 9% fewer active members at December 31, 2020, as compared to the end of 2019, and 41% fewer active members at the end of 2019 as compared to the end of 2018. Although our rate of loss of active members in 2020 was less than in 2019, we have not in recent years been as effective as in the past in replacing terminated members. These losses in the number of active members was a significant factor contributing to the decrease in our recent year-over-year sales. If we cannot stabilize or increase the number of our members, or if we lose one or more key member leaders, sales of our products could be further materially and adversely affected. The replacement of members could be difficult because, in our efforts to attract and retain members, we compete with other direct selling organizations, including but not limited to those in the personal care, cosmetic product and nutritional supplement industries.

 

Our number of active members or their productivity could further decline in the future.  We cannot accurately predict fluctuations in the number or the productivity of members because we primarily rely upon existing members to train new members and to motivate new and existing members. Operating results could be adversely affected if our existing and new business opportunities and products do not generate sufficient economic incentive or interest to retain existing members and to attract new members.

 

 

The number and productivity of our members could be harmed by several factors, including:

 

 

adverse publicity or negative perceptions regarding us, our products, our method of distribution or our competitors;

 

 

lack of interest in, or the technical failure of, existing or new products;

 

 

lack of interest in our existing compensation plan for members or in enhancements or other changes to that compensation plan;

 

 

our actions to enforce our policies and procedures;

 

 

regulatory actions or charges or private actions against us or others in our industry, such as the 100-day campaign initiated in China in January 2019 (as well as its extension and aftermath, including the related look-back review);

 

 

general economic, business and political conditions, including the recent political unrest in Hong Kong;

 

 

changes in management or the loss of one or more key member leaders;

 

 

entry of new competitors, or new products or compensation plan enhancements by existing competitors, in our markets; and

 

 

potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain members in such market.

 

Although virtually all of our members are independent contractors, improper member actions that violate laws or regulations could harm our business.

 

Virtually all of our members are independent contractors and, accordingly, we are not in a position to directly provide the same direction, motivation and oversight as we would if these members were our own employees.  As a result, there can be no assurance that our members will participate in our marketing strategies or plans, accept our introduction of new products, or comply with our member policies and procedures.  Extensive federal, state, local and foreign laws regulate our business, our products and our network marketing program.  Because we operate in a number of foreign countries, our policies and procedures for our members differ due to the different legal requirements of each country in which we do business.  While we have implemented member policies and procedures designed to govern member conduct and to protect the goodwill associated with our trademarks and trade names, it can be difficult to enforce these policies and procedures because of the large number of members and their independent status.

 

Given the size and diversity of our member force, we experience problems with members from time to time, especially with respect to our members in foreign markets. For example, if our members engage in illegal activities in China, those actions could be attributed to us. Chinese laws regarding how and when members may assemble and the activities that they may conduct, or the conditions under which the activities may be conducted, are subject to significant regulatory discretion resulting in interpretations and enforcement that sometimes vary from province to province, among different levels of government, and from time to time. Members can be accused of violating one or more of the laws regulating these activities, notwithstanding training that we attempt to provide. Enforcement measures regarding these violations, which can include arrests, raise the uncertainty and perceived risk associated with conducting this business, especially among those who are aware of the enforcement actions but not the specific activities leading to the enforcement action. We believe that this has led some existing members in China - who are signed up as members in Hong Kong - to leave the business or curtail their selling activities and has led some potential members to choose not to participate. Among other things, we are managing this risk with more training and public relations efforts that are designed, among other things, to distinguish our company from businesses that make no attempt to comply with the law. This environment creates uncertainty about the future of doing this type of business in China generally and under our current business model, specifically.

 

In addition, members often desire to enter a market before we have received approval to do business in order to gain an advantage in the marketplace.  Improper member activity in new geographic markets could result in adverse publicity and can be particularly harmful to our ability to ultimately enter these markets.  Violations by our members of applicable law or of our policies and procedures in dealing with customers could reflect negatively on our products and operations, and harm our business reputation.  In addition, it is possible that a judicial or administrative body could hold us civilly or criminally accountable based on vicarious liability because of the actions of our members.  If any of the above or related events involving our members occur, our business, financial condition, or results of operations could be materially adversely affected.

 

An increase in the amount of compensation paid to members would reduce profitability.

 

We incur significant expense in the payment of compensation to our members, which represented approximately 42% and 46% of net sales during 2020 and 2019, respectively.  We compensate our members by paying commissions, bonuses, and certain awards and prizes.  Factors impacting the overall commission payout include the growth and depth of the member network, the member retention rate, the type and scope of promotions and incentives, local promotional programs and business development agreements.  Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Any increase in compensation payments to members as a percentage of net sales will reduce our profitability. 

 

Our compensation plan includes a cap that may be enforced on member compensation paid out on a weekly dollar limit or as a percentage of product sales. There can be no assurance that enforcement of this cap will ensure profitability (which depends on many other factors).  Moreover, enforcement of this cap could cause key members affected by the cap to leave and join other companies.

 

We may be held responsible for certain taxes or assessments relating to the activities of our members and service providers, which could harm our financial condition and operating results.

 

Our members and service providers are subject to taxation, and in some instances, legislation or governmental agencies impose an obligation on us to collect the taxes, such as value added taxes, and to maintain appropriate records.  In addition, we are subject to the risk in some jurisdictions of being responsible for social security and similar taxes with respect to our members.

 

 

Legal, Regulatory, Tax, Currency and Trade Policy Risks

 

Our business in China is subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company.

 

In contrast to our operations in other parts of the world, our China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. We operate an e-commerce direct selling platform in Hong Kong and recognize the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties.  In addition, through a Chinese entity, we sell products in China using an e-commerce retail platform. Chinese members may elect to participate in either or both of the Chinese entity and the Hong Kong entity.

 

We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

We continually evaluate our business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. We work on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted.

 

Should the government authorities determine that our activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on our business, financial condition and results of operations.

 

The Chinese government scrutinizes the activities of direct selling companies. Our business continues to be subject to regulations and examinations by municipal and provincial level regulators. At times, actions by government regulators have impacted our members’ activities in certain locations and have resulted in a few cases of enforcement actions. In each of these cases, we helped our members with their defense of the legality of their conduct.

 

Our business and the value of our company can be adversely affected by Chinese government scrutiny, even if that scrutiny does not result in investigations of our business. For example, one or more parties encouraged the Beijing City governmental authorities to conduct an investigation of our business, which resulted in a meeting in January 2016 involving members of our Beijing office staff, Beijing City governmental officials, and two complainants. Even though the Beijing City governmental officials advised our staff and the complainants at that meeting that there was insufficient evidence to warrant an investigation of us, mischaracterizations of the meeting immediately appeared in several “news reports.” Similarly, a subsequent meeting between several Guangzhou City government officials and members of our Guangzhou office staff that resulted in our providing routine information about our business to the government officials was mischaracterized in an online posting made immediately following the meeting. Although we remain in regular contact with Chinese government officials and take other steps to address the risks posed by these events, these government officials have significant discretion in the application and enforcement of laws and regulations. As a result, our business and the value of our company remain vulnerable to Chinese government scrutiny, whether or not initiated by third parties, which scrutiny could result in changes to our business and/or the Chinese or Hong Kong government taking action against us.

 

Various other factors could harm our business in Hong Kong and China, such as worsening economic conditions in Hong Kong or China, adverse developments relating to the industry in which we conduct our business, adverse local publicity, negative changes to our business and/or social media coverage, geopolitical or trade tensions between the U.S. and China or other events that may be out of our control. For example, in January 2019 the Chinese government announced a 100-day campaign focusing on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. It is further understood that the campaign is specifically focused on the business practices of direct selling companies. Similarly, during the third quarter of 2007, we learned that the Chinese government was expected to impose a more intense enforcement program against illegal pyramid scheme activities (or “chain sale” activities in transliterated Chinese terms). In January 2019 we, like some of our peers, voluntarily decided to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China as we did in 2007. We did this because we learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies and did not want to run the risk of being inadvertently entangled in the government enforcement actions as the provincial and local government formulate and implement their interpretive guidance and rule-making. Although we have recently been able to relax some restrictions on member activities in certain markets, it may again in the future be necessary or advisable to suspend member activities or take similar actions, and the resulting periods of reduced activity may have a material adverse effect on our business.

 

 

Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has recently been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers as purveyors of substandard products are driven from the market.

 

Although we attempt to work closely with both national and local Chinese governmental agencies in conducting our business, our efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding our policies prohibiting such activities.

 

Any determination that our operations or activities, or the activities of our individual members, employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on our future ability to obtain business licenses or expand into new locations, changes to our business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm our business, financial condition and results of operations. 

 

Changes in government trade and economic policies, including the imposition or threatened imposition of tariffs and other restrictive trade policies, and ongoing political and economic disputes between the United States and other jurisdictions, particularly China, may have a negative effect on global economic conditions and our business, financial results and financial condition.

 

The United States has in recent years enacted tariffs on certain items. Further, there are ongoing discussions and activities regarding changes to other U.S. trade policies and treaties. In response, a number of our markets, particularly China, have implemented tariffs on U.S. imports or otherwise imposed non-tariff barriers such as slow-walking custom clearance of American-made products in response to these U.S. actions. These developments, together with the threat of new tariffs and other restrictive trade policies, may have a material adverse effect on global economic conditions and the stability of global financial markets, and they may significantly reduce global trade and, in particular, adversely affect trade and economic relations between China and the United States.

 

Tensions between China and the United States have become particularly acute following the China legislature’s passage of a national security law in June 2020 that changes the way Hong Kong has been governed since the territory was handed over by the United Kingdom to China in 1997. This law criminalizes secessionist activities, subversion, terrorism, and collusion with a foreign country or with external elements to endanger national security in Hong Kong. The U.S. State Department has announced that the U.S. no longer considers Hong Kong to have significant autonomy from China, and the U.S. administration is taking action to end many of the U.S. government’s special trade and economic relations with Hong Kong. Further, on July 14, 2020 the U.S. enacted the Hong Kong Autonomy Act (and the U.S. President issued a related Executive Order), authorizing the U.S. administration to impose sanctions against individuals and entities determined to materially contribute to the erosion of Hong Kong's autonomy, as well as to punish financial institutions that facilitate certain significant transactions.   The U.S. has since imposed sanctions on a number of individuals, and China has responded in kind.  These and other recent actions may represent an escalation in political and economic tensions involving the U.S, China and Hong Kong, which could harm our business. A continued deterioration in these political or economic relations or other future unforeseen problems could disrupt our China and Hong Kong business (including our Hong Kong office and employees), adversely affect the distribution of our products, reduce our net sales, increase the cost of conducting our operations, or result in retaliatory actions against U.S. interests, any of which could have a material adverse effect on our results of operations, financial condition and business.

 

In addition, any actions by non-U.S. markets to implement further trade or economic policy changes, including limiting foreign investment or trade, imposing currency controls restricting the international transfer of funds, increasing regulatory scrutiny or taking other actions which impact U.S. companies' ability to obtain necessary licenses or approvals could negatively impact our business.

 

Trade and economic policy changes are subject to a number of uncertainties and are only one part of the larger dynamic of political and economic relations amongst countries. The ultimate reaction of other countries, and the individuals in each of these countries, and the impact of actions on the United States, China, Hong Kong, the global economy and our business, financial condition and results of operations, cannot be predicted at this time.

 

Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business.

 

Our direct selling system is subject to extensive laws, governmental regulations, administrative determinations, court decisions and similar constraints.  These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, often referred to as “pyramid” schemes, which compensate participants for recruiting additional participants irrespective of product sales, use high pressure recruiting methods and/or do not involve legitimate products. They also seek to ensure that claims regarding the ability of participants to earn money are truthful and substantiated.

 

Complying with these widely varying and sometimes inconsistent rules and regulations can be difficult and may require the devotion of significant resources on our part.  There can be no assurance that we or our members are in compliance with all of these regulations.  Our failure or our members’ failure to comply with these regulations or new regulations could lead to the imposition of significant penalties or claims and could negatively impact our business.  If we are unable to continue business in existing markets or commence operations in new markets because of these laws, our revenue and profitability may decline.

 

We are also subject to the risk that new laws or regulations might be implemented or that current laws or regulations might change, which could require us to change or modify the way we conduct our business in certain markets or the loss of necessary licenses.  This could be particularly detrimental to us if we have to change or modify the way we conduct business, or cannot conduct any business, in markets that represent a significant percentage of our revenue.

 

 

Challenges by third parties to the legality of our business operations could harm our business.

 

We are also subject to the risk of private party challenges to the legality of our operations, including our direct selling system.  The regulatory requirements concerning direct selling systems generally do not include “bright line” rules and are inherently fact-based and subject to judicial or administrative interpretation. An adverse judicial or administrative determination against us with respect to our direct selling system, or in proceedings not involving us directly but which challenge the legality of other direct selling marketing systems, could have a material adverse effect on our business.  There is also risk that challenges and settlements involving other parties could provide incentives for similar actions by members against us and other direct selling companies.  Moreover, challenges to our business system and operations in important markets may come from short sellers, hedge funds, other investors, bloggers and reporters.  Other companies in our industry have recently faced such challenges.  Any challenges regarding us or others in our industry could harm our business if such challenges result in the imposition of any fines or damages on our business, create adverse publicity, increase scrutiny or investigations of us or our industry, detrimentally affect our efforts to recruit or motivate members and attract customers, or interpret laws in a manner inconsistent with our current business practices.

 

We are currently involved in, and may in the future face, lawsuits, claims, and governmental proceedings and inquiries that could harm our business.

 

We are currently, and have in the past, been a party to lawsuits, claims and governmental proceedings and inquiries. Prosecuting and defending these matters may require significant expense and attention of our management and can expose us to adverse publicity, regardless of the outcome. Further, in the event of an adverse outcome, we could be required to pay substantial damages, fines or penalties and cease or be prevented from conducting certain practices or activities.

 

The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of our securities and/or the Company's public disclosures. We have fully cooperated with the SEC and continue to do so. The amount of time needed to resolve this matter is uncertain, and we cannot predict the outcome or whether we will face additional governmental inquiries or other actions. The SEC could bring enforcement actions against us or individuals, including our officers or directors. Such actions, if brought, could result in dispositions, judgments, settlements, injunctions, cease and desist orders, or other financial or non-financial penalties. The imposition of any sanctions or penalties, or the implementation of remedial measures could have a material adverse effect on our business.

 

Such matters can be complex, can extend for a protracted period of time, and can result in unpredictable expense. There can be no assurance that we will be able to successfully defend or resolve any such litigation, claims or governmental proceedings or inquiries, or that the significant money, time and effort spent in defending these matters, or any related adverse publicity, will not adversely affect our business, financial condition and results of operations.

 

Currency exchange rate fluctuations could lower our revenue and net income.

 

In 2020, 96% of our revenue was recorded by subsidiaries located outside of North America.  Revenue transactions and related commission payments, as well as other incurred expenses, are typically denominated in the local currency.  Accordingly, our international subsidiaries generally use the local currency as their functional currency.  The results of operations of our international subsidiaries are exposed to foreign currency exchange rate fluctuations during consolidation since we translate into U.S. dollars using the average exchanges rates for the period.  As exchange rates vary, revenue and other operating results may differ materially from our expectations.  Additionally, we may record significant gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of inter-company balances.  

 

Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar.  We also purchase a significant majority of inventories in U.S. dollars.  Our foreign currency exchange rate exposure to the South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Vietnamese dong, Thai baht, Indian rupee, Canadian dollar, Mexican peso, Peruvian sol and European euro collectively represented approximately 18% and 10% of our revenue in 2020 and 2019, respectively.  Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, India, Canada, Central America, South America and Europe.  Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar.  Finally, we also experience indirect exchange rate exposure due to the concentration of our sales to members residing in China and the impact of fluctuations in the value of the Chinese yuan on our members’ purchasing power.

 

Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition.  Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

 

Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income.

 

In the course of doing business we may be subject to various taxes, such as sales and use, value-added, and franchise. We are also subject to income taxes in the United States and numerous foreign jurisdictions. We earn a substantial portion of our income in foreign jurisdictions. Economic and political conditions make tax rules in any jurisdiction, including the United States, subject to significant change. There have been recent changes in U.S. tax law that impact how U.S. multinational corporations are taxed on foreign earnings. There have also been proposals to reform foreign tax laws that could significantly affect the Company’s tax position. Although we cannot predict whether or in what form these proposals will pass, several of the proposals considered, if enacted into law, could have an adverse impact on our income tax expense and cash flows.

 

Our parent corporation is domiciled in the United States. Under tax treaties, we are eligible to receive foreign tax credits in the United States for taxes paid abroad. Taxes paid to foreign taxing authorities may exceed the credits available to us, resulting in the payment of a higher overall effective tax rate on our worldwide operations.

 

Our effective income tax rate in the future could be adversely affected by a number of factors, including changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws, and the outcome of income tax audits in various jurisdictions around the world.

 

 

We are currently, and may in the future be subject to examinations of our tax returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and governmental bodies. We regularly assess the likelihood of an adverse outcome resulting from these examinations to determine the adequacy of our provision for taxes, which is subject to significant discretion. There can be no assurance as to the outcome of these examinations. If our effective tax rates were to increase, particularly in the U.S., or if the ultimate determination of taxes owed is for an amount in excess of amounts previously accrued, our financial results or operations could be adversely affected.

 

In addition, our operations are subject to regulations designed to ensure that appropriate levels of customs duties are assessed on the importation of our products. The failure to properly calculate, report and pay such duties when we are subject to them could have a material adverse effect on our financial condition and results of operations. Any change in the laws or regulations regarding such duties, or any interpretation thereof, could result in an increase in the cost of doing business.

 

Transfer pricing regulations affect our business and results of operations.

 

In many countries, including the United States, we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned by our United States or local entities and are taxed accordingly. We have adopted transfer pricing agreements with our subsidiaries to regulate inter-company transfers, which agreements are subject to transfer pricing laws that regulate the flow of funds between the subsidiaries and the parent corporation for product purchases, management services, and contractual obligations, such as the payment of member compensation. There can be no assurance that we will be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures or otherwise may have a material adverse effect on our financial results or operations.

 

Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets. 

 

The formulation, manufacturing, packaging, labeling, importation, advertising, distribution, sale and storage of certain of our products are subject to extensive regulation by various federal agencies, including the Food and Drug Administration (the “FDA”), the FTC, the Consumer Product Safety Commission and the United States Department of Agriculture and by various agencies of the states, localities and foreign countries in which our products are manufactured, distributed and sold.  For example, the FDA requires us and our suppliers to meet relevant current good manufacturing practice (cGMP) regulations for the preparation, packing and storage of foods and over-the-counter (OTC) drugs.  We are also now required to report serious adverse events associated with consumer use of certain of our products.  Other laws and regulations govern or restrict the claims that may be made about our products and the information that must be included and excluded on labels.

 

In markets outside the United States, prior to commencing operations or marketing new products, we may be required to obtain approvals, licenses, or certifications from a ministry of health or a comparable agency. Moreover, a foreign jurisdiction may pass laws that would prohibit the use of certain ingredients in their particular market.  Compliance with these regulations can create delays and added expense in introducing new products to certain markets.

 

Failure by our members or us to comply with those regulations could lead to the imposition of significant penalties or claims and could materially and adversely affect our business.  If we are not able to satisfy the various regulations, then we would have to cease sales of that product in that market.  In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect the marketing of our products, resulting in significant loss of revenues.

 

We cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, could have on our business.  These potential effects could include, however, requirements for the reformulation of certain products to meet new standards, the recall or discontinuance of certain products, additional recordkeeping and reporting requirements, expanded documentation of the properties of certain products, expanded or different labeling, or additional scientific substantiation.  Any or all of these requirements could have a material adverse effect on our business, financial condition, or results of operations.

 

New regulations governing the marketing and sale of nutritional supplements could harm our business.

 

There has been an increasing movement in the United States and other markets to increase the regulation of dietary supplements, which could impose additional restrictions or requirements in the future.  In the United States, for example, some legislators and industry critics continue to push for increased regulatory authority by the FDA over nutritional supplements.   Our business could be harmed if more restrictive legislation is successfully introduced and adopted in the future.  In particular, the adoption of legislation requiring FDA approval of supplements or ingredients could delay or inhibit our ability to introduce new supplements.  We face similar pressures in our other markets, particularly in China where certain government ministries announced in January 2019 a comprehensive 100-day campaign focusing on companies involved in the sale of certain products, including nutritional supplements and health products.  This campaign, which may not have formally concluded, is also currently the subject of a “look-back review” being conducted by various Chinese governmental agencies, and could result in new legislation or regulation.  In the United States, the FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising (“Guides”) require disclosure of material connections between an endorser and the company they are endorsing and require the disclosure of typical results when these are different from those reported by the endorser.  The requirements and restrictions of the Guides may diminish the impact of our marketing efforts and negatively impact our sales results.  If we or our members fail to comply with these Guides, the FTC could bring an enforcement action against us and we could be fined and/or forced to alter our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute nutritional supplements or impose additional burdens or requirements on nutritional supplement companies or require us to reformulate our products.

 

 

Regulations governing the production and marketing of our personal care products could harm our business.

 

Our personal care products are subject to various domestic and foreign laws and regulations that regulate cosmetic products and set forth regulations for determining whether a product can be marketed as a “cosmetic” or requires further approval as an over-the-counter drug.  A determination that our cosmetic products impact the structure or function of the human body, or improper marketing claims by our members, may lead to a determination that such products require pre-market approval as a drug.  Such regulations in any given market can limit our ability to import products and can delay product launches as we go through the registration and approval process for those products.  Furthermore, if we fail to comply with these regulations, we could face enforcement action against us and we could be fined, forced to alter or stop selling our products and/or required to adjust our operations.  Our operations also could be harmed if new laws or regulations are enacted that restrict our ability to market or distribute our personal care products or impose additional burdens or requirements on the contents of our personal care products or require us to reformulate our products.

 

If we are found not to be in compliance with good manufacturing practices our operations could be harmed.

 

Regulations on good manufacturing practices and adverse event reporting requirements for the nutritional supplement industry are in effect and require good manufacturing processes for us and our vendors, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.   We are also required to report serious adverse events associated with consumer use of our products.  Our operations could be harmed if regulatory authorities make determinations that we or our vendors are not in compliance with the regulations.  A finding of noncompliance may result in administrative warnings, penalties or actions impacting our ability to continue selling certain of our products.  In addition, compliance with these regulations has increased and may further increase the cost of manufacturing certain of our products as we work with our vendors to assure they are qualified and in compliance.

 

Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business.

 

Our failure to comply with FTC or state regulations, or with regulations in foreign markets that cover our product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by members for which we may be held responsible, may result in enforcement actions and imposition of penalties or otherwise materially and adversely affect the distribution and sale of our products. Our claims about the level of financial success that can be expected by our members are also subject to FTC review and enforcement.  Member activities in our existing markets that violate applicable governmental laws or regulations could result in governmental or private actions against us in markets where we operate. Given the size of our member force, we cannot ensure that our members will comply with applicable legal requirements.

 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act.

 

We are subject to anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (“FCPA”), which generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business as well as requiring companies and their intermediaries to maintain accurate books and records. In recent years there has been a substantial increase in anti-bribery law enforcement activity by the Department of Justice ("DOJ") and the SEC relating to certain countries in which we have business, including China. For example, in 2017, a U.S. based direct selling company announced that it was the target of an investigation being conducted by the SEC to determine whether certain activities related to the direct selling company's operations in China violated the FCPA. Also, in 2017, another U.S. based direct selling company announced that it had initiated a voluntary probe of its operations in China to determine if violations of the FCPA had occurred.

 

Our policies mandate compliance with anti-bribery laws by our employees and agents, including the requirements to maintain accurate information and internal controls. However, we may be liable for actions of our employees and agents, even if such actions are inconsistent with our policies. Being subject to an investigation by the DOJ or the SEC for an alleged violation of the FCPA could cause us to incur significant expenses and distractions that could adversely affect our business. Violations of the FCPA, or a similar anti-bribery law, may result in criminal or civil sanctions, including contract cancellations or debarment, and loss of reputation, which could have a material adverse effect on our results of operations and financial condition.

 

We do not have a comprehensive product liability insurance program and product liability claims could hurt our business.

 

Currently, we do not have a comprehensive product liability insurance program, although the insurance carried by our suppliers may cover certain product liability claims against us.  As a marketer of dietary supplements, cosmetics and other products that are ingested by consumers or applied to their bodies, we may become subjected to various product liability claims, including that:

 

 

our products contain contaminants or unsafe ingredients;

 

 

our products include inadequate instructions as to their uses; or

 

 

our products include inadequate warnings concerning side effects and interactions with other substances.

 

If our suppliers’ product liability insurance fails to cover product liability claims or other product liability claims, or any product liability claims exceeds the amount of coverage provided by such policies or if we are unsuccessful in any third-party claim against the manufacturer or if we are unsuccessful in collecting any judgment that may be recovered by us against the manufacturer, we could be required to pay substantial monetary damages which could materially harm our business, financial condition and results of operations. As a result, we may become required to pay high premiums and accept high deductibles in order to secure adequate insurance coverage in the future.  Especially since we do not have direct product liability insurance, it is possible that product liability claims and the resulting adverse publicity could negatively affect our business.

 

 

Intellectual Property, Information Technology and Cybersecurity Risks

 

We may be unable to protect or use our intellectual property rights.

 

We rely on trade secret, copyright and trademark laws and confidentiality agreements with employees and third parties, all of which offer only limited protection of our confidential information and trademarks.  Moreover, the laws of some countries in which we market our products, including China, may not afford effective protection of our intellectual property rights.  The unauthorized copying, use or other misappropriation of our confidential information, trademarks and other intellectual property could enable third parties to benefit from such property without paying us for it.  This could have a material adverse effect on our business, operating results and financial condition.  If we resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome, expensive and result in inadequate remedies.  It is also possible that our use of our intellectual property rights could be found to infringe on prior rights of others and, in that event, we could be compelled to stop or modify the infringing use, which could be burdensome and expensive.

 

We rely on and are subject to risks associated with our reliance upon information technology systems.

 

Our success is dependent on the accuracy, reliability, and proper use of information processing systems and management information technology.  Our information technology systems are designed and selected to facilitate order entry and customer billing, maintain member records, accurately track purchases and member compensation payments, manage accounting operations, generate reports, and provide customer service and technical support.  Any interruption in these systems could have a material adverse effect on our business, financial condition, and results of operations.

 

There can be no assurance that there will not be delays or interruptions in our information technology services.  An interruption or delay in availability of these services could, if it lasted long enough, prevent us from accepting orders, cause members to leave our business, or otherwise materially adversely affect our business.

 

System disruptions or failures, cybersecurity risks, and compromises of data could harm our business.

 

Because of our diverse geographic operations and our internationally applicable member compensation plans, our business is highly dependent on the secure and efficient functioning of our information technology systems, and the security of personal and sensitive business data. We collect certain personal information, including payment data, from members and consumers, as well as our employees. We also develop and maintain sensitive and proprietary business information. Any systems failure or interruption, breach in security, or loss of data, whatever the cause, could adversely affect our operations and financial results.

 

Systems disruptions and data breaches can derive from natural disasters, accidental technological events or human error, but can also result from fraud or malice on the part of external or internal parties.  Our systems, networks and software, like those of other companies, have been and are likely to continue to be, the target of cybersecurity threats and attacks, which may range from isolated or random attempts to sophisticated and targeted measures directed specifically at us. The risk of a systems disruption or data breach, particularly through cyber-attack or cyber intrusion, has increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. A material systems disruption or data breach affecting us could damage our reputation, deter members from purchasing our products, and result in cost and liability to us.

 

Although we have implemented technical and administrative safeguards to maintain the security and integrity of our information technology systems and data, there can be no assurance that our security efforts and measures will be effective in a continually evolving threat environment. In addition to the risks presented by malicious actors and natural disasters, many systems disruptions and data breaches are reportedly caused by human error. Therefore, despite our security policies and mandatory training, our systems and data are exposed to the risk that human error could either create a vulnerability that could be exploited by an attacker, or expose our systems and data to unintended risk of compromise. In addition, as described below, most of our information technology systems and data are hosted by third-party vendors over which we have limited control. We anticipate that we will be required to expend additional resources in order to continue to enhance our technical and administrative safeguards, and to investigate and remediate any vulnerabilities in our systems, networks and software. 

 

In any case, a data breach or other significant disruption of our information systems or those related to our third-party vendors, including as a result of cyber-attacks, could (1) disrupt the proper functioning of our systems and networks and therefore operations, (2) result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of personal, confidential, sensitive or otherwise valuable data or other information, (3) result in a violation of applicable privacy, cybersecurity, data breach notification requirements under applicable laws, regulations and contractual provisions, subjecting us to additional regulatory scrutiny, and exposing us to possible fines, lawsuits and related financial liability, (4) require significant management attention and financial resources to investigate and remedy the breach or disruption, and (5) harm our reputation, cause a decrease in the number of our members and revenue, and otherwise damage our business.  The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

 

Our systems, software and data reside on third-party servers, exposing us to risks that disruption or intrusion of those servers could temporarily or permanently interrupt our access and damage our business.

 

Most of our systems, software and data reside in the “cloud” on servers operated by third-party vendors to which we have limited access.  We assess the risks presented by these third-party vendors, and our contracts with them contain representations, warranties and other provisions related to the security of our data, and of the systems and software on which we rely. We are, however, limited in our ability to mitigate the risks of a systems disruption or data breach affecting our third-party vendors.  Moreover, any delay or failure in payment of the third-party vendors, disputes with such vendors, or business interruption or failure of the third-party vendors could result in loss of or interruption in access to our systems, software or data.  It is possible that our systems, software and data could in the future be moved to servers of different third parties or to our own servers.  Any such move could result in temporary or permanent loss of access to our systems, software or data.  Any protracted loss of such access would materially and adversely affect our business, financial condition and results of operations.

 

 

Common Stock Risks

 

Our common stock is particularly subject to volatility because of the industry and markets in which we operate.

 

The market prices of securities of direct selling companies have been extremely volatile, particularly those of companies that derive a substantial portion of their revenue from China and/or Hong Kong. These companies have experienced stock market price fluctuations that have often been disproportionate to their operating performance.  These broad fluctuations could adversely affect the market price of our common stock.

 

Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive.

 

The public market for our common stock has historically been very volatile experiencing wide fluctuations in trading volumes and prices. There are a number of factors that may contribute to this volatility, including the following:

 

 

active participation of speculative traders in our stock (including short sellers);

 

 

limited trading activity in our common stock;

 

 

the sale of a large number of shares of our common stock from time to time;

 

 

market rumors regarding our business operations;

 

 

government scrutiny of our business;

 

 

adverse publicity related to our business or industry; and

 

 

fluctuations in our operating results.

 

This market volatility for our stock may make it more difficult for holders of our stock to sell shares when they want and at prices they find attractive. There can be no assurance that a larger or more liquid market will be developed or maintained for our common stock.

 

 

Item 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

Item 2. PROPERTIES

 

In January 2019 we relocated our corporate headquarters from Rolling Hills Estates, California, to Hong Kong. We renewed our lease for 7,300 square feet of office space in Hong Kong in July 2020 with a term expiring in June 2023. In June 2020, we extended our lease for 4,900 square feet of office space in Rolling Hills Estates, California with a term now expiring in September 2030. To help further develop the market for our products in North America, we lease retail space in Rowland Heights, California; Richmond, British Columbia; and Metuchen, New Jersey.

 

We lease eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. We also lease a factory in Zhongshan, China. We contract with third parties for fulfillment and distribution operations in all of our international markets. We believe that our existing office space is in good condition, and is suitable and adequate for the conduct of our business.

 

Item 3. LEGAL PROCEEDINGS

 

None.

 

Item 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

Part II

 

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock is currently traded on the NASDAQ Capital Market (“Nasdaq”) under the symbol “NHTC.” On February 22, 2021, the closing price of our common stock as reported by Nasdaq was $7.04 per share.

 

At February 22, 2021, there were approximately 95 record holders of our common stock (although we believe that the number of beneficial owners of our common stock is substantially greater).

 

During 2021, the Company expects to pay a quarterly cash dividend of $0.20 on each share of common stock outstanding. However, any future cash dividends will be at the sole discretion of the Board of Directors, and will depend on the Company's results of operations, financial condition, capital requirements and other factors considered relevant by the Board of Directors.

 

Item 6. SELECTED FINANCIAL DATA

 

Not applicable under smaller reporting company disclosure rules.

 

 

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Business Overview

 

We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. We also operate in Russia and Kazakhstan through our engagement with a local service provider. See Note 12 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report for further information about our net sales by geographic area.

 

As of December 31, 2020, we were conducting business through 52,230 active members, compared to 57,410 in 2019. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. For further information regarding some of the risks associated with our loss of members, see “Item 1A. Risk Factors - Our recent loss of a significant number of members is adversely affecting our business…”.

 

We generate approximately 94% of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing 79% of net sales in the latest fiscal year. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular, regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and our potential inability to obtain necessary product registrations. We continually evaluate our operations for compliance with applicable laws and regulations, and this process can and has resulted in the identification of certain matters of potential noncompliance, which we work to satisfactorily address. For further information regarding some of the risks associated with the conduct of our business in China and Hong Kong, see “Item 1A. Risk Factors,” and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...”, “Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong….”, and “Risk Factors - Our business in China is subject to compliance with a myriad of applicable laws and regulations...”.

 

China has been and continues to be our most important business development project. We operate an e-commerce direct selling platform in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities require a direct selling license in China, which we do not currently hold. We previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that we withdraw our application. We understand that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. We applied to withdraw our application in November 2019, and the governmental authorities approved the withdrawal of our application shortly thereafter. In connection with the withdrawal of our application, we received a refund in March 2020 of a consumer protection fund deposit of CNY 20 million ($2.9 million) that we made upon the submission of our application. We expect to reapply for a direct selling license in China when we believe that circumstances are again ripe for doing so. If we are ultimately able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.

 

 

In January 2019, the Chinese government announced a 100-day campaign focused on companies involved in the sale of food, equipment, daily necessities, small home electrical appliances and services that are claimed to promote health. The Chinese government ministries in charge of this campaign indicated that they are targeting illegal practices in the industry, particularly the manufacture and sale of counterfeit and substandard products, and false advertising and misleading claims as to the health benefits of products and services. It is understood that the campaign is specifically focused on the business practices of direct selling companies. During the campaign, we understand that the government is not issuing any additional direct selling licenses, is not issuing certifications of quality or other approvals of various healthcare products, and is reviewing its regulatory oversight of the industry. Since it was implemented, the campaign and associated negative media coverage have had a significant adverse impact on our business, as consumers have widely curtailed their purchases within the affected industries. We, like some of our peers, voluntarily decided in January 2019 to temporarily suspend our member activities, such as product roadshows, product trainings and larger company-sponsored events, in China. We did this because we learned that the 100-day campaign was announced in broad outlines by the central government, and the interpretation and enforcement of the campaign was delegated to the provincial and local governments. We consider it a top priority for our business to develop an understanding of and cooperate with all levels and jurisdictions of the government agencies, and did not want to run the risk of being inadvertently entangled in government enforcement actions as the provincial and local governments formulate and implement their interpretive guidance and rule-making. Although we have recently been able to relax some restrictions on member activities in certain markets, it may again in the future be necessary or advisable to suspend member activities or take similar actions from time to time, and such periods of reduced activity may have a material adverse effect on our business.

 

Although the 100-day campaign was due to expire on or about April 18, 2019, we are not aware of any information indicating that the campaign has formally concluded. However, on August 27, 2019, the Chinese government announced that it would conduct a “look-back review” to evaluate the 100-day campaign. As part of this review, we understand that various Chinese governmental agencies formed a working group to assess the 100-day campaign, particularly focusing on the health market and its supervision in certain provinces. We understand that during September 2019 the working group evaluated the performance and results of a number of organizations and governmental departments in these provinces and made recommendations for various improvements. It was noted that each province had opened a number of investigative cases, had successfully closed numerous cases, and had imposed various fines and penalties. We understand that the look-back review continued after September 2019, and we are not aware that this review has been completed. As a result, the business environment in China for health product companies continues to be challenging, which has recently been exacerbated by negative social media sentiment expressed for these types of companies. We believe that the campaign, as well as its extension and aftermath (including the look-back review), will continue to negatively impact our business in China in the near-term, but will ultimately benefit us and Chinese consumers in the long-term as purveyors of substandard products are driven from the market.

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country. We have significant business in China and in 2020 generated approximately 79% of our revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China. The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-19, while the governments of other countries in which we operate are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but we have taken steps to adapt some of our marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. We also canceled both of our major member events planned for 2020, although some relatively small member events were held in the second half of the year. The severity of the impact on us of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which we are unable to accurately predict. Regardless, these disruptions have materially negatively impacted our financial results throughout 2020, and we expect that our financial results for the near-term may be adversely affected. For example, in February 2021 several coronavirus outbreaks caused the Chinese government to abruptly reintroduce restrictions on personal mobility and strongly discourage gathering and travel ahead of the Chinese New Year. These measures effectively lengthened the traditional holiday and reduced the number of working days in the first quarter of 2021, and may have a significant short-term effect on the level of our sales. The disruptions associated with the COVID-19 pandemic have also adversely affected the operations of some of our third-party logistics providers, and we expect that the future operations of these logistics providers and other third parties with whom we work may be adversely affected by these disruptions. We will continue to assess the operational and financial impact of the COVID-19 pandemic. See “Item 1A. Risk Factors - Epidemics, such as the COVID-19 pandemic, or natural disasters, terrorists attacks or acts of war…”.

 

Recent political and social developments in Hong Kong, along with the impact of the COVID-19 pandemic and related government control measures, are also adversely affecting our Hong Kong operations and recently led us to cease conducting member meetings and events in Hong Kong. Inasmuch as member meetings and events located in Hong Kong have in the past served as an important component of our product marketing and distribution efforts, we believe that this action has negatively affected our operations and financial performance. If current conditions continue or further deteriorate, we anticipate that our business, financial condition and results of operations will be adversely affected. See “Item 1A. Risk Factors - Our Hong Kong operations are being adversely affected by recent political and social developments in Hong Kong...”. 

 

 

Although the recently enacted tariffs and the trade disputes between the United States and China have not materially impacted our business to date, they may have negatively impacted the value of the Chinese yuan. For example, the value of the Chinese yuan relative to that of the U.S. dollar decreased during much of 2018 and 2019, which we believe negatively affected our Hong Kong revenues because the prices at which our Chinese members could purchase our products was effectively increased. In the event that political and trade tensions involving the United States, China and Hong Kong continue or intensify, our business could be negatively impacted in the future. For more information, see “Item 1A. Risk Factors,” and more specifically under the caption “Risk Factors - Changes in government trade and economic policies...”.

 

Our Hong Kong net sales (substantially all of which were derived from products shipped to members residing in China) for 2020 were substantially lower than 2019. The substantial decline in net sales during 2020 resulted in modest income from operations for the year, as well as modest positive operating cash flows. We anticipate that our financial performance for the near-term may continue to be adversely impacted.

 

Statement of Operations Presentation

 

We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recognized when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. We bill members for shipping charges and recognize the freight revenue in net sales. We have elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrue for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Event and training revenue is deferred and recognized as the event or training occurs.

 

Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.

 

Member commissions are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay commissions, although our Chinese members may participate in our compensation plan through our other subsidiaries. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:

 

 

through commissions paid on the accumulated bonus volume from product purchases made by their down-line members and customers; and

 

 

through retail profits on sales of products purchased by members at wholesale prices and resold at retail prices (for purchasers in some of our smaller markets and purchasers from our China subsidiary, sales are for personal consumption only and income may not be earned through retail profits).

 

Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases.

 

 

Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Members can also earn additional income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for fiscal 2020 and 2019 represented 42% and 46% of net sales, respectively. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. We may also enter into performance-based agreements for business or market development, which can result in additional compensation to specific members.

 

Selling, general and administrative expenses consist of administrative compensation and benefits, travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses (including stock-based compensation). In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions that are designed to increase both product awareness and member recruitment). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly. 

 

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar. 

 

Results of Operations

 

The following table sets forth our operating results as a percentage of net sales for the periods indicated:

 

   

Year Ended December 31,

 
   

2020

   

2019

 

Net sales

    100.0 %     100.0 %
Cost of sales     27.4       25.9  

Gross profit

    72.6       74.1  

Operating expenses:

               
Commissions expense     42.2       45.8  
Selling, general and administrative expenses     29.3       35.1  
Goodwill impairment           2.3  

Total operating expenses

    71.5       83.2  

Income (loss) from operations

    1.1       (9.1 )
Other income, net     1.3       1.8  

Income (loss) before income taxes

    2.4       (7.3 )
Income tax provision     1.0        

Net income (loss)

    1.4 %     (7.3 )%

 

 

Net Sales

 

The following table sets forth revenue by market for the periods indicated (in thousands):

 

   

Year Ended December 31,

 
   

2020

   

2019

 

Americas1

  $ 3,791       6.1 %   $ 5,431       7.0 %

Hong Kong2

    49,169       79.2       62,724       80.8  

China

    2,940       4.7       2,941       3.8  

Taiwan

    3,034       4.9       3,126       4.0  

South Korea

    280       0.5       368       0.5  

Japan

    260       0.4       180       0.2  

Singapore

    76       0.1       72       0.1  

Malaysia

    282       0.5       220       0.3  

Russia and Kazakhstan

    888       1.4       980       1.2  

Europe

    1,050       1.7       1,370       1.8  

India

    301       0.5       202       0.3  

Total

  $ 62,071       100.0 %   $ 77,614       100.0 %

 


1 United States, Canada, Mexico and Peru.

2 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

 

Net sales were $62.1 million for the year ended December 31, 2020 compared with $77.6 million a year ago, a decrease of $15.5 million, or 20%.  Hong Kong net sales, substantially all of which were derived from the sale of products shipped to members residing in China, decreased $13.6 million, or 22%, over the prior year. This decrease in Hong Kong net sales was mitigated by increased administrative fees of $2.3 million resulting from the modification of our fee structure associated with certain electronic (eWallet) accounts held by our Hong Kong members.  The overall decrease in our Hong Kong net sales primarily resulted from the impact of the COVID-19 pandemic in China, and the related powerful measures implemented by the Chinese government to control the virus, including the required closure of some businesses and restrictions on public gatherings and travel. We believe that the decrease in our net sales can also be attributed to the continuing impact of China’s 100-day campaign and the related look-back review. Due to both of these factors, the operating environment for our business in China remains restrictive.

 

Outside of our Hong Kong business, net sales decreased $2.0 million, or 13%, compared with the prior year, due primarily to the spread of COVID-19 and efforts to control it in a number of countries around the world.

 

As of December 31, 2020, deferred revenue was $3.1 million, which primarily consisted of $1.0 million in unshipped product orders and unredeemed product vouchers, as well as $2.0 million pertaining to auto ship advances.

 

Gross Profit

 

Gross profit was 72.6% of net sales for the year ended December 31, 2020 compared with 74.1% of net sales for the year ended December 31, 2019. The gross profit margin percentage decrease was primarily attributable to higher logistics costs and product promotions, partially offset by, as referenced above, the additional administrative fees recognized as revenue in 2020.

 

Commissions Expense

 

Commissions were 42.2% of net sales for the year ended December 31, 2020 compared with 45.8% of net sales for the year ended December 31, 2019. The decrease in commissions as a percentage of net sales largely resulted from lower estimated costs for on-going incentive programs during the current year, as well as the additional administrative fees recognized as revenue in 2020.

 

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $18.2 million for the year ended December 31, 2020 compared with $27.2 million for the year ended December 31, 2019. Selling, general and administrative expenses decreased by $9.0 million, or 33%, mainly due to lower employee-related expenses, professional fees, and event costs as we did not hold any major events in 2020 due to the COVID-19 pandemic.

 

Goodwill Impairment

 

An impairment charge of $1.8 million was recognized for the year ended December 31, 2019 due to the early adoption of Accounting Standards Update 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. Such impairment pertained to goodwill that arose from a merger transaction with MarketVision Communication Corp. in March 2004.

 

Income Taxes

 

An income tax provision of $647,000 was recognized for the year ended December 31, 2020 compared with $14,000 for the year ended December 31, 2019. The tax provision for 2020 includes an estimate for the Global Intangible Low-Taxed Income ("GILTI") inclusion, as well an income tax benefit of $512,000 from the carryback of net operating losses arising from the 2019 tax year under CARES Act enacted in March 2020 (described below under “– Critical Accounting Policies and Estimates – Income Taxes”), which were carried back in August 2020 to offset taxable income in tax year 2016. No GILTI inclusion was reflected in the 2019 tax provision due to losses in foreign jurisdictions.

 

Liquidity and Capital Resources

 

At December 31, 2020, our cash and cash equivalents totaled $92.4 million. Total cash and cash equivalents decreased by $3.7 million from December 31, 2019 to December 31, 2020, primarily due to cash dividends paid in 2020, offset by net cash provided by operating activities during the year and by the CNY 20 million ($2.9 million) refund received in March 2020 in connection with the withdrawal of our Chinese direct selling license application. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2020, we had $68.4 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $12.5 million held in banks located in China subject to foreign currency controls.

 

At December 31, 2020, the ratio of current assets to current liabilities was 4.64 to 1.00 and we had $78.2 million of working capital. Working capital as of December 31, 2020 decreased $3.8 million compared to our working capital as of December 31, 2019.

 

Cash provided by operations during 2020 was $1.9 million compared to $18.6 million cash used in operations during 2019. The improvement in operating cash flows resulted primarily from improved profitability during 2020 and a decrease in accrued commission payments.

 

Cash flows used in investing activities totaled $211,000 and $189,000 during 2020 and 2019, respectively.

 

 

Cash flows used in financing activities during 2020 included dividend payments of $0.20 per common share during each quarter of 2020, totaling an aggregate of $9.1 million. On February 8, 2021, the Board of Directors declared another quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 5, 2021 to stockholders of record on February 23, 2021. During 2021, we expect to continue paying a quarterly cash dividend of $0.20 on each share of common stock outstanding. However, any future cash dividends will be at the sole discretion of the Board of Directors, and will depend on our results of operations, financial condition, capital requirements and other factors considered relevant by the Board of Directors.

 

Cash flows used in financing activities during 2019 included the repurchase of common stock totaling $10.1 million and dividend payments totaling $7.3 million. On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady 2012 Irrevocable Trust (the “Broady Trust”) on a basis roughly proportional to his family’s ownership interest. During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs. On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with further purchases under the foregoing stock repurchase program. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs. During December 2019, the Company purchased a total of 97,785 shares of common stock for an aggregate purchase price of $552,000, plus transaction costs.

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and are made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of December 31, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.

 

We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently do not believe that will be necessary.

 

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia, India, South America and Europe. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a prospective China direct selling license application.

 

 

Quarterly Results of Operations (Unaudited)

 

The following table sets forth unaudited quarterly operating results for each of the last eight fiscal quarters. The information for each of these quarters has been prepared on the same basis as the audited annual financial statements included elsewhere in this annual report and, in the opinion of management, includes all adjustments, which includes only normal recurring adjustments, necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements and related notes included in “Item 8. Financial Statements and Supplementary Data” of this annual report. These quarterly operating results are not necessarily indicative of our operating results for any future period.

 

   

2020

   

2019

 
   

4th Quarter

   

3rd Quarter

   

2nd Quarter

   

1st Quarter

   

4th Quarter

   

3rd Quarter

   

2nd Quarter

   

1st Quarter

 

(In Thousands, Except Per Share Data)

Net sales

  $ 16,595     $ 14,124     $ 16,404     $ 14,948     $ 17,835     $ 17,023     $ 23,428     $ 19,328  

Gross profit

    12,571       10,489       11,587       10,434       12,733       12,652       18,021       14,104  

Income (loss) from operations

    1,266       668       183       (1,448 )     (3,246 )     (1,064 )     (4 )     (2,709 )

Net income (loss)

    747       635       34       (573 )     (2,842 )     (1,243 )     397       (1,923 )

Net income (loss) per common share:

                                                               

Basic

  $ 0.07     $ 0.06     $ 0.00     $ (0.05 )   $ (0.27 )   $ (0.12 )   $ 0.04     $ (0.17 )

Diluted

  $ 0.07     $ 0.06     $ 0.00     $ (0.05 )   $ (0.27 )   $ (0.12 )   $ 0.04     $ (0.17 )

 

Critical Accounting Policies and Estimates 

 

A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this report. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to member commissions and income taxes.

 

Revenue Recognition.  All revenue is recognized when the performance obligations under a contract, including product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product orders and unredeemed product vouchers are recorded as deferred revenue. Such amounts totaled $1.0 million and $2.4 million at December 31, 2020 and 2019, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.

 

Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $2.0 million at both December 31, 2020 and 2019.

 

 

Commissions Expense. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.

 

Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period. We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period. Any resulting change in total cost is recognized over the remaining qualification period. Long-term promotions and incentives (lasting up to one year) can, in particular, result in uncertain ultimate cost. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $3.5 million and $2.9 million at December 31, 2020 and 2019, respectively.

 

Income Taxes.  Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods. As of December 31, 2020, we do not have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. The Tax Act, enacted on December 22, 2017 by the U.S. government, required a one-time repatriation tax on certain un-repatriated earnings of foreign subsidiaries at a rate of 15.5% tax on post-1986 foreign earnings held in cash and an 8% rate on all other post-1986 earnings. Due to the adoption of a territorial tax regime, any foreign source portion of a qualified dividend received by a 10% U.S. corporate shareholder is exempt from U.S. federal tax, therefore resulting in any future repatriation having a minimal effect on our effective tax rate. For state income tax purposes, we will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. state corporate tax rate(s). As of December 31, 2020, we have not recorded a state deferred tax liability for earnings to be repatriated in the future because the portion of all earnings which are no longer deemed reinvested indefinitely as of December 31, 2020 have already been repatriated. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2020.

 

The U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted on March 27, 2020. The CARES Act was enacted to provide tax relief to companies impacted by the COVID-19 pandemic. In addition to other broad changes, the CARES Act allows for a 5-year carryback period for net operating losses arising in tax years beginning after 2017 and before 2021, effectively taking advantage of differences in tax rate as a result of enactment of the Tax Act. We booked a tax benefit of $512,000 during 2020 due to the net operating loss generated in the taxable year ended December 31, 2019.

 

We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate.

 

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable under smaller reporting company disclosure rules.

 

 

 

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

NATURAL HEALTH TRENDS CORP.

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

Page

 

 

Report of Independent Registered Public Accounting Firm

34

Consolidated Balance Sheets

35

Consolidated Statements of Operations

36

Consolidated Statements of Comprehensive Income (Loss)

37

Consolidated Statements of Stockholders’ Equity

38

Consolidated Statements of Cash Flows

39

Notes to Consolidated Financial Statements

40

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

  

To the Shareholders and Board of Directors of

Natural Health Trends Corp.

 

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Natural Health Trends Corp. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Commissions Expense and the Related Accrued Commissions

 

As described in Note 1 to the consolidated financial statements, the Company accrues weekly commissions when earned, and estimates and accrues all costs associated with certain incentives independent members may earn during a designated incentive period as the members meet the qualification requirements, which may range from several weeks to up to a year.  

 

The principal consideration for our determination that performing procedures related to commissions expense and the related accrued commissions is a critical audit matter is there was significant judgment by management in determining the amounts to accrue for each of its member compensation programs, which in turn, led to significant audit judgement, subjectivity, and effort in performing audit procedures and evaluating audit evidence related to these accounts.

 

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, (i) obtaining an understanding of the Company’s estimation process relating to commission-based member incentives; (ii) testing the Company’s information technology general controls, including internal controls over the algorithm used to compute  commissions expense; (iii) performing analytical procedures on commissions expense as it relates to net sales; and (iv) testing the mathematical accuracy of the schedule of commissions expense and related accrued commissions prepared by management.

 

 

/s/ Marcum LLP

Marcum LLP

 

We have served as the Company’s auditor since 2017.

 

Los Angeles, CA

February 26, 2021

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)

 

  

December 31,

 
  

2020

  

2019

 

ASSETS

        

Current assets:

        
Cash and cash equivalents $92,367  $96,035 
Inventories  3,779   6,404 
Other current assets  3,595   5,936 

Total current assets

  99,741   108,375 
Property and equipment, net  539   735 
Operating lease right-of-use assets  3,745   3,135 
Restricted cash  525   3,390 
Deferred tax asset  731   2,039 
Other assets  661   823 

Total assets

 $105,942  $118,497 

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        
Accounts payable $580  $680 
Income taxes payable  1,481   173 
Accrued commissions  3,496   2,931 
Other accrued expenses  1,922   2,387 
Deferred revenue  3,091   4,506 
Amounts held in eWallets  8,503   12,938 
Operating lease liabilities  1,163   1,655 
Other current liabilities  1,270   1,032 

Total current liabilities

  21,506   26,302 
Income taxes payable  13,748   15,365 
Deferred tax liability  216   202 
Operating lease liabilities  2,775   1,564 

Total liabilities

  38,245   43,433 

Commitments and contingencies (Note 8)

          

Stockholders’ equity:

        
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2020 and 2019  13   13 
Additional paid-in capital  86,102   86,102 
Retained earnings  7,822   16,117 
Accumulated other comprehensive loss  (336)  (1,264)
Treasury stock, at cost; 1,556,875 shares at December 31, 2020 and 2019  (25,904)  (25,904)

Total stockholders’ equity

  67,697   75,064 

Total liabilities and stockholders’ equity

 $105,942  $118,497 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

 

  

Year Ended December 31,

 
  

2020

  

2019

 
Net sales $62,071  $77,614 
Cost of sales  16,990   20,104 

Gross profit

  45,081   57,510 

Operating expenses:

        
Commissions expense  26,204   35,549 
Selling, general and administrative expenses  18,208   27,220 
Goodwill impairment     1,764 

Total operating expenses

  44,412   64,533 

Income (loss) from operations

  669   (7,023)
Other income, net  821   1,426 

Income (loss) before income taxes

  1,490   (5,597)
Income tax provision  647   14 

Net income (loss)

 $843  $(5,611)

Net income (loss) per common share:

        

Basic

 $0.08  $(0.52)

Diluted

 $0.07  $(0.52)

Weighted-average number of common shares outstanding:

        

Basic

  10,630   10,871 

Diluted

  11,424   10,871 

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In Thousands)

 

   

Year Ended December 31,

 
   

2020

   

2019

 

Net income (loss)

  $ 843     $ (5,611 )

Other comprehensive income (loss), net of tax:

               

Foreign currency translation adjustments

    920       (28 )

Unrealized gains on available-for-sale securities

    8       14  

Comprehensive income (loss)

  $ 1,771     $ (5,625 )

 

See accompanying notes to consolidated financial statements.

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In Thousands, Except Share Data)

 

  

Preferred Stock

  

Common Stock

  

Additional Paid-In

  

Retained

  

Accumulated Other Comprehensive

  

Treasury Stock

     
  

Shares

  

Amount

  

Shares

  

Amount

  

Capital

  

Earnings

  

Loss

  

Shares

  

Amount

  

Total

 

BALANCE, December 31, 2018

    $   12,979,414  $13  $86,415  $44,431  $(1,250)  (1,603,322) $(39,748) $89,861 

Net loss

                 (5,611)           (5,611)

Repurchase of common stock

                       (1,093,641)  (10,117)  (10,117)

Common stock issued

              (313)  (15,359)     1,140,088   23,961   8,289 

Dividends declared, $0.64/share

                 (7,344)           (7,344)

Foreign currency translation adjustments

                    (28)        (28)

Unrealized gains on available-for-sale securities

                    14         14 

BALANCE, December 31, 2019

        12,979,414   13   86,102   16,117   (1,264)  (1,556,875)  (25,904)  75,064 

Net income

                 843            843 

Dividends declared, $0.80/share

                 (9,138)           (9,138)

Foreign currency translation adjustments

                    920         920 

Unrealized gains on available-for-sale securities

                    8         8 

BALANCE, December 31, 2020

    $   12,979,414  $13  $86,102  $7,822  $(336)  (1,556,875) $(25,904) $67,697 

 

See accompanying notes to consolidated financial statements. 

 

 

 

NATURAL HEALTH TRENDS CORP.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

 

   

Year Ended December 31,

 
   

2020

   

2019

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               
Net income (loss)   $ 843     $ (5,611 )

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

               
Depreciation and amortization     410       387  
Noncash lease expense     1,532       1,760  
Deferred income taxes     1,339       (820 )
Goodwill impairment           1,764  

Changes in assets and liabilities:

               
Inventories     2,700       5,820  
Other current assets     2,322       (554 )
Other assets     181        
Accounts payable     (102 )     (953 )
Income taxes payable     (311 )     (1,731 )
Accrued commissions     566       (9,598 )
Other accrued expenses     (471 )     (2,797 )
Deferred revenue     (1,433 )     (2,315 )
Amounts held in eWallets     (4,491 )     (1,742 )
Operating lease liabilities     (1,427 )     (1,807 )
Other current liabilities     227       (108 )
Long-term incentive           (333 )

Net cash provided by (used in) operating activities

    1,885       (18,638 )

CASH FLOWS FROM INVESTING ACTIVITIES:

               
Purchases of property and equipment     (211 )     (189 )

Net cash used in investing activities

    (211 )     (189 )

CASH FLOWS FROM FINANCING ACTIVITIES:

               
Repurchase of common stock           (10,117 )
Dividends paid     (9,138 )     (7,344 )

Net cash used in financing activities

    (9,138 )     (17,461 )
Effect of exchange rates on cash, cash equivalents and restricted cash     931       62  

Net decrease in cash, cash equivalents and restricted cash

    (6,533 )     (36,226 )
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period     99,425       135,651  

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period

  $ 92,892     $ 99,425  

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:

               

Cash paid (refunded) for income taxes, net

  $ (2,097 )   $ 1,985  

Issuance of treasury stock for employee awards, net

  $     $ 8,289  

Right-of-use assets obtained in exchange for operating lease liabilities

  $ 2,747     $ 5,082  

 

See accompanying notes to consolidated financial statements.

 

 

NATURAL HEALTH TRENDS CORP.

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current liabilities occurred.

 

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2020 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

 

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in  March 2020 in connection with the withdrawal of its application. In November 2019, the Company funded a similar bank deposit account in the amount of VND 10 million ($433,000 and $432,000 at December 31, 2020 and 2019, respectively) for purposes of submitting a direct selling license application in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $410,000 and $387,000 during 2020 and 2019, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

 

Goodwill

 

During the fourth quarter of 2019, the Company elected to early adopt the guidance of Accounting Standards Update ("ASU") 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The Company estimated fair value based on market capitalization after considering recent trends in its stock price. Upon comparing such fair value with its carrying amount, the Company recognized an impairment loss of $1.8 million in December 2019.

 

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

 

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $335,000 and $355,000 was recognized during 2020 and 2019, respectively.

 

 

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

 

Net Income (Loss) Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country.   The Company has significant business in China and in 2020 generated approximately 79% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China.  The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-19, while the governments of other countries in which the Company operates are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company also canceled both of its major member events planned for 2020, although some relatively small member events were held in the second half of the year. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU was effective for interim and annual periods beginning after December 15, 2019, and early adoption was permitted.  The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods.  It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU was effective for interim and annual periods beginning after December 15, 2020, and early adoption was permitted.  The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company's consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

 

 

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 10% of sales. Sales returns were 1% and 2% of sales for 2020 and 2019, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the year ended December 31, 2020 is primarily due to a decrease of $1.4 million in unshipped product orders and unredeemed product vouchers. See Note 4 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 12 for additional information.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

 

 

3.     NET INCOME (LOSS) PER COMMON SHARE

 

The following table illustrates the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):

 

  

Year Ended December 31,

 
  

2020

  

2019

 
  

Income

  

Shares

  

Per Share

  

Loss

  

Shares

  

Per Share

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $843   10,630  $0.08  $(5,611)  10,871  $(0.52)

Effect of dilutive securities:

                        

Non-vested restricted stock

     794               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $843   11,424  $0.07  $(5,611)  10,871  $(0.52)

 

In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 459,654 shares were not included for the year ended  December 31, 2019.

 

 

 

4.     BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Cash and cash equivalents:

        
Cash $23,977  $13,720 
Cash equivalents  68,390   82,315 
   92,367   96,035 
Restricted cash  525   3,390 
  $92,892  $99,425 
         

Inventories:

        
Finished goods $3,071  $6,142 
Raw materials  1,047   1,249 
Reserve for obsolescence  (339)  (987)
  $3,779  $6,404 

Property and equipment:

        
Office equipment $449  $578 
Office software  1,001   1,037 
Machinery  30   28 
Furniture and fixtures  254   327 
Leasehold improvements  839   1,001 
Construction in progress  41    

Property and equipment, at cost

  2,614   2,971 
Accumulated depreciation and amortization  (2,075)  (2,236)
  $539  $735 

Other accrued expenses:

        
Sales returns $189  $373 
Employee-related expense  1,149   1,258 
Warehousing, inventory-related and other  584   756 
  $1,922  $2,387 

Deferred revenue:

        
Unshipped product and unredeemed product vouchers $1,005  $2,390 
Auto ship advances  1,977   1,985 
Other  109   131 
  $3,091  $4,506 

 

As of December 31, 2020, cash and cash equivalents include $12.5 million held in banks located within China subject to foreign currency controls.

 

 

 

5.     FAIR VALUE MEASUREMENTS

 

Investments by category included in cash equivalents at the end of each period were as follows (in thousands):

 

    

December 31, 2020

  

December 31, 2019

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $21,042  $  $21,042  $11,659  $  $11,659 

Time deposits

 

Level 2

  5,458      5,458   13,544      13,544 

Municipal debt securities

 

Level 2

  30,280   (5)  30,275   347      347 

Corporate debt securities

 

Level 2

  11,621   (6)  11,615   56,784   (19)  56,765 

Total investments

   $68,401  $(11) $68,390  $82,334  $(19) $82,315 

 


1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

 

6.     LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030. Effective  July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through  June 2023. To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third-party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost were as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Operating leases

 $1,716  $2,024 

Short-term leases

  299   284 

Total lease cost

 $2,015  $2,308 

 

Cash paid for amounts included in the measurement of operating leases liabilities was $1.6 million and $2.0 million for 2020 and 2019, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of December 31, 2020 were as follows:

 

Weighted-average remaining lease term (in years)

  5.5 

Weighted-average discount rate

  3.4%

 

As most of the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of December 31, 2020 were as follows (in thousands):

 

2021

 $1,184 

2022

  1,081 

2023

  583 

2024

  261 

2025

  261 

Thereafter

  990 

Total lease payments

 $4,360 

Less: imputed interest

  (422)

Present value of lease liabilities

 $3,938 

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

 

 

7.     INCOME TAXES

 

The components of income (loss) before income taxes consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Domestic

 $(1,663) $(4,917)

Foreign

  3,153   (680)

Income (loss) before income taxes

 $1,490  $(5,597)

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Current taxes:

        

Federal

 $(512) $399 

State

  1   33 

Foreign

  626   398 

Total current taxes

  115   830 
         
Deferred taxes:        
Federal  346   (381)
State  6   (47)
Foreign  180   (388)
Total deferred taxes  532   (816)

Income tax provision

 $647  $14 

 

A reconciliation of the reported income tax provision to the provision (benefit) that would result from applying the domestic federal statutory tax rate to pretax income (loss) is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Income tax at federal statutory rate

 $313  $(1,175)

Effect of permanent differences

  121   260 

Global Intangible Low-Taxed Income

  555   364 

Change in valuation allowance

  51   106 

Foreign rate differential

  72   13 

Foreign tax credits

  (98)  10 
Stock-based compensation  164   98 
Net operating loss carryback  (512)   

Goodwill impairment

     375 

Other reconciling items

  (19)  (37)

Income tax provision

 $647  $14 

 

Income (loss) before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):

 

      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2020

  

2019

 

Cayman Islands

  % $2,589  $(2,746)

Hong Kong

  16.5%  267   3,441 

China

  25.0%  716   (1,644)

 

 

Deferred income taxes consist of the following (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Deferred tax assets:

        
Net operating losses $628  $1,477 
Stock-based compensation  510   925 
Operating lease liabilities  460   335 
Other  60   73 

Total deferred tax assets

  1,658   2,810 
Valuation allowance  (340)  (289)

Net deferred tax assets

  1,318   2,521 

Deferred tax liabilities:

        
Operating lease assets  (438)  (313)
Foreign deferreds  (216)  (202)
Prepaids  (113)  (109)
Other  (36)  (60)

Total deferred tax liabilities

  (803)  (684)

Net deferred tax assets

 $515  $1,837 

 

The effective income tax rate for the year ended December 31, 2020 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on  March 27, 2020. The CARES Act makes broad changes to the Internal Revenue Code of 1986, as amended, including, but not limited to, the ability to carry net operating losses generated in tax years 2018, 2019 or 2020 back to the each of the five tax years preceding the tax year of such loss.  The effective income tax rate for the year ended December 31, 2019 was impacted by permanent differences including a true-up of the GILTI provision for the tax year ended December 31, 2018 and goodwill impairment for the year ended December 31, 2019.

 

As of December 31, 2020, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of December 31, 2020, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of December 31, 2020, the Company no longer has U.S. federal net operating losses due to its filing in  August 2020 to carry back $3.6 million of losses generated in the tax year ended  December 31, 2019 to offset taxable income from the tax year ended  December 31, 2016The Company has U.S. state net operating loss carryforwards of $3.5 million that begin expiring in 2039. At December 31, 2020, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of December 31, 2020, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of December 31, 2020 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2020.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. The audit was expanded to include the 2017 and 2018 tax years, and a request has been submitted to also include the 2019 tax year. For purposes of this audit, fiscal years since 2007 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2016.

 

 

 
 
8.     COMMITMENTS AND CONTINGENCIES

 

On  January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. On  May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On  June 3, 2019, lead plaintiff filed an amended complaint. On  January 17, 2020, after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On  February 14, 2020, plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On  April 9, 2020, plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.

 

The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

 

The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

 

 

9.     STOCKHOLDERS’ EQUITY

 

Authorized Shares

 

The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each quarter of 2020, totaling an aggregate of $9.1 million. The following table summarizes the Company’s cash dividend activity during 2019 (in thousands, except per share data):

 

Declaration Date

 

Per Common Share

  

Amount

 

Payment Date

October 29, 2019 (special)

 $0.40  $4,608 

November 29, 2019

January 27, 2019 (special)

  0.08   912 

March 15, 2019

January 27, 2019

  0.16   1,824 

March 15, 2019

  $0.64  $7,344  

 

Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

 

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady 2012 Irrevocable Trust (the “Broady Trust”) on a basis roughly proportional to his family’s ownership interest in the Company (See Note 10). During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, were completed May 31, 2019 and resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

 

On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs. During December 2019, the Company purchased a total of 97,785 shares of common stock for an aggregate purchase price of $552,000, plus transaction costs.

 

As of December 31, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At December 31, 2020, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of an employee’s termination of service to the Company under specified circumstances.

 

On August 9, 2019, the Compensation ‎Committee amended the 2014 Long-Term Incentive Plan (the "LTI Plan") to provide that all then unpaid cash benefits earned by currently employed ‎participants under the LTI Plan with respect to performance periods that concluded on or prior to December 31, 2018 ‎shall be paid in the form of an award of shares of restricted stock under the 2016 ‎Plan. Accordingly, on August 9, 2019, the Company awarded 1,117,485 shares of restricted common stock to ‎certain of its employees (subject to quarterly vesting for the three-year period following the date of award) in lieu of ‎aggregate unpaid cash benefits of $7.9 million earned under the LTI Plan for performance periods ending on or ‎prior to December 31, 2018.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2018

  45,486  $21.61 

Granted

  1,140,088   7.27 

Vested

  (227,892)  9.84 

Nonvested at December 31, 2019

  957,682   7.34 
Vested  (391,410)  7.53 
Nonvested at December 31, 2020  566,272   7.21 

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for 2020 were as follows (in thousands):

 

  

Foreign Currency Translation Adjustments

  

Unrealized Gains (Losses) on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2019

 $(1,245) $(19) $(1,264)

Other comprehensive income

  920   8   928 

Balance, December 31, 2020

 $(325) $(11) $(336)

 

 

 

 

10.     RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing.  The Company recognized royalties of $83,000 and $96,000 during 2020 and 2019, respectively, under this agreement.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. An amendment to the agreement effective March 20, 2020 extends the term of the agreement for an additional five years to March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the first quarter of 2019Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

 

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in the open market as part of the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note 9.

 

 

11.     EMPLOYEE BENEFIT PLANS

 

     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2020 and 2019, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $68,000 and $85,000 for 2020 and 2019, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

 

 

12.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.

 

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales:

        
Primary Reporting Segment $58,243  $73,693 
China  2,940   2,941 
Russia and Kazakhstan  888   980 

Total net sales

 $62,071  $77,614 
         

Income (loss) from operations:

        
Primary Reporting Segment $9,277  $9,339 
China  330   (1,719)
Russia and Kazakhstan  (96)  (115)

Total income (loss) from operations for reportable segments

  9,511   7,505 
Unallocated corporate expenses  (8,842)  (14,528)
Other income, net  821   1,426 

Income (loss) before income taxes

 $1,490  $(5,597)

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales from external customers:

        

United States

 $1,573  $2,003 

Canada

  765   1,048 

Peru

  1,453   2,380 

Hong Kong1

  49,169   62,724 

China

  2,940   2,941 

Taiwan

  3,034   3,126 

Russia and Kazakhstan

  888   980 

Europe

  1,050   1,370 

Other foreign countries

  1,199   1,042 

Total net sales

 $62,071  $77,614 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales by product and service:

        

Product sales

 $55,840  $73,048 

Administrative fees, freight and other

  6,991   6,106 

Less: sales returns

  (760)  (1,540)

Total net sales

 $62,071  $77,614 

 

During June 2020, the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue in 2020. Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

 

 

The Company’s long-lived assets by geographic area are as follows (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Long-lived assets:

        

United States

 $227  $379 

Hong Kong

  146   135 

China

  47   57 

Other foreign countries

  119   164 

Total long-lived assets

 $539  $735 

 

 

13.     SUBSEQUENT EVENT

 

On February 8, 2021, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 5, 2021 to stockholders of record on February 23, 2021. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

 

 

Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

Not applicable.

 

Item 9A. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of December 31, 2020. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation and as disclosed in “Management’s Annual Report on Internal Control over Financial Reporting” below, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2020.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

 

pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

 

 

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

 Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management evaluates the effectiveness of our internal control over financial reporting by using the criteria established in Internal Control – Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).  Based on this criteria, management concluded that our internal control over financial reporting as of December 31, 2020 was effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

 

Item 9B. OTHER INFORMATION

 

None.

 

 

Part III 

 

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2020.

 

Item 11. EXECUTIVE COMPENSATION

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2020.

 

Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2020.

 

Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2020.

 

Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this Item is incorporated by reference from the definitive proxy statement to be filed with the SEC within 120 days after December 31, 2020.

 

 

 

Part IV

 

Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

Documents filed as part of this Form 10-K:

 

1.

Financial Statements. See Index to Consolidated Financial Statements under “Item 8. Financial Statements and Supplementary Data” of this report.

2.

Financial Statement Schedules. Financial statement schedules have been omitted because they are not required, not applicable, or because the required information is shown in the financial statements or notes thereto.

3.

Exhibits. The exhibits listed on the accompanying Exhibit Index are filed as a part of, and are incorporated by reference into, this report. We will furnish any of the exhibits referenced in the accompanying Exhibit Index to a requesting shareholder upon payment of a fee equal to our reasonable expenses in furnishing such exhibit(s).

 

EXHIBIT INDEX

 

Exhibit

Number

 

 

Exhibit Description

3.1

 

Certificate of Incorporation of Natural Health Trends Corp. dated March 21, 2005, and Certificate of Amendment to the Certificate of Incorporation dated May 15, 2020 (incorporated by reference to Exhibit 3.1 to Quarterly Report on Form 10-Q filed on August 5, 2020).

3.2

 

Second Amended and Restated Bylaws of Natural Health Trends Corp. effective February 6, 2020 (incorporated by reference to Exhibit 3.2 to Annual Report on Form 10-K filed on March 9, 2020).

4.1

 

Specimen Certificate for shares of common stock, $.001 par value per share, of Natural Health Trends Corp. (incorporated by reference to Exhibit 4.01 to Annual Report on Form 10-K filed on May 8, 2006).

4.2

 

Description of Securities (incorporated by reference to Exhibit 4.2 to Annual Report on Form 10-K filed on March 9, 2020).

+10.1

 

Natural Health Trends Corp. 2016 Equity Incentive Plan (incorporated by reference to Appendix C to Definitive Proxy Statement filed on March 4, 2016).

+10.2

 

First Amendment to the Natural Health Trends Corp. 2016 Equity Incentive Plan dated October 10, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed October 11, 2019).

+10.3

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Annual Report on Form 10-K filed March 4, 2016).

+10.4

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (Exempt Award to “U.S. Person” Under Regulation D) (incorporated by reference to Exhibit 10.4 to Annual Report on Form 10-K filed on March 9, 2020).

+10.5

 

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (Exempt Award to “Non-U.S. Person” Under Regulation S) (incorporated by reference to Exhibit 10.5 to Annual Report on Form 10-K filed on March 9, 2020).

+10.6

 

Natural Health Trends Corp. Annual Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix A to Definitive Proxy Statement filed on March 4, 2016).

+10.7

 

Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Appendix B to Definitive Proxy Statement filed on March 4, 2016).

+10.8

 

First Amendment to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) (incorporated by reference to Exhibit 10.5 to Annual Report on Form 10-K filed on March 10, 2017).

+10.9

 

Second Amendment to the Natural Health Trends Corp. 2014 Long-Term Incentive Plan (Restated as of January 1, 2016) dated August 9, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed August 13, 2019).

+10.10

 

Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Chris T. Sharng, dated April 23, 2007 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2007).

+10.11

 

Employment Agreement (including form of Non-Competition and Proprietary Rights Assignment Agreement) for Timothy S. Davidson dated April 23, 2007 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed on April 26, 2007).

+10.12

 

Form of Indemnification Agreement dated February 11, 2015, between Natural Health Trends Corp. and each of its directors and executive officers (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on February 12, 2015).

21.1

 

Subsidiaries of Natural Health Trends Corp. (filed herewith).

24.1

 

Power of Attorney (see signature page).

31.1

 

Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2

 

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1

 

Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

 

 

 

101.INS

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL   Inline XBRL Taxonomy Extension Calculation
101.DEF   Inline XBRL Taxonomy Extension Definition
101.LAB   Inline XBRL Taxonomy Extension Labels
101.PRE   Inline XBRL Taxonomy Extension Presentation
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
     
    + Management contract or compensatory plan

 

Item 16. FORM 10-K SUMMARY

 

None.

 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

  

 

NATURAL HEALTH TRENDS CORP.

 

 

 

Date: February 26, 2021

/s/ Chris T. Sharng

 

Chris T. Sharng

 

President

 

(Principal Executive Officer)

 

POWER OF ATTORNEY

 

KNOW ALL MEN BY THESE PRESENTS that each of Natural Health Trends Corp., a Delaware corporation, and the undersigned directors and officers of Natural Health Trends Corp., hereby constitutes and appoints Chris T. Sharng and Timothy S. Davidson, or any one of them, its, his or her true and lawful attorney-in-fact and agent, for it, him or her and in its, his or her name, place and stead, in any and all capacities, with full power to act alone, to sign any and all amendments to this report, and to file each such amendment to the report, with all exhibits thereto, and any and all other documents in connection therewith, with the Securities and Exchange Commission, hereby granting unto said attorney-in-fact and agent full power and authority to do and perform any and all acts and things requisite and necessary to be done in and about the premises as fully to all intents and purposes as it, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Chris T. Sharng

 

President and Director

 

February 26, 2021

Chris T. Sharng

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Timothy S. Davidson

 

Senior Vice President and Chief Financial Officer

 

February 26, 2021

Timothy S. Davidson

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Randall A. Mason

 

Chairman of the Board and Director

 

February 26, 2021

Randall A. Mason

 

 

 

 

 

 

 

 

 

/s/ George K. Broady

 

Director

 

February 26, 2021

George K. Broady

 

 

 

 

 

 

 

 

 

/s/ Yiu T. Chan

 

Director

 

February 26, 2021

Yiu T. Chan

 

 

 

 

 

 

 

 

 

/s/ Ching C. Wong

 

Director

 

February 26, 2021

Ching C. Wong

 

 

 

 

 

 

59
EX-21.1 2 ex_207026.htm EXHIBIT 21.1 ex_207026.htm

Exhibit 21.1

  

SUBSIDIARIES OF THE REGISTRANT

AS OF DECEMBER 31, 2020

 

NATURAL HEALTH TRENDS CORP.

A DELAWARE CORPORATION

 

 

Name

 

Jurisdiction

 

 

 

NHT Global, Inc.

 

United States (Delaware)

NHTC International, LLC

 

United States (Delaware)

NHT Global (Canada) Company 

 

Canada

NHTC Holding Company

 

Cayman Islands

NHTC Trading Company

 

Cayman Islands

NHT Global Taiwan Company

 

Cayman Islands

NHT Global CIS Company

 

Cayman Islands

NHT Global (China) Commodities Co., Ltd.

 

China

NHT Global (Zhongshan) Cosmetics Co., Ltd.

 

China

NHT Global Hong Kong Limited

 

Hong Kong

Natural Health Trends Japan, Inc.

 

Japan

NHTC Global Singapore Pte. Ltd.

 

Singapore

NHTC Wellness Products Malaysia Sdn. Bhd.

 

Malaysia

NHTK Ltd.

 

South Korea

NHT Global Europe S.R.L.

 

Italy

NHT Global Peru S.A.C.

 

Peru

Natural Health Trends (Thailand) Ltd.

 

Thailand

NHT Global Limited Company

 

Vietnam

PT Natural Health Trends Indonesia

 

Indonesia

NHTC (India) Private Limited

 

India

NHTGLOBAL BOLIVIA S.R.L.

 

Bolivia

 

The names of omitted subsidiaries when considered in the aggregate as a single subsidiary do not constitute a significant subsidiary as of the end of the year covered by this report.

 

 

 

 
EX-31.1 3 ex_207027.htm EXHIBIT 31.1 ex_207027.htm

Exhibit 31.1

 

CERTIFICATION

 

I, Chris T. Sharng, certify that:

 

1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
       

Date: February 26, 2021

 

/s/ Chris T. Sharng

 

 

 

Chris T. Sharng

 

 

 

President

 

 

 

(Principal Executive Officer)

 

 

 

 
EX-31.2 4 ex_207028.htm EXHIBIT 31.2 ex_207028.htm

Exhibit 31.2

 

CERTIFICATION

 

I, Timothy S. Davidson, certify that:

 

1.     I have reviewed this report on Form 10-K of Natural Health Trends Corp.;

 

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.      The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.     The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 
       

Date: February 26, 2021

 

/s/ Timothy S. Davidson

 

 

 

Timothy S. Davidson

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

 

 

 
EX-32.1 5 ex_207029.htm EXHIBIT 32.1 ex_207029.htm

Exhibit 32.1

 

 

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Natural Health Trends Corp. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

1.        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

 
       

Date: February 26, 2021

 

/s/ Chris T. Sharng

 

 

 

Chris T. Sharng

 

 

 

President

 

 

 

(Principal Executive Officer)

 

 

 

 
       

Date: February 26, 2021

 

/s/ Timothy S. Davidson

 

 

 

Timothy S. Davidson

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

  

The foregoing certifications are not deemed filed with the United States Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 

 

 
EX-101.SCH 6 nhtc-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 2 - Revenue link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 3 - Net Income (Loss) Per Common Share link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 4 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 6 - Leases link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 7 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 9 - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 10 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 11 - Employee Benefit Plans link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 12 - Segment Information link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 13 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 4 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 6 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 7 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 9 - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 12 - Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 2 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 6 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 6 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 7 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 9 - Stockholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 9 - Stockholders' Equity - Dividend Activity (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 9 - Stockholders' Equity - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 10 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 11 - Employee Benefit Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 12 - Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 12 - Segment Information - Operating Information by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 12 - Segment Information - Net Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 12 - Segment Information - Net Sales by Product and Service (Details) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 12 - Segment Information - Long-lived Assets (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 13 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 nhtc-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 nhtc-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 nhtc-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Net Income (Loss) Per Common Share Income tax at federal statutory rate Note 4 - Balance Sheet Components Note 5 - Fair Value Measurements Note 6 - Leases Note 7 - Income Taxes Note 9 - Stockholders' Equity Note 12 - Segment Information Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Income Tax Disclosure [Text Block] Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Unrealized gains on available-for-sale securities Note 5 - Fair Value Measurements - Investments (Details) Note 6 - Leases - Lease Cost (Details) Note 6 - Leases - Maturity of Lease Liabilities (Details) Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Note 7 - Income Taxes - Foreign Rate Differentials (Details) Note 7 - Income Taxes - Deferred Income Taxes (Details) Other current liabilities Note 9 - Stockholders' Equity - Dividend Activity (Details) Note 9 - Stockholders' Equity - Restricted Stock Activity (Details) Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Note 12 - Segment Information - Operating Information by Geographic Area (Details) Note 12 - Segment Information - Net Sales by Geographic Area (Details) Note 12 - Segment Information - Net Sales by Product and Service (Details) Note 12 - Segment Information - Long-lived Assets (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Granted, wtd. avg. price (in dollars per share) Vested, wtd. avg. price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Nonvested balance, wtd. avg. price (in dollars per share) Nonvested balance, wtd. avg. price (in dollars per share) Foreign currency translation adjustments us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Nonvested at December 31, 2018 (in shares) Nonvested at December 31, 2019 (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested (in shares) Corporate Debt Securities [Member] Nonvested Restricted Stock Shares Activity [Table Text Block] Deferred revenue us-gaap_AccruedLiabilitiesCurrent Accrued Liabilities, Current, Total Income taxes payable Lessee, Operating Leases [Text Block] Accounts payable Employee-related expense Other accrued expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Accrued commissions us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Issuance of treasury stock for employee awards, net us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Non-vested restricted stock (in shares) SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Cash paid (refunded) for income taxes, net Product and Service, Other [Member] Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Product [Member] us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Property and equipment: Net income (loss) available to common stockholders Net income (loss) available to common stockholders plus assumed conversions Non-vested restricted stock Deferred tax asset Business Description and Basis of Presentation [Text Block] Award Type [Domain] us-gaap_RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents, Total Award Type [Axis] Net income (loss) Net income (loss) Restricted Stock [Member] Antidilutive Securities [Axis] Office software Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Property, Plant and Equipment, Net, Ending Balance Bank Time Deposits [Member] us-gaap_PropertyPlantAndEquipmentGross Property and equipment, at cost Machinery Furniture and fixtures Construction in progress Leasehold improvements us-gaap_Dividends Dividends declared CASH FLOWS FROM INVESTING ACTIVITIES: Fair value Long-term incentive Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty Related Party Transaction, Other Revenues from Transactions with Related Party Income taxes payable us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Intersegment Eliminations [Member] CANADA Related Party Transactions Disclosure [Text Block] us-gaap_IncreaseDecreaseInAccruedLiabilities Other accrued expenses Income tax provision Income tax provision CHINA us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_OperatingExpenses Total operating expenses us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match Cash Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Other current liabilities UNITED KINGDOM us-gaap_RoyaltyExpense Royalty Expense Amendment Flag HONG KONG Other comprehensive income (loss), net of tax: us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income (loss) City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_TreasuryStockSharesAcquired Treasury Stock, Shares, Acquired (in shares) Repurchase of common stock (in shares) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue us-gaap_SharesOutstanding BALANCE (in shares) BALANCE (in shares) Preferred stock, outstanding (in shares) Current Fiscal Year End Date us-gaap_LeaseCost Total lease cost Weighted-average discount rate Document Fiscal Period Focus Operating leases Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term leases Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF Weighted-average remaining lease term (in years) (Year) Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Public Float Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers us-gaap_DividendsCommonStock Dividends, Common Stock, Total Entity Well-known Seasoned Issuer Goodwill impairment Goodwill, Impairment Loss us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key us-gaap_DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction, Total Administrative Fees, Freight and Other [Member] Information related to administrative fees, freight and other. Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One us-gaap_TreasuryStockValueAcquiredCostMethod Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock Entity Address, City or Town Geographic Concentration Risk [Member] Entity Address, Country Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_TreasuryStockValue Treasury stock, at cost; 1,556,875 shares at December 31, 2020 and 2019 PERU Entity Common Stock, Shares Outstanding Municipal Bonds [Member] us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Investments [Domain] Revenue from Contract with Customer Benchmark [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Investment Type [Axis] Local Phone Number us-gaap_TableTextBlock Notes Tables us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross Related Party [Axis] Related Party [Domain] us-gaap_AreaOfLand Area of Land (Square Foot) Selling, general and administrative expenses Commissions expense TAIWAN, PROVINCE OF CHINA us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Retained earnings VIET NAM Accumulated other comprehensive loss Money Market Funds [Member] Changes in assets and liabilities: Cash and cash equivalents: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Commissions, Policy [Policy Text Block] Subsequent Event [Member] us-gaap_OperatingLeaseLiabilityNoncurrent Operating lease liabilities Restricted cash Present value of lease liabilities Subsequent Event Type [Axis] Operating lease liabilities us-gaap_ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized Subsequent Event Type [Domain] Retirement Benefits [Text Block] Subsequent Events [Text Block] Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: imputed interest us-gaap_DeferredIncomeTaxExpenseBenefit Total deferred taxes 2023 2024 2025 Thereafter Fair Value of Financial Instruments, Policy [Policy Text Block] 2021 2022 Foreign Currency Transactions and Translations Policy [Policy Text Block] Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other assets Earnings Per Share, Policy [Policy Text Block] Operating expenses: us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage Income Tax, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Depreciation and amortization Office Equipment, Office Software and Capitalized Internal-use Software Development [Member] Represents office equipment, office software and capitalized internal-use software development. us-gaap_AssetsCurrent Total current assets nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day) Represents period to receive cash proceeds from credit card processors for cash and cash equivalents. nhtc_RestrictedCashCollateralRequirementPercentage Restricted Cash, Collateral Requirement Percentage Represents collateral requirement percentage of restricted cash. Stockholders' Equity Note Disclosure [Text Block] Amounts Held in Distributor EWallets [Policy Text Block] Represents the policy of amounts held in customer eWallets. Treasury stock, shares (in shares) Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2020 and 2019 Office equipment Represents other equipment. Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Common stock, authorized (in shares) Common Stock, Shares Authorized (in shares) Common stock, issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Effect of permanent differences Effect of permanent differences. us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total Valuation allowance Statistical Measurement [Domain] us-gaap_OperatingLeasePayments Operating Lease, Payments Maximum [Member] Net operating loss carryback The amount of income tax expense or benefit for the period computed by applying the net operating loss carryforward. Minimum [Member] Ownership [Domain] Global Intangible Low-Taxed Income Amount of Tax Cuts and Jobs Act for Global Intangible Low-tax Income for effective income tax rate reconciliation. Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred tax assets Statistical Measurement [Axis] Income Tax Foreign Rate Differential [Table Text Block] Tabular disclosure of income tax foreign rate differential. Ownership [Axis] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax assets Department for International Tax Cooperation [Member] Represents Department for International Tax Cooperation. Preferred stock, issued (in shares) Total long-lived assets Geographical [Axis] Geographical [Domain] Operating lease liabilities nhtc_DeferredTaxAssetsOperatingLeaseLiabilities Represents operating lease liabilities for deferred tax assets. us-gaap_DeferredTaxAssetsGross Total deferred tax assets Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized (in shares) Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] us-gaap_DeferredIncomeTaxLiabilities Total deferred tax liabilities Europe [Member] Inventories Inventory, Net, Total Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share (in dollars per share) Raw materials us-gaap_InventoryValuationReserves Reserve for obsolescence Finished goods Dividends Declared January 27, 2019 [Member] Represents dividends declared January 27, 2019. Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Special Dividends Declared October 29, 2019 [Member] Represents special dividends declared October 29, 2019. Fair Value Hierarchy and NAV [Axis] nhtc_AgeRequirementFor401kContributions Age Requirement For 401K Contributions (Year) Represents age requirement for 401 K contributions. Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Other us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities nhtc_ContractWithCustomerRefundLiabilitySalesReturns Less: sales returns Represents sales returns for refund liability for contract with customer. Special Dividends Declared January 27, 2019 [Member] Represents special dividends declared January 27, 2019. Inventories: us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) CASH FLOWS FROM OPERATING ACTIVITIES: Schedule of Segment Reporting Information, by Segment [Table Text Block] Statement [Line Items] Furniture and Fixtures [Member] us-gaap_NumberOfReportableSegments Number of Reportable Segments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Stock-based compensation us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Additional paid-in capital Accumulated Foreign Currency Adjustment Attributable to Parent [Member] AOCI Attributable to Parent [Member] Stockholders’ equity: Property, Plant and Equipment, Policy [Policy Text Block] Other income, net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Net operating losses Amounts held in eWallets Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current. Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period Deferred tax assets: Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 8) Director [Member] Noncash lease expense Represents the amount of lessee's noncash lease expense during the period. Deferred income taxes Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange. Effect of exchange rates on cash, cash equivalents and restricted cash us-gaap_OperatingIncomeLoss Income (loss) from operations Income (loss) from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by (used in) operating activities Other us-gaap_DeferredTaxLiabilitiesOther us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent Revenue from Contract with Customers, Historical Sales Returns, Percent Represents the percentage of historical sales returns. nhtc_RevenueFromContractWithCustomersSalesReturnsPercent Revenue from Contract with Customers, Sales Returns, Percent Represents the percentage of sales returns. us-gaap_GrossProfit Gross profit nhtc_IncreaseDecreaseInAccruedSalesCommissions Accrued commissions Amount of increase (decrease) in accrued sales commissions. Cost of sales Counterparty Name [Axis] nhtc_IncreaseDecreaseInOperatingLeaseLiabilities Operating lease liabilities Amount of increase (decrease) in operating lease liabilities. Counterparty Name [Domain] nhtc_IncreaseDecreaseInCapitalizedContractCostLiability Amounts held in eWallets Amount of increase (decrease) in capitalized contract cost liability. nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm Revenue from Contract with Customer, Sales Returns Policy Term (Day) Represents the sales returns policy term. Deferred tax liability Consolidation Items [Domain] Operating lease assets us-gaap_DeferredTaxLiabilitiesLeasingArrangements Consolidation Items [Axis] us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings Foreign deferreds Concentration Risk, Credit Risk, Policy [Policy Text Block] Prepaids us-gaap_DeferredTaxLiabilitiesPrepaidExpenses Dividends Dividends paid Deferred tax liabilities: Unshipped Product [Member] Information pertaining to unshipped product. Auto ship advances [Member] Information pertaining to auto ship advances. Sales returns Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns. Schedule of Additional Balance Sheet Components [Table Text Block] Tabular disclosure of additional balance sheet components. us-gaap_PaymentsForRepurchaseOfCommonStock Repurchase of common stock Warehousing, inventory-related and other Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense. Retained Earnings [Member] Net sales State Treasury Stock [Member] State us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount us-gaap_CurrentForeignTaxExpenseBenefit Foreign Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Additional Paid-in Capital [Member] Share Repurchase Program [Domain] Common Stock [Member] Federal us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Preferred Stock [Member] Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] us-gaap_CurrentIncomeTaxExpenseBenefit Total current taxes nhtc_LesseeNumberOfBranches Lessee, Number of Branches Represents the lessees' number of branches. Rolling Hills Estates [Member] Information pertaining to Rolling Hills Estates. Foreign Richmond, British Columbia [Member] Information pertaining to Richmond, British Columbia. Metuchen, New Jersey [Member] Information pertaining to Metuchen, New Jersey. Income (loss) before income taxes Income (loss) before income taxes State Administration of Taxation, China [Member] Domestic Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] nhtc_CommonStockPercentageOfBeneficialStockOutstanding Common Stock, Percentage of Beneficial Stock Outstanding Represents the percentage of beneficial stock outstanding. Inland Revenue, Hong Kong [Member] BHS [Member] Information pertaining to BHS. State and Local Jurisdiction [Member] Equity Incentive Plan 2016 [Member] Information pertaining to the 2016 Equity Incentive Plan. Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] nhtc_NumberOfProductOrders Number of Product Orders Represents the number of product orders. Income Tax Authority [Domain] Aberdeen [Member] Information pertaining to Aberdeen. Domestic Tax Authority [Member] Shipment of Apparel Products [Member] Information pertaining to shipment of apparel products. Foreign Tax Authority [Member] Royalty Agreement and License [Member] Information pertaining to the Royalty Agreement and License. nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement Related Party Transaction, Additional Extension Period of Agreement (Year) Represents the additional extension period of the agreement in related party transaction. nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement Related Party Transaction, Automatic Renewal Period of Agreement (Year) Represents the automatic renewal period of the agreement in related party transaction. Revenue from Contract with Customer [Text Block] nhtc_NumberOfDaysTerminationNotice Number of Days Termination Notice (Day) Represents the number of days for termination notice. Document Annual Report Primary Reporting Segment [Member] Information pertaining to the primary reporting segment. Russia and Kazakhstan [Member] Information pertaining to Russia and Kazakhstan. Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Sharng Holdings [Member] Information pertaining to Sharng Holdings. Unrelated Third Party [Member] Information pertaining to the unrelated third party. Entity Incorporation, State or Country Code Accounting Policies [Abstract] Document Transition Report Other Foreign Countries [Member] Information pertaining to other foreign countries. Selling, General and Administrative Expenses [Member] Entity Interactive Data Current Dividends declared, per share (in dollars per share) Common Stock, Dividends, Per Share, Declared (in dollars per share) Dividends per share (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) Security Exchange Name Title of 12(b) Security Income Statement Location [Axis] Income Statement Location [Domain] Other accrued expenses: Segments [Axis] Segments [Domain] Weighted-average number of common shares outstanding: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Net income (loss) per common share: Statement [Table] us-gaap_MinorityInterestOwnershipPercentageByParent Noncontrolling Interest, Ownership Percentage by Parent Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) Basic (in dollars per share) Deferred revenue: Statement of Cash Flows [Abstract] Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Statement of Stockholders' Equity [Abstract] Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Available-for-sale Securities [Table Text Block] Other comprehensive income Income Statement [Abstract] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Open Market Purchases [Member] Information pertaining to the open market purchases. Broady Trust [Member] Information pertaining to the Broady Trust. CASH FLOWS FROM FINANCING ACTIVITIES: Other reconciling items Statutory Tax Rate Change in valuation allowance nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction Represents the ratio of number of shares authorized to be repurchased in private transaction. nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired Common stock issued Amount of decrease in additional paid in capital (APIC) resulting from treasury stock acquired. Common stock issued (in shares) Represents the number of treasury shares reissued. Common stock issued Represents the value of treasury shares reissued. Dividends [Axis] Dividends [Domain] Foreign tax credits us-gaap_StockholdersEquity Total stockholders’ equity Balance, December 31, 2019 Balance, December 31, 2020 us-gaap_AccruedIncomeTaxesNoncurrent Income taxes payable Goodwill impairment us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses Class of Stock [Axis] Stock-based compensation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Dividends Payable [Table Text Block] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Gross unrealized losses Operating Segments [Member] Adjusted cost Foreign rate differential EX-101.PRE 10 nhtc-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 nhtc20201231_10k_htm.xml IDEA: XBRL DOCUMENT 0000912061 2020-01-01 2020-12-31 0000912061 2020-06-30 0000912061 2021-02-22 0000912061 2020-12-31 0000912061 2019-12-31 0000912061 2019-01-01 2019-12-31 0000912061 us-gaap:PreferredStockMember 2018-12-31 0000912061 us-gaap:CommonStockMember 2018-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000912061 us-gaap:RetainedEarningsMember 2018-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000912061 us-gaap:TreasuryStockMember 2018-12-31 0000912061 2018-12-31 0000912061 us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0000912061 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000912061 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000912061 us-gaap:PreferredStockMember 2019-12-31 0000912061 us-gaap:CommonStockMember 2019-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000912061 us-gaap:RetainedEarningsMember 2019-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000912061 us-gaap:TreasuryStockMember 2019-12-31 0000912061 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000912061 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000912061 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0000912061 us-gaap:PreferredStockMember 2020-12-31 0000912061 us-gaap:CommonStockMember 2020-12-31 0000912061 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000912061 us-gaap:RetainedEarningsMember 2020-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000912061 us-gaap:TreasuryStockMember 2020-12-31 0000912061 srt:MinimumMember 2020-01-01 2020-12-31 0000912061 srt:MaximumMember 2020-01-01 2020-12-31 0000912061 country:CN 2019-12-31 0000912061 country:VN 2019-11-30 0000912061 country:VN 2020-12-31 0000912061 country:VN 2019-12-31 0000912061 country:KP 2020-12-31 0000912061 srt:MinimumMember nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember 2020-01-01 2020-12-31 0000912061 srt:MaximumMember nhtc:OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember 2020-01-01 2020-12-31 0000912061 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0000912061 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000912061 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000912061 country:HK us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2020-03-11 2020-03-11 0000912061 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000912061 nhtc:UnshippedProductMember 2020-12-31 0000912061 nhtc:UnshippedProductMember 2019-12-31 0000912061 nhtc:AutoShipAdvancesMember 2020-12-31 0000912061 nhtc:AutoShipAdvancesMember 2019-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2020-12-31 0000912061 us-gaap:ProductAndServiceOtherMember 2019-12-31 0000912061 country:CN 2020-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2019-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000912061 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000912061 country:HK 2020-12-31 0000912061 nhtc:RollingHillsEstatesMember 2020-12-31 0000912061 nhtc:RollingHillsEstatesMember 2020-06-30 0000912061 nhtc:RichmondBritishColumbiaMember 2020-12-31 0000912061 nhtc:MetuchenNewJerseyMember 2020-12-31 0000912061 nhtc:DepartmentForInternationalTaxCooperationMember 2020-01-01 2020-12-31 0000912061 nhtc:DepartmentForInternationalTaxCooperationMember 2019-01-01 2019-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2020-01-01 2020-12-31 0000912061 us-gaap:InlandRevenueHongKongMember 2019-01-01 2019-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2020-01-01 2020-12-31 0000912061 us-gaap:StateAdministrationOfTaxationChinaMember 2019-01-01 2019-12-31 0000912061 us-gaap:DomesticCountryMember 2020-12-31 0000912061 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0000912061 us-gaap:ForeignCountryMember 2020-12-31 0000912061 2020-01-01 2020-03-31 0000912061 2020-04-01 2020-06-30 0000912061 2020-07-01 2020-09-30 0000912061 2020-10-01 2020-12-31 0000912061 nhtc:SpecialDividendsDeclaredOctober292019Member 2019-01-01 2019-12-31 0000912061 nhtc:SpecialDividendsDeclaredJanuary272019Member 2019-01-01 2019-12-31 0000912061 nhtc:DividendsDeclaredJanuary272019Member 2019-01-01 2019-12-31 0000912061 2015-07-28 0000912061 2016-01-12 0000912061 nhtc:BroadyTrustMember 2019-05-16 0000912061 srt:DirectorMember 2019-05-16 0000912061 nhtc:OpenMarketPurchasesMember 2019-05-31 0000912061 2019-05-01 2019-05-31 0000912061 2019-08-01 2019-09-30 0000912061 2019-12-01 2019-12-31 0000912061 nhtc:EquityIncentivePlan2016Member 2020-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2019-02-01 2019-02-01 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2019-08-09 2019-08-09 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2018-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2019-01-01 2019-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2019-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2020-01-01 2020-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentivePlan2016Member 2020-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000912061 srt:DirectorMember 2020-03-20 0000912061 nhtc:BHSMember nhtc:RoyaltyAgreementAndLicenseMember 2020-01-01 2020-12-31 0000912061 nhtc:BHSMember nhtc:RoyaltyAgreementAndLicenseMember 2019-01-01 2019-12-31 0000912061 nhtc:RoyaltyAgreementAndLicenseMember nhtc:BHSMember 2020-03-20 2020-03-20 0000912061 nhtc:ShipmentOfApparelProductsMember nhtc:AberdeenMember 2019-01-01 2019-03-31 0000912061 nhtc:AberdeenMember nhtc:SharngHoldingsMember 2020-12-31 0000912061 nhtc:AberdeenMember srt:DirectorMember 2020-12-31 0000912061 nhtc:UnrelatedThirdPartyMember nhtc:AberdeenMember 2020-12-31 0000912061 nhtc:AberdeenMember 2020-01-01 2020-12-31 0000912061 nhtc:BroadyTrustMember 2019-05-17 2019-05-17 0000912061 nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-12-31 0000912061 nhtc:PrimaryReportingSegmentMember 2019-01-01 2019-12-31 0000912061 country:CN 2020-01-01 2020-12-31 0000912061 country:CN 2019-01-01 2019-12-31 0000912061 nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-12-31 0000912061 nhtc:RussiaAndKazakhstanMember 2019-01-01 2019-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:PrimaryReportingSegmentMember 2019-01-01 2019-12-31 0000912061 us-gaap:OperatingSegmentsMember country:CN 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember country:CN 2019-01-01 2019-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember nhtc:RussiaAndKazakhstanMember 2019-01-01 2019-12-31 0000912061 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000912061 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0000912061 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-12-31 0000912061 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-12-31 0000912061 country:US 2020-01-01 2020-12-31 0000912061 country:US 2019-01-01 2019-12-31 0000912061 country:CA 2020-01-01 2020-12-31 0000912061 country:CA 2019-01-01 2019-12-31 0000912061 country:PE 2020-01-01 2020-12-31 0000912061 country:PE 2019-01-01 2019-12-31 0000912061 country:HK 2020-01-01 2020-12-31 0000912061 country:HK 2019-01-01 2019-12-31 0000912061 country:TW 2020-01-01 2020-12-31 0000912061 country:TW 2019-01-01 2019-12-31 0000912061 srt:EuropeMember 2020-01-01 2020-12-31 0000912061 srt:EuropeMember 2019-01-01 2019-12-31 0000912061 nhtc:OtherForeignCountriesMember 2020-01-01 2020-12-31 0000912061 nhtc:OtherForeignCountriesMember 2019-01-01 2019-12-31 0000912061 us-gaap:ProductMember 2020-01-01 2020-12-31 0000912061 us-gaap:ProductMember 2019-01-01 2019-12-31 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2020-01-01 2020-12-31 0000912061 nhtc:AdministrativeFeesFreightAndOtherMember 2019-01-01 2019-12-31 0000912061 country:US 2020-12-31 0000912061 country:US 2019-12-31 0000912061 country:GB 2020-12-31 0000912061 country:GB 2019-12-31 0000912061 nhtc:OtherForeignCountriesMember 2020-12-31 0000912061 nhtc:OtherForeignCountriesMember 2019-12-31 0000912061 us-gaap:SubsequentEventMember 2021-02-08 2021-02-08 iso4217:USD shares thunderdome:item iso4217:USD shares utr:D iso4217:CNY iso4217:VND pure utr:Y utr:sqft 0000912061 Natural Health Trends Corp. false --12-31 FY 2020 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 50000000 50000000 12979414 12979414 1556875 1556875 0.64 0.80 P2D P5D P3Y P5Y P5Y P7Y P14D P1Y P5Y 0 0.20 0.20 0.20 0.20 0.20 0.20 0.20 P3Y P3Y P5Y P1Y 0.045 1 1 10-K true 2020-12-31 false 001-36849 DE 59-2705336 Units 1205-07, 12F Mira Place Tower A 132 Nathan Road, Tsimshatsui Kowloon HK 852 3107-0800 Common Stock, par value $0.001 per share NHTC NASDAQ No No Yes Yes Non-accelerated Filer true false false 39932227 11422539 92367000 96035000 3779000 6404000 3595000 5936000 99741000 108375000 539000 735000 3745000 3135000 525000 3390000 731000 2039000 661000 823000 105942000 118497000 580000 680000 1481000 173000 3496000 2931000 1922000 2387000 3091000 4506000 8503000 12938000 1163000 1655000 1270000 1032000 21506000 26302000 13748000 15365000 216000 202000 2775000 1564000 38245000 43433000 0 0 13000 13000 86102000 86102000 7822000 16117000 -336000 -1264000 25904000 25904000 67697000 75064000 105942000 118497000 62071000 77614000 16990000 20104000 45081000 57510000 26204000 35549000 18208000 27220000 0 1764000 44412000 64533000 669000 -7023000 821000 1426000 1490000 -5597000 647000 14000 843000 -5611000 0.08 -0.52 0.07 -0.52 10630000 10871000 11424000 10871000 843000 -5611000 920000 -28000 8000 14000 1771000 -5625000 0 0 12979414 13000 86415000 44431000 -1250000 -1603322 -39748000 89861000 0 0 0 -5611000 0 0 -5611000 -0 -0 -0 -0 -0 -0 -0 1093641 10117000 10117000 0 0 0 0 313000 -15359000 0 1140088 23961000 8289000 -0 -0 -0 7344000 -0 -0 7344000 0 0 0 0 -28000 0 -28000 0 0 0 0 14000 0 14000 0 0 12979414 13000 86102000 16117000 -1264000 -1556875 -25904000 75064000 0 0 0 843000 0 0 843000 -0 -0 -0 9138000 -0 -0 9138000 0 0 0 0 920000 0 920000 0 0 0 0 8000 0 8000 0 0 12979414 13000 86102000 7822000 -336000 -1556875 -25904000 67697000 843000 -5611000 410000 387000 1532000 1760000 1339000 -820000 0 1764000 -2700000 -5820000 -2322000 554000 -181000 -0 -102000 -953000 -311000 -1731000 566000 -9598000 -471000 -2797000 -1433000 -2315000 -4491000 -1742000 -1427000 -1807000 227000 -108000 0 -333000 1885000 -18638000 211000 189000 -211000 -189000 -0 10117000 9138000 7344000 -9138000 -17461000 931000 62000 -6533000 -36226000 99425000 135651000 92892000 99425000 -2097000 1985000 0 8289000 2747000 5082000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">1.</em>     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Nature of Operations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Natural Health Trends Corp., a Delaware corporation (whether or <em style="font: inherit;">not</em> including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 25.5pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 25.5pt;"><i>Reclassification</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Certain income taxes payable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. <em style="font: inherit;">No</em> change in total current liabilities occurred.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results <em style="font: inherit;"> may </em>differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within <span style="-sec-ix-hidden:c69711124">two</span> to <span style="-sec-ix-hidden:c69711127">five</span> days.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times <em style="font: inherit;"> may </em>exceed insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Restricted Cash</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In <em style="font: inherit;"> June 2015, </em>the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019</em>) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in <em style="font: inherit;"> March 2020</em><i> </i>in connection with the withdrawal of its application. In <em style="font: inherit;"> November 2019, </em>the Company funded a similar bank deposit account in the amount of VND 10 million ($433,000 and $432,000 at <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively) for purposes of submitting a direct selling license application in Vietnam.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Inventories</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Inventories are stated at the lower of cost or net realizable value, using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c69711161">three</span> to <span style="-sec-ix-hidden:c69711162">five</span> years for office equipment, office software and capitalized internal-use software development costs and <span style="-sec-ix-hidden:c69711163">five</span> to <span style="-sec-ix-hidden:c69711164">seven</span> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $410,000 and $387,000 during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Goodwill</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2019,</em> the Company elected to early adopt the guidance of Accounting Standards Update ("ASU") <em style="font: inherit;">2017</em>-<em style="font: inherit;">04,</em> <i>Intangibles - Goodwill and Other (Topic <em style="font: inherit;">350</em>): Simplifying the Test for Goodwill Impairment</i>, which eliminates Step <em style="font: inherit;">2</em> from the goodwill impairment test. The Company estimated fair value based on market capitalization after considering recent trends in its stock price. Upon comparing such fair value with its carrying amount, the Company recognized an impairment loss of $1.8 million in <em style="font: inherit;"> December 2019.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than <em style="font: inherit;">not</em> recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than <em style="font: inherit;">not</em> that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are <em style="font: inherit;">no</em> significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than <em style="font: inherit;">fifty</em> percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are <em style="font: inherit;">not</em> provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Amounts Held in eWallets</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company requires commission payments of certain members in Hong Kong and other markets to be <em style="font: inherit;">first</em> recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Foreign Currency</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $335,000 and $355,000 was recognized during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i style="background-color: rgba(0, 0, 0, 0); font-size: 10pt; text-indent: 0pt;"/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i style="background-color: rgba(0, 0, 0, 0); font-size: 10pt; text-indent: 0pt;">Commissions Expense</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally <em style="font: inherit;">two</em> weeks following the end of the weekly sales period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In some markets, the Company also pays certain bonuses on purchases by up to <em style="font: inherit;">three</em> generations of personally sponsored members, as well as bonuses on commissions earned by up to <em style="font: inherit;">seven</em> generations of personally sponsored members. Independent members <em style="font: inherit;"> may </em>also earn incentives based on meeting certain qualifications during a designated incentive period, which <em style="font: inherit;"> may </em>range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which <em style="font: inherit;"> may </em>result in additional compensation to specific members.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income (Loss) Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Certain Risks and Concentrations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In late <em style="font: inherit;">2019</em> or early <em style="font: inherit;">2020</em> an outbreak of COVID-<em style="font: inherit;">19</em> was <em style="font: inherit;">first</em> identified in China and subsequently spread around the world. On <em style="font: inherit;"> March 11, 2020 </em>the World Health Organization declared the COVID-<em style="font: inherit;">19</em> outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country.   The Company has significant business in China and in <em style="font: inherit;">2020</em> generated approximately 79% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China.  The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-<em style="font: inherit;">19,</em> while the governments of other countries in which the Company operates are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company also canceled both of its major member events planned for <em style="font: inherit;">2020,</em> although some relatively small member events were held in the <em style="font: inherit;">second</em> half of the year. The severity of the impact on the Company of the COVID-<em style="font: inherit;">19</em> pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout <em style="font: inherit;">2020,</em> and the Company expects that its financial results for the near-term <em style="font: inherit;"> may </em>be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s <em style="font: inherit;">third</em>-party logistics providers, and it expects that the future operations of these logistics providers and other <em style="font: inherit;">third</em> parties with whom it works <em style="font: inherit;"> may </em>be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has <em style="font: inherit;">not</em> implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in <em style="font: inherit;"> August 2015, </em>but in <em style="font: inherit;">2019</em> a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in <em style="font: inherit;"> November 2019, </em>and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to <em style="font: inherit;">third</em> parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member <em style="font: inherit;"> may </em>elect to participate separately or in both.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be <em style="font: inherit;">no</em> assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws <em style="font: inherit;"> may </em>be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that <em style="font: inherit;"> may </em>violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are <em style="font: inherit;">not</em> in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><em style="font: inherit;">No</em> single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total sales. Sales are made to the Company’s members and <em style="font: inherit;">no</em> single customer accounted for <em style="font: inherit;">10%</em> or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company’s<i> Premium Noni Juice, Enhanced Essential Probiotics </i>and<i> Triotein™ </i>products each account for at least <em style="font: inherit;">10%</em> of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p><p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"/> <p style="text-align: left; text-indent: 0pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i/></p><p style="text-align: left; text-indent: 0pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Fair Value of Financial Instruments</i></p> <p style="text-align: left; text-indent: 25.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="text-align: left; text-indent: 25.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i/></p><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>.  The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em>  ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">13,</em> <i>Fair Value Measurement</i> <i>(Topic <em style="font: inherit;">820</em>): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.</i> This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU was effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>and early adoption was permitted.  The adoption of this standard did <em style="font: inherit;">not</em> have a material impact on the Company's consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes</i> <i>(Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes.</i> This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods.  It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU was effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2020, </em>and early adoption was permitted.  The Company elected to early adopt the new standard during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> Such adoption did <em style="font: inherit;">not</em> have a material impact on the Company's consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 25.5pt;"><i>Reclassification</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -27pt; text-align: left; text-indent: 25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 25.5pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Certain income taxes payable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. <em style="font: inherit;">No</em> change in total current liabilities occurred.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results <em style="font: inherit;"> may </em>differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Cash and Cash Equivalents</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) <em style="font: inherit;">320,</em> <i>Investments - Debt and Equity Securities</i>. As such, the Company determined its investments in debt securities held at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within <span style="-sec-ix-hidden:c69711124">two</span> to <span style="-sec-ix-hidden:c69711127">five</span> days.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times <em style="font: inherit;"> may </em>exceed insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Restricted Cash</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In <em style="font: inherit;"> June 2015, </em>the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2019</em>) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in <em style="font: inherit;"> March 2020</em><i> </i>in connection with the withdrawal of its application. In <em style="font: inherit;"> November 2019, </em>the Company funded a similar bank deposit account in the amount of VND 10 million ($433,000 and $432,000 at <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively) for purposes of submitting a direct selling license application in Vietnam.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> 20000000 2900000 10000000 433000 432000 1 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Inventories</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Inventories are stated at the lower of cost or net realizable value, using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c69711161">three</span> to <span style="-sec-ix-hidden:c69711162">five</span> years for office equipment, office software and capitalized internal-use software development costs and <span style="-sec-ix-hidden:c69711163">five</span> to <span style="-sec-ix-hidden:c69711164">seven</span> years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $410,000 and $387,000 during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> 410000 387000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Goodwill</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2019,</em> the Company elected to early adopt the guidance of Accounting Standards Update ("ASU") <em style="font: inherit;">2017</em>-<em style="font: inherit;">04,</em> <i>Intangibles - Goodwill and Other (Topic <em style="font: inherit;">350</em>): Simplifying the Test for Goodwill Impairment</i>, which eliminates Step <em style="font: inherit;">2</em> from the goodwill impairment test. The Company estimated fair value based on market capitalization after considering recent trends in its stock price. Upon comparing such fair value with its carrying amount, the Company recognized an impairment loss of $1.8 million in <em style="font: inherit;"> December 2019.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> 1800000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than <em style="font: inherit;">not</em> recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than <em style="font: inherit;">not</em> that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are <em style="font: inherit;">no</em> significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than <em style="font: inherit;">fifty</em> percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are <em style="font: inherit;">not</em> provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Amounts Held in eWallets</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company requires commission payments of certain members in Hong Kong and other markets to be <em style="font: inherit;">first</em> recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Foreign Currency</i></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $335,000 and $355,000 was recognized during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> -335000 -355000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i style="background-color: rgba(0, 0, 0, 0); font-size: 10pt; text-indent: 0pt;">Commissions Expense</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally <em style="font: inherit;">two</em> weeks following the end of the weekly sales period.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In some markets, the Company also pays certain bonuses on purchases by up to <em style="font: inherit;">three</em> generations of personally sponsored members, as well as bonuses on commissions earned by up to <em style="font: inherit;">seven</em> generations of personally sponsored members. Independent members <em style="font: inherit;"> may </em>also earn incentives based on meeting certain qualifications during a designated incentive period, which <em style="font: inherit;"> may </em>range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which <em style="font: inherit;"> may </em>result in additional compensation to specific members.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Net Income (Loss) Per Common Share</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has <em style="font: inherit;">not</em> yet recognized, if any, is assumed to be used to repurchase shares.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Certain Risks and Concentrations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In late <em style="font: inherit;">2019</em> or early <em style="font: inherit;">2020</em> an outbreak of COVID-<em style="font: inherit;">19</em> was <em style="font: inherit;">first</em> identified in China and subsequently spread around the world. On <em style="font: inherit;"> March 11, 2020 </em>the World Health Organization declared the COVID-<em style="font: inherit;">19</em> outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country.   The Company has significant business in China and in <em style="font: inherit;">2020</em> generated approximately 79% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China.  The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-<em style="font: inherit;">19,</em> while the governments of other countries in which the Company operates are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company also canceled both of its major member events planned for <em style="font: inherit;">2020,</em> although some relatively small member events were held in the <em style="font: inherit;">second</em> half of the year. The severity of the impact on the Company of the COVID-<em style="font: inherit;">19</em> pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout <em style="font: inherit;">2020,</em> and the Company expects that its financial results for the near-term <em style="font: inherit;"> may </em>be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s <em style="font: inherit;">third</em>-party logistics providers, and it expects that the future operations of these logistics providers and other <em style="font: inherit;">third</em> parties with whom it works <em style="font: inherit;"> may </em>be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has <em style="font: inherit;">not</em> implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in <em style="font: inherit;"> August 2015, </em>but in <em style="font: inherit;">2019</em> a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in <em style="font: inherit;"> November 2019, </em>and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to <em style="font: inherit;">third</em> parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member <em style="font: inherit;"> may </em>elect to participate separately or in both.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be <em style="font: inherit;">no</em> assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws <em style="font: inherit;"> may </em>be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that <em style="font: inherit;"> may </em>violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are <em style="font: inherit;">not</em> in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><em style="font: inherit;">No</em> single market other than Hong Kong had net sales greater than <em style="font: inherit;">10%</em> of total sales. Sales are made to the Company’s members and <em style="font: inherit;">no</em> single customer accounted for <em style="font: inherit;">10%</em> or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although <em style="font: inherit;">no</em> single member accounted for <em style="font: inherit;">10%</em> or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company’s<i> Premium Noni Juice, Enhanced Essential Probiotics </i>and<i> Triotein™ </i>products each account for at least <em style="font: inherit;">10%</em> of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> 0.79 <p style="text-align: left; text-indent: 0pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i>Fair Value of Financial Instruments</i></p> <p style="text-align: left; text-indent: 25.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="text-align: left; text-indent: 25.5pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.</p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="text-align: left; text-indent: 27pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to <em style="font: inherit;">not</em> fair value existing eligible items.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Recent Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> June </em><em style="font: inherit;">2016,</em> the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic <em style="font: inherit;">326</em> to the FASB ASC. In <em style="font: inherit;"> November 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11,</em> <i>Codification Improvements to Topic <em style="font: inherit;">326,</em> Financial Instruments - Credit Losses</i>.  The amendments to ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> clarify, correct and make improvements to Topic <em style="font: inherit;">326.</em>  ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> as well as the updates in ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">11</em> are effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2022, </em>and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:27pt;">In <em style="font: inherit;"> August 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">13,</em> <i>Fair Value Measurement</i> <i>(Topic <em style="font: inherit;">820</em>): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.</i> This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU was effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019, </em>and early adoption was permitted.  The adoption of this standard did <em style="font: inherit;">not</em> have a material impact on the Company's consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes</i> <i>(Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes.</i> This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods.  It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU was effective for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2020, </em>and early adoption was permitted.  The Company elected to early adopt the new standard during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> Such adoption did <em style="font: inherit;">not</em> have a material impact on the Company's consolidated financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Other recently issued accounting pronouncements did <em style="font: inherit;">not</em> or are <em style="font: inherit;">not</em> believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">2.</em> REVENUE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Revenue Recognition</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do <em style="font: inherit;">not</em> contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from <span style="-sec-ix-hidden:c69711252">14</span> days to <span style="-sec-ix-hidden:c69711253">one</span> year, and their historical return rates, which range from 1% to 10% of sales. Sales returns were 1% and 2% of sales for <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively.  <em style="font: inherit;">No</em> material changes in estimates have been recognized during the periods presented. See Note <em style="font: inherit;">4</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Deferred Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> is primarily due to a decrease of $1.4 million in unshipped product orders and unredeemed product vouchers. See Note <em style="font: inherit;">4</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Disaggregation of Revenue</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a <em style="font: inherit;">third</em>-party service provider. See Note <em style="font: inherit;">12</em> for additional information.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Arrangements with Multiple Performance Obligations</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company’s contracts with customers <em style="font: inherit;"> may </em>include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Practical Expedients</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company generally expenses sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less. These costs are recorded in commissions expense.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company does <em style="font: inherit;">not</em> provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.01 0.10 0.01 0.02 1400000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">3.</em>     NET INCOME (LOSS) PER COMMON SHARE</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The following table illustrates the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 459,654 shares were <em style="font: inherit;">not</em> included for the year ended <em style="font: inherit;"> December 31, 2019.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Income</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Loss</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net income (loss) available to common stockholders</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,630</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-vested restricted stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net income (loss) per common share:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net income (loss) available to common stockholders plus assumed conversions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,611</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.52</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 843000 10630000 0.08 -5611000 10871000 -0.52 0 794000 0 0 843000 11424000 0.07 -5611000 10871000 -0.52 459654 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">4.</em>     BALANCE SHEET COMPONENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of certain balance sheet amounts are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Cash</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">13,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Cash equivalents</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">82,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Restricted cash</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99,425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Finished goods</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Raw materials</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Reserve for obsolescence</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Office equipment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">449</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Office software</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,037</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Machinery</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Furniture and fixtures</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Leasehold improvements</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Construction in progress</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, at cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Accumulated depreciation and amortization</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Sales returns</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Employee-related expense</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Warehousing, inventory-related and other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Unshipped product and unredeemed product vouchers</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Auto ship advances</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, cash and cash equivalents include $12.5 million held in banks located within China subject to foreign currency controls.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Cash</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">23,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">13,720</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Cash equivalents</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">82,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">92,367</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96,035</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Restricted cash</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">525</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">3,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">92,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">99,425</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Inventories:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Finished goods</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">3,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6,142</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Raw materials</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,249</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt">Reserve for obsolescence</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,779</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,404</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Office equipment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">449</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">578</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Office software</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,037</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Machinery</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Furniture and fixtures</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">254</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Leasehold improvements</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Construction in progress</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">41</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, at cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,971</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Accumulated depreciation and amortization</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Sales returns</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Employee-related expense</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,149</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Warehousing, inventory-related and other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">584</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,922</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Unshipped product and unredeemed product vouchers</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Auto ship advances</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,977</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,985</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,091</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,506</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 23977000 13720000 68390000 82315000 92367000 96035000 525000 3390000 92892000 99425000 3071000 6142000 1047000 1249000 339000 987000 3779000 6404000 449000 578000 1001000 1037000 30000 28000 254000 327000 839000 1001000 41000 0 2614000 2971000 2075000 2236000 539000 735000 189000 373000 1149000 1258000 584000 756000 1922000 2387000 1005000 2390000 1977000 1985000 109000 131000 3091000 4506000 12500000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">5.</em>     FAIR VALUE MEASUREMENTS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Investments by category included in cash equivalents at the end of each period were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; padding: 0pt; vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 1</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Municipal debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%;"> </td><td style="width: 9%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup><sup style="vertical-align:top;line-height:120%;font-size:pt"><i> </i></sup><i>FASB Topic <em style="font: inherit;">820,</em> Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">1:</em> Quoted market prices in active markets for identical assets or liabilities.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">2:</em> Observable market-based inputs or unobservable inputs that are corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><i>Level <em style="font: inherit;">3:</em> Unobservable inputs that are <em style="font: inherit;">not</em> corroborated by market data.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2019</em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fair Value Level<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%; border-bottom: thin solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Adjusted Cost</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Gross Unrealized Losses</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Fair Value</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%; padding: 0pt; vertical-align: middle;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 1</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Time deposits</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,458</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,544</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Municipal debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,280</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><em style="font: inherit;">Level 2</em></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,621</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,615</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,784</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">56,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%;"> </td><td style="width: 9%;"><em style="font: inherit;"> </em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,390</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 21042000 -0 21042000 11659000 -0 11659000 5458000 -0 5458000 13544000 -0 13544000 30280000 5000 30275000 347000 -0 347000 11621000 6000 11615000 56784000 19000 56765000 68401000 11000 68390000 82334000 19000 82315000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">6.</em>     LEASES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In <em style="font: inherit;"> June 2020, </em>the Company extended the Rolling Hills Estates office lease for an additional <span style="-sec-ix-hidden:c69711448">five</span> years with a term now expiring in <em style="font: inherit;"> September 2030. </em>Effective <em style="font: inherit;"> July 1, 2020,</em><i> </i>the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through <em style="font: inherit;"> June 2023</em><i>.</i> To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in <em style="font: inherit;"> November 2025, </em><em style="font: inherit;"> February 2024, </em>and <em style="font: inherit;"> November 2022, </em>respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with <em style="font: inherit;">third</em> parties for fulfillment and distribution operations in all of its international markets. <em style="font: inherit;">None</em> of the Company’s <em style="font: inherit;">third</em>-party logistics contracts contain a lease as the Company does <em style="font: inherit;">not</em> have the right to access the warehouses or move its inventories at will.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The components of lease cost were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,024</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">299</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,308</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">Cash paid for amounts included in the measurement of operating leases liabilities was $1.6 million and $2.0 million for <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> respectively.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The weighted-average remaining lease term and discount rate related to operating leases as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As most of the Company’s leases do <em style="font: inherit;">not</em> provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The annual scheduled lease payments of our operating lease liabilities as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">990</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">For all asset classes, the Company elected <em style="font: inherit;">not</em> to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of <em style="font: inherit;">12</em> months or less. Additionally, for all asset classes, the Company choose <em style="font: inherit;">not</em> to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> 7300 4900 1600 2000 8 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,024</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Short-term leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">299</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">284</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,015</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,308</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average discount rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> 1716000 2024000 299000 284000 2015000 2308000 1600000 2000000.0 P5Y6M 0.034 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">583</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">261</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">990</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(422</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1184000 1081000 583000 261000 261000 990000 4360000 422000 3938000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">7.</em>     INCOME TAXES</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of income (loss) before income taxes consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The components of the income tax provision consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">398</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%">Deferred taxes:</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Federal</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">State</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Foreign</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Total deferred taxes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(816</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">A reconciliation of the reported income tax provision to the provision (benefit) that would result from applying the domestic federal statutory tax rate to pretax income (loss) is as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">260</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Global Intangible Low-Taxed Income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Stock-based compensation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Net operating loss carryback</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other reconciling items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Income (loss) before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Statutory Tax Rate</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman Islands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Deferred income taxes consist of the following (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Net operating losses</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Stock-based compensation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Operating lease liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Valuation allowance</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Operating lease assets</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Foreign deferreds</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Prepaids</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,837</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The effective income tax rate for the year ended <em style="font: inherit;"> December 31, </em><em style="font: inherit;">2020</em> includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on <em style="font: inherit;"> March 27, 2020.</em><i> </i>The CARES Act makes broad changes to the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended, including, but <em style="font: inherit;">not</em> limited to, the ability to carry net operating losses generated in tax years <em style="font: inherit;">2018,</em> <em style="font: inherit;">2019</em> or <em style="font: inherit;">2020</em> back to the each of the <em style="font: inherit;">five</em> tax years preceding the tax year of such loss.  The effective income tax rate for the year ended <em style="font: inherit;"> December 31, 2019 </em>was impacted by permanent differences including a true-up of the GILTI provision for the tax year ended <em style="font: inherit;"> December 31, 2018 </em>and goodwill impairment for the year ended <em style="font: inherit;"> December 31, 2019.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, the Company does <span style="-sec-ix-hidden:c69711512">not</span> have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than <em style="font: inherit;">not</em> to realize the tax benefits of their deferred assets. As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than <em style="font: inherit;">not</em> that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, the Company <em style="font: inherit;">no</em> longer has U.S. federal net operating losses due to its filing in <em style="font: inherit;"> August 2020</em><i> </i>to carry back $3.6 million of losses generated in the tax year ended <em style="font: inherit;"> December 31, 2019</em><i> </i>to offset taxable income from the tax year ended <em style="font: inherit;"> December 31, 2016</em><i>. </i>The Company has U.S. state net operating loss carryforwards of $3.5 million that begin expiring in <em style="font: inherit;">2039.</em> At <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is <em style="font: inherit;">no</em> longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are <em style="font: inherit;">not</em> deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, the Company has <em style="font: inherit;">not</em> recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of <em style="font: inherit;"> December 31, 2020 </em>have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in <em style="font: inherit;">2017,</em> repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to <em style="font: inherit;">no</em> impact on federal tax expense. All undistributed earnings in excess of <em style="font: inherit;">50%</em> of current earnings on an annual basis are intended to be reinvested indefinitely as of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2018,</em> the Company was notified that it was selected for audit of the <em style="font: inherit;">2016</em> tax year by the U.S. Internal Revenue Service. The audit was expanded to include the <em style="font: inherit;">2017</em> and <em style="font: inherit;">2018</em> tax years, and a request has been submitted to also include the <em style="font: inherit;">2019</em> tax year. For purposes of this audit, fiscal years since <em style="font: inherit;">2007</em> are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. <em style="font: inherit;">No</em> adjustments have been proposed at this time. The Company is <em style="font: inherit;">no</em> longer subject to state income tax examinations for years prior to <em style="font: inherit;">2016.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,663</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,917</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,153</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> -1663000 -4917000 3153000 -680000 1490000 -5597000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">399</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">626</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">398</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">830</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%">Deferred taxes:</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Federal</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">346</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">State</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Foreign</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(388</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Total deferred taxes</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">532</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(816</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> -512000 399000 1000 33000 626000 398000 115000 830000 346000 -381000 6000 -47000 180000 -388000 532000 -816000 647000 14000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax at federal statutory rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,175</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effect of permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">260</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Global Intangible Low-Taxed Income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">555</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign rate differential</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Stock-based compensation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Net operating loss carryback</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(512</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other reconciling items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax provision</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 313000 -1175000 121000 260000 555000 364000 51000 106000 72000 13000 -98000 10000 164000 98000 -512000 0 0 375000 -19000 -37000 647000 14000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Statutory Tax Rate</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cayman Islands</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,589</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">267</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">716</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,644</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 0 2589000 -2746000 0.165 267000 3441000 0.250 716000 -1644000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Net operating losses</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">1,477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Stock-based compensation</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">510</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Operating lease liabilities</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">460</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">335</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Valuation allowance</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(340</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(289</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,521</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Operating lease assets</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(438</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(313</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Foreign deferreds</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(216</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(202</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Prepaids</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(36</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(60</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">515</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,837</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 628000 1477000 510000 925000 460000 335000 60000 73000 1658000 2810000 340000 289000 1318000 2521000 438000 313000 216000 202000 113000 109000 36000 60000 803000 684000 515000 1837000 3600000 3500000 2800000 <div style="display: none;"> <b> </b> </div> <b><em style="font: inherit;">8.</em>     COMMITMENTS AND CONTINGENCIES</b> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">On <em style="font: inherit;"> January 8, 2019, </em>the Company and its <em style="font: inherit;">two</em> executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned <i>Kauffman v. Natural Health Trends Corp.</i>, Case <em style="font: inherit;">No.</em> <em style="font: inherit;">2:19</em>-cv-<em style="font: inherit;">00163.</em> On <em style="font: inherit;"> May 3, 2019, </em>the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On <em style="font: inherit;"> June 3, 2019, </em>lead plaintiff filed an amended complaint. On <em style="font: inherit;"> January 17, 2020, </em>after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On <em style="font: inherit;"> February 14, 2020, </em>plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On <em style="font: inherit;"> April 9, 2020, </em>plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon <em style="font: inherit;">four</em> weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">9.</em>     STOCKHOLDERS’ EQUITY</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Authorized Shares</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company is authorized to issue <em style="font: inherit;">two</em> classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Dividends</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company declared and paid cash dividends of $0.20 per common share during each quarter of <em style="font: inherit;">2020,</em> totaling an aggregate of $9.1 million. The following table summarizes the Company’s cash dividend activity during <em style="font: inherit;">2019</em> (in thousands, except per share data):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 39.3%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Declaration Date</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Common Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 30.7%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Payment Date</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">October 29, 2019 (special)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">November 29, 2019</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">January 27, 2019 (special)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">912</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 15, 2019</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">January 27, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 15, 2019</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Stock Repurchases</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">On <em style="font: inherit;"> January 12, 2016, </em>the Board of Directors authorized an increase to the Company’s stock repurchase program <em style="font: inherit;">first</em> approved on <em style="font: inherit;"> July 28, 2015 </em>from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">18</em> of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company <em style="font: inherit;"> may </em>enter into <em style="font: inherit;">one</em> or more plans that are compliant with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does <em style="font: inherit;">not</em> require the Company to acquire a specific number of shares, and <em style="font: inherit;"> may </em>be suspended from time to time or discontinued.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">On <em style="font: inherit;"> May 16, 2019, </em>the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady <em style="font: inherit;">2012</em> Irrevocable Trust (the “Broady Trust”) on a basis roughly proportional to his family’s ownership interest in the Company (See Note <em style="font: inherit;">10</em>). During <em style="font: inherit;"> May 2019, </em>the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, were completed <em style="font: inherit;"> May 31, 2019 </em>and resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> August 6, 2019, </em>the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During <em style="font: inherit;"> August </em>and <em style="font: inherit;"> September 2019, </em>the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs. During <em style="font: inherit;"> December 2019, </em>the Company purchased a total of 97,785 shares of common stock for an aggregate purchase price of $552,000, plus transaction costs.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, $21.9 million of the <em style="font: inherit;">$70.0</em> million stock repurchase program approved on <em style="font: inherit;"> July 28, 2015 </em>and increased on <em style="font: inherit;"> January 12, 2016 </em>remained available for future purchases, inclusive of related estimated income tax.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Restricted Stock</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">At the Company’s annual meeting of stockholders held on <em style="font: inherit;"> April 7, 2016, </em>the Company’s stockholders approved the Natural Health Trends Corp. <em style="font: inherit;">2016</em> Equity Incentive Plan (the <em style="font: inherit;">“2016</em> Plan”) to replace its <em style="font: inherit;">2007</em> Equity Incentive Plan. The <em style="font: inherit;">2016</em> Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) <em style="font: inherit;"> may </em>be issued pursuant to awards granted. At <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020</em>, 1,219,583 shares remained available for issuance under the <em style="font: inherit;">2016</em> Plan.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> February 1, 2019, </em>the Company granted 22,603 shares of restricted common stock under the <em style="font: inherit;">2016</em> Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal <em style="font: inherit;">2018</em> performance incentives totaling $377,000. The shares vest on a quarterly basis over the next <span style="-sec-ix-hidden:c69711711">three</span> years and are subject to forfeiture in the event of an employee’s termination of service to the Company under specified circumstances.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">On <em style="font: inherit;"> August 9, 2019, </em>the Compensation ‎Committee amended the <em style="font: inherit;">2014</em> Long-Term Incentive Plan (the "LTI Plan") to provide that all then unpaid cash benefits earned by currently employed ‎participants under the LTI Plan with respect to performance periods that concluded on or prior to <em style="font: inherit;"> December 31, 2018 </em>‎shall be paid in the form of an award of shares of restricted stock under the <em style="font: inherit;">2016</em> ‎Plan. Accordingly, on <em style="font: inherit;"> August 9, 2019, </em>the Company awarded 1,117,485 shares of restricted common stock to ‎certain of its employees (subject to quarterly vesting for the <span style="-sec-ix-hidden:c69711715">three</span>-year period following the date of award) in lieu of ‎aggregate unpaid cash benefits of $7.9 million earned under the LTI Plan for performance periods ending on or ‎prior to <em style="font: inherit;"> December 31, 2018.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The following table summarizes the Company’s restricted stock activity under the <em style="font: inherit;">2016</em> Plan:</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,140,088</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(227,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Vested</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Nonvested at December 31, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">566,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>Accumulated Other Comprehensive Loss</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The changes in accumulated other comprehensive loss by component for <em style="font: inherit;">2020</em> were as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">920</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">928</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> 5000000 0.001 50000000 0.001 0.20 9100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 39.3%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Declaration Date</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Per Common Share</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Amount</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 30.7%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Payment Date</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">October 29, 2019 (special)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">November 29, 2019</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">January 27, 2019 (special)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">912</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 15, 2019</em></p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">January 27, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">0.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,824</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">March 15, 2019</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,344</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> </tbody></table> 0.40 4608000 0.08 912000 0.16 1824000 0.64 7344000 15000000.0 70000000.0 8000000.0 0.05 4700000 612729 6700000 383127 2900000 97785 552000 21900000 2500000 1219583 22603 377000 1117485 7900000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Shares</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Wtd. Avg. Price at Date of Issuance</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2018</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,140,088</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(227,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Nonvested at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">957,682</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.34</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 18pt;">Vested</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(391,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Nonvested at December 31, 2020</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">566,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.21</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 45486 21.61 1140088 7.27 227892 9.84 957682 7.34 391410 7.53 566272 7.21 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Foreign Currency Translation Adjustments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Unrealized Gains (Losses) on Available-For-Sale Investments</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">Total</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">920</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">928</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(325</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(336</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td></tr> </tbody></table> -1245000 -19000 -1264000 920000 8000 928000 -325000 -11000 -336000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">10.</em>     RELATED PARTY TRANSACTIONS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called <i>ReStor</i>™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing.  The Company recognized royalties of $83,000 and $96,000 during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively, under this agreement.  The Company is <em style="font: inherit;">not</em> required to purchase any product under the agreement, and the agreement <em style="font: inherit;"> may </em>be terminated under certain circumstances with <em style="font: inherit;">no</em> notice. An amendment to the agreement effective <em style="font: inherit;"> March 20, 2020 </em>extends the term of the agreement for an additional <span style="-sec-ix-hidden:c69711776">five</span> years to <em style="font: inherit;"> March 31, 2025, </em>after which it shall be automatically renewed for successive <span style="-sec-ix-hidden:c69711777">one</span>-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019</em><i>. </i>Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated <em style="font: inherit;">third</em> party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section <em style="font: inherit;">402</em> of the Sarbanes-Oxley Act of <em style="font: inherit;">2002</em><i>.</i> The Company, through advice from its legal counsel, concluded that there is <em style="font: inherit;">not</em> a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section <em style="font: inherit;">402</em><i>.</i> This relationship between the Company and Aberdeen ceased following the completion of this transaction.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.75pt;">On <em style="font: inherit;"> May 17, 2019, </em>the Company entered into a Stock Repurchase Agreement with The George K. Broady <em style="font: inherit;">2012</em> Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> under the Securities Exchange Act of <em style="font: inherit;">1934,</em> provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in the open market as part of the stock repurchase program authorized by the Company’s Board of Directors on <em style="font: inherit;"> May 16, 2019. </em>The Company’s purchases from the Broady Trust concluded on <em style="font: inherit;"> May 31, 2019, </em>were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note <em style="font: inherit;">9.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.05 83000 96000 P90D 1 7100 0.40 0.40 0.20 420 0.4105 178324 1900000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">11.</em>     EMPLOYEE BENEFIT PLANS</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:10.5pt;">     The Company has a <em style="font: inherit;">401</em>(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the <em style="font: inherit;">first</em> day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. <em style="font: inherit;">No</em> profit sharing has been paid under the plan. The Company recorded compensation expense of $68,000 and $85,000 for <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em>, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> 0.90 P21Y 0.045 1 68000 85000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">12.</em>    SEGMENT INFORMATION</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:7.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a <em style="font: inherit;">third</em>-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a <span style="-sec-ix-hidden:c69711825">single</span> reporting segment (the “Primary Reporting Segment”).</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and <em style="font: inherit;">not</em> by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are <em style="font: inherit;">not</em> presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s operating information by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Primary Reporting Segment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">58,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">73,693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Russia and Kazakhstan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Primary Reporting Segment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(1,719</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Russia and Kazakhstan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total income (loss) from operations for reportable segments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,505</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Unallocated corporate expenses</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(14,528</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other income, net</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">1,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s net sales by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,048</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,724</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,370</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0"/> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><sup style="vertical-align:top;line-height:120%;font-size:pt"><em style="font: inherit;">1</em></sup> <i>Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item <em style="font: inherit;">1A.</em> Risk Factors”.</i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s net sales by product and service are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales by product and service:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,048</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">During <em style="font: inherit;"> June 2020, </em>the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue in <em style="font: inherit;">2020.</em> Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">The Company’s long-lived assets by geographic area are as follows (in thousands):</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Primary Reporting Segment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">58,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">73,693</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">2,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Russia and Kazakhstan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) from operations:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Primary Reporting Segment</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,277</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">9,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">China</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">330</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(1,719</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 18pt;">Russia and Kazakhstan</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">(115</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total income (loss) from operations for reportable segments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,511</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,505</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Unallocated corporate expenses</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(8,842</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">(14,528</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">Other income, net</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">821</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">1,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income (loss) before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,490</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(5,597</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr> </tbody></table> 58243000 73693000 2940000 2941000 888000 980000 62071000 77614000 9277000 9339000 330000 -1719000 -96000 -115000 9511000 7505000 -8842000 -14528000 821000 1426000 1490000 -5597000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales from external customers:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,573</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,003</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Canada</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,048</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Peru</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong<sup style="vertical-align:top;line-height:120%;font-size:pt">1</sup></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,169</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62,724</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Taiwan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,126</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Russia and Kazakhstan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">888</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,370</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,042</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1573000 2003000 765000 1048000 1453000 2380000 49169000 62724000 2940000 2941000 3034000 3126000 888000 980000 1050000 1370000 1199000 1042000 62071000 77614000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">Year Ended December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net sales by product and service:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,840</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">73,048</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Administrative fees, freight and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,991</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,106</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: sales returns</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,540</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total net sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">62,071</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,614</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 55840000 73048000 6991000 6106000 760000 1540000 62071000 77614000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2020</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><em style="font: inherit;">2019</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-lived assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">227</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">379</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Hong Kong</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">146</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">135</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">China</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">57</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other foreign countries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">119</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">164</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total long-lived assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">539</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 227000 379000 146000 135000 47000 57000 119000 164000 539000 735000 <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b><em style="font: inherit;">13.</em>     SUBSEQUENT EVENT</b></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25.5pt;">On <em style="font: inherit;"> February 8, 2021, </em>the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on <em style="font: inherit;"> March 5, 2021 </em>to stockholders of record on <em style="font: inherit;"> February 23, 2021. </em>Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> 0.20 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”. FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Feb. 22, 2021
Jun. 30, 2020
Document Information [Line Items]      
Entity Central Index Key 0000912061    
Entity Registrant Name Natural Health Trends Corp.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2020    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Document Transition Report false    
Entity File Number 001-36849    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 59-2705336    
Entity Address, Address Line One Units 1205-07, 12F Mira Place Tower A 132 Nathan Road, Tsimshatsui    
Entity Address, City or Town Kowloon    
Entity Address, Country HK    
City Area Code 852    
Local Phone Number 3107-0800    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol NHTC    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 39,932,227
Entity Common Stock, Shares Outstanding   11,422,539  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 92,367 $ 96,035
Inventories 3,779 6,404
Other current assets 3,595 5,936
Total current assets 99,741 108,375
Property and equipment, net 539 735
Operating lease right-of-use assets 3,745 3,135
Restricted cash 525 3,390
Deferred tax asset 731 2,039
Other assets 661 823
Total assets 105,942 118,497
Current liabilities:    
Accounts payable 580 680
Income taxes payable 1,481 173
Accrued commissions 3,496 2,931
Other accrued expenses 1,922 2,387
Deferred revenue 3,091 4,506
Amounts held in eWallets 8,503 12,938
Operating lease liabilities 1,163 1,655
Other current liabilities 1,270 1,032
Total current liabilities 21,506 26,302
Income taxes payable 13,748 15,365
Deferred tax liability 216 202
Operating lease liabilities 2,775 1,564
Total liabilities 38,245 43,433
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2020 and 2019 13 13
Additional paid-in capital 86,102 86,102
Retained earnings 7,822 16,117
Accumulated other comprehensive loss (336) (1,264)
Treasury stock, at cost; 1,556,875 shares at December 31, 2020 and 2019 (25,904) (25,904)
Total stockholders’ equity 67,697 75,064
Total liabilities and stockholders’ equity $ 105,942 $ 118,497
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 5,000,000 5,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 50,000,000 50,000,000
Common stock, issued (in shares) 12,979,414 12,979,414
Treasury stock, shares (in shares) 1,556,875 1,556,875
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net sales $ 62,071 $ 77,614
Cost of sales 16,990 20,104
Gross profit 45,081 57,510
Operating expenses:    
Commissions expense 26,204 35,549
Selling, general and administrative expenses 18,208 27,220
Goodwill impairment 0 1,764
Total operating expenses 44,412 64,533
Income (loss) from operations 669 (7,023)
Other income, net 821 1,426
Income (loss) before income taxes 1,490 (5,597)
Income tax provision 647 14
Net income (loss) $ 843 $ (5,611)
Net income (loss) per common share:    
Basic (in dollars per share) $ 0.08 $ (0.52)
Diluted (in dollars per share) $ 0.07 $ (0.52)
Weighted-average number of common shares outstanding:    
Basic (in shares) 10,630 10,871
Diluted (in shares) 11,424 10,871
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net income (loss) $ 843 $ (5,611)
Other comprehensive income (loss), net of tax:    
Foreign currency translation adjustments 920 (28)
Unrealized gains on available-for-sale securities 8 14
Comprehensive income (loss) $ 1,771 $ (5,625)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
BALANCE (in shares) at Dec. 31, 2018 0 12,979,414       (1,603,322)  
Balance, December 31, 2019 at Dec. 31, 2018 $ 0 $ 13 $ 86,415 $ 44,431 $ (1,250) $ (39,748) $ 89,861
Net income (loss) $ 0 $ 0 0 (5,611) 0 $ 0 (5,611)
Repurchase of common stock (in shares) 0 0       (1,093,641)  
Repurchase of common stock $ 0 $ 0 0 0 0 $ (10,117) (10,117)
Common stock issued (in shares) 0 0       1,140,088  
Common stock issued $ 0 $ 0   (15,359) 0 $ 23,961 8,289
Common stock issued     (313)        
Dividends declared 0 0 0 (7,344) 0 0 (7,344)
Foreign currency translation adjustments 0 0 0 0 (28) 0 (28)
Unrealized gains on available-for-sale securities $ 0 $ 0 0 0 14 $ 0 14
BALANCE (in shares) at Dec. 31, 2019 0 12,979,414       (1,556,875)  
Balance, December 31, 2020 at Dec. 31, 2019 $ 0 $ 13 86,102 16,117 (1,264) $ (25,904) 75,064
Net income (loss) 0 0 0 843 0 0 843
Dividends declared 0 0 0 (9,138) 0 0 (9,138)
Foreign currency translation adjustments 0 0 0 0 920 0 920
Unrealized gains on available-for-sale securities $ 0 $ 0 0 0 8 $ 0 8
BALANCE (in shares) at Dec. 31, 2020 0 12,979,414       (1,556,875)  
Balance, December 31, 2020 at Dec. 31, 2020 $ 0 $ 13 $ 86,102 $ 7,822 $ (336) $ (25,904) $ 67,697
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Stockholders' Equity (Parentheticals) - $ / shares
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dividends declared, per share (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.80 $ 0.64
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 843 $ (5,611)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 410 387
Noncash lease expense 1,532 1,760
Deferred income taxes 1,339 (820)
Goodwill, Impairment Loss 0 1,764
Changes in assets and liabilities:    
Inventories 2,700 5,820
Other current assets 2,322 (554)
Other assets 181 0
Accounts payable (102) (953)
Income taxes payable (311) (1,731)
Accrued commissions 566 (9,598)
Other accrued expenses (471) (2,797)
Deferred revenue (1,433) (2,315)
Amounts held in eWallets (4,491) (1,742)
Operating lease liabilities (1,427) (1,807)
Other current liabilities 227 (108)
Long-term incentive 0 (333)
Net cash provided by (used in) operating activities 1,885 (18,638)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (211) (189)
Net cash used in investing activities (211) (189)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repurchase of common stock 0 (10,117)
Dividends paid (9,138) (7,344)
Net cash used in financing activities (9,138) (17,461)
Effect of exchange rates on cash, cash equivalents and restricted cash 931 62
Net decrease in cash, cash equivalents and restricted cash (6,533) (36,226)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period 99,425 135,651
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period 92,892 99,425
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Cash paid (refunded) for income taxes, net (2,097) 1,985
Issuance of treasury stock for employee awards, net 0 8,289
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,747 $ 5,082
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Nature of Operations and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]

1.     NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations

 

Natural Health Trends Corp., a Delaware corporation (whether or not including its subsidiaries, the “Company”), is an international direct-selling and e-commerce company. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand.

 

The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia, Thailand and Vietnam; South Korea; Japan; India; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current liabilities occurred.

 

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2020 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in  March 2020 in connection with the withdrawal of its application. In November 2019, the Company funded a similar bank deposit account in the amount of VND 10 million ($433,000 and $432,000 at December 31, 2020 and 2019, respectively) for purposes of submitting a direct selling license application in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $410,000 and $387,000 during 2020 and 2019, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

 

Goodwill

 

During the fourth quarter of 2019, the Company elected to early adopt the guidance of Accounting Standards Update ("ASU") 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The Company estimated fair value based on market capitalization after considering recent trends in its stock price. Upon comparing such fair value with its carrying amount, the Company recognized an impairment loss of $1.8 million in December 2019.

 

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

 

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $335,000 and $355,000 was recognized during 2020 and 2019, respectively.

 

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

 

Net Income (Loss) Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country.   The Company has significant business in China and in 2020 generated approximately 79% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China.  The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-19, while the governments of other countries in which the Company operates are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company also canceled both of its major member events planned for 2020, although some relatively small member events were held in the second half of the year. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU was effective for interim and annual periods beginning after December 15, 2019, and early adoption was permitted.  The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods.  It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU was effective for interim and annual periods beginning after December 15, 2020, and early adoption was permitted.  The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company's consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.4
Note 2 - Revenue
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

2. REVENUE

 

Revenue Recognition

 

All revenue is recognized when the performance obligations under a contract, including any product vouchers sold on a stand-alone basis in Hong Kong, are satisfied. Product sales are recognized when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. These contracts are generally short-term in nature.

 

Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience. The reserve is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 10% of sales. Sales returns were 1% and 2% of sales for 2020 and 2019, respectively.  No material changes in estimates have been recognized during the periods presented. See Note 4 for additional information.

 

The Company has elected to account for shipping and handling activities performed after title has passed to members as a fulfillment cost, and accrues for the costs of shipping and handling if revenue is recognized before the contractually obligated shipping and handling activities occurs. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs. Costs of events and member training are included within selling, general and administrative expenses.

 

Various taxes on the sale of products to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.

 

Deferred Revenue

 

The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product orders and unredeemed product vouchers are considered a contract liability and are recorded as deferred revenue. The decrease in deferred revenue for the year ended December 31, 2020 is primarily due to a decrease of $1.4 million in unshipped product orders and unredeemed product vouchers. See Note 4 for additional information.

 

Disaggregation of Revenue

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the Chinese market where it sells to some consumers through an e-commerce retail platform and the Russia and Kazakhstan market where the Company operates through the engagement of a third-party service provider. See Note 12 for additional information.

 

Arrangements with Multiple Performance Obligations

 

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenues to each performance obligation based on its relative standalone selling price. The Company generally determines standalone selling prices based on the prices charged for individual products to similar customers.

 

Practical Expedients

 

The Company generally expenses sales commissions when incurred because the amortization period would be one year or less. These costs are recorded in commissions expense.

 

The Company does not provide certain disclosures about unsatisfied performance obligations for contracts with an original expected length of one year or less.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Net Income (Loss) Per Common Share
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Earnings Per Share [Text Block]

3.     NET INCOME (LOSS) PER COMMON SHARE

 

The following table illustrates the computation of basic and diluted net income (loss) per common share for the periods indicated (in thousands, except per share data):

 

  

Year Ended December 31,

 
  

2020

  

2019

 
  

Income

  

Shares

  

Per Share

  

Loss

  

Shares

  

Per Share

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $843   10,630  $0.08  $(5,611)  10,871  $(0.52)

Effect of dilutive securities:

                        

Non-vested restricted stock

     794               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $843   11,424  $0.07  $(5,611)  10,871  $(0.52)

 

In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. As such, non-vested restricted stock totaling 459,654 shares were not included for the year ended  December 31, 2019.

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Balance Sheet Components
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

4.     BALANCE SHEET COMPONENTS

 

The components of certain balance sheet amounts are as follows (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Cash and cash equivalents:

        
Cash $23,977  $13,720 
Cash equivalents  68,390   82,315 
   92,367   96,035 
Restricted cash  525   3,390 
  $92,892  $99,425 
         

Inventories:

        
Finished goods $3,071  $6,142 
Raw materials  1,047   1,249 
Reserve for obsolescence  (339)  (987)
  $3,779  $6,404 

Property and equipment:

        
Office equipment $449  $578 
Office software  1,001   1,037 
Machinery  30   28 
Furniture and fixtures  254   327 
Leasehold improvements  839   1,001 
Construction in progress  41    

Property and equipment, at cost

  2,614   2,971 
Accumulated depreciation and amortization  (2,075)  (2,236)
  $539  $735 

Other accrued expenses:

        
Sales returns $189  $373 
Employee-related expense  1,149   1,258 
Warehousing, inventory-related and other  584   756 
  $1,922  $2,387 

Deferred revenue:

        
Unshipped product and unredeemed product vouchers $1,005  $2,390 
Auto ship advances  1,977   1,985 
Other  109   131 
  $3,091  $4,506 

 

As of December 31, 2020, cash and cash equivalents include $12.5 million held in banks located within China subject to foreign currency controls.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Fair Value Measurements
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

5.     FAIR VALUE MEASUREMENTS

 

Investments by category included in cash equivalents at the end of each period were as follows (in thousands):

 

    

December 31, 2020

  

December 31, 2019

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $21,042  $  $21,042  $11,659  $  $11,659 

Time deposits

 

Level 2

  5,458      5,458   13,544      13,544 

Municipal debt securities

 

Level 2

  30,280   (5)  30,275   347      347 

Corporate debt securities

 

Level 2

  11,621   (6)  11,615   56,784   (19)  56,765 

Total investments

   $68,401  $(11) $68,390  $82,334  $(19) $82,315 

 


1 FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Leases
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

6.     LEASES

 

The Company leases 7,300 square feet of office space in Hong Kong and 4,900 square feet of office space in Rolling Hills Estates, California for its corporate staff. In June 2020, the Company extended the Rolling Hills Estates office lease for an additional five years with a term now expiring in September 2030. Effective  July 1, 2020, the Company modified the terms of its largest Hong Kong office lease resulting in a lease extension through  June 2023. To help further develop the market for its products in North America, the Company leases 1,600 square feet of retail space in each of Rowland Heights, California and Richmond, British Columbia and 2,000 square feet of retail space in Metuchen, New Jersey. The Rowland Heights, Richmond and Metuchen locations have terms expiring in November 2025, February 2024, and November 2022, respectively.

 

The Company leases eight branch offices throughout China, and additional office space in Peru, Japan, Taiwan, South Korea, Singapore, Malaysia, Vietnam, Indonesia, Thailand, India, and the Cayman Islands. The Company also leases a factory in Zhongshan, China. The Company contracts with third parties for fulfillment and distribution operations in all of its international markets. None of the Company’s third-party logistics contracts contain a lease as the Company does not have the right to access the warehouses or move its inventories at will.

 

The components of lease cost were as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Operating leases

 $1,716  $2,024 

Short-term leases

  299   284 

Total lease cost

 $2,015  $2,308 

 

Cash paid for amounts included in the measurement of operating leases liabilities was $1.6 million and $2.0 million for 2020 and 2019, respectively.

 

The weighted-average remaining lease term and discount rate related to operating leases as of December 31, 2020 were as follows:

 

Weighted-average remaining lease term (in years)

  5.5 

Weighted-average discount rate

  3.4%

 

As most of the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate, or the rate of each of its subsidiaries if available, based on the information available at the lease commencement date to determine the present value of lease payments.

 

The annual scheduled lease payments of our operating lease liabilities as of December 31, 2020 were as follows (in thousands):

 

2021

 $1,184 

2022

  1,081 

2023

  583 

2024

  261 

2025

  261 

Thereafter

  990 

Total lease payments

 $4,360 

Less: imputed interest

  (422)

Present value of lease liabilities

 $3,938 

 

For all asset classes, the Company elected not to recognize assets or liabilities at the acquisition date for leases that, at the acquisition date, have a remaining lease term of 12 months or less. Additionally, for all asset classes, the Company choose not to separate nonlease components from lease components and instead account for the combined lease and nonlease components associated with that lease component as a single lease component.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

7.     INCOME TAXES

 

The components of income (loss) before income taxes consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Domestic

 $(1,663) $(4,917)

Foreign

  3,153   (680)

Income (loss) before income taxes

 $1,490  $(5,597)

 

The components of the income tax provision consist of the following (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Current taxes:

        

Federal

 $(512) $399 

State

  1   33 

Foreign

  626   398 

Total current taxes

  115   830 
         
Deferred taxes:        
Federal  346   (381)
State  6   (47)
Foreign  180   (388)
Total deferred taxes  532   (816)

Income tax provision

 $647  $14 

 

A reconciliation of the reported income tax provision to the provision (benefit) that would result from applying the domestic federal statutory tax rate to pretax income (loss) is as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Income tax at federal statutory rate

 $313  $(1,175)

Effect of permanent differences

  121   260 

Global Intangible Low-Taxed Income

  555   364 

Change in valuation allowance

  51   106 

Foreign rate differential

  72   13 

Foreign tax credits

  (98)  10 
Stock-based compensation  164   98 
Net operating loss carryback  (512)   

Goodwill impairment

     375 

Other reconciling items

  (19)  (37)

Income tax provision

 $647  $14 

 

Income (loss) before income taxes and the statutory tax rate for each country that materially contributed to the foreign rate differential presented above is as follows (in thousands):

 

      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2020

  

2019

 

Cayman Islands

  % $2,589  $(2,746)

Hong Kong

  16.5%  267   3,441 

China

  25.0%  716   (1,644)

 

Deferred income taxes consist of the following (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Deferred tax assets:

        
Net operating losses $628  $1,477 
Stock-based compensation  510   925 
Operating lease liabilities  460   335 
Other  60   73 

Total deferred tax assets

  1,658   2,810 
Valuation allowance  (340)  (289)

Net deferred tax assets

  1,318   2,521 

Deferred tax liabilities:

        
Operating lease assets  (438)  (313)
Foreign deferreds  (216)  (202)
Prepaids  (113)  (109)
Other  (36)  (60)

Total deferred tax liabilities

  (803)  (684)

Net deferred tax assets

 $515  $1,837 

 

The effective income tax rate for the year ended December 31, 2020 includes an estimate for the Global Intangible Low-Taxed Income (“GILTI”) inclusion along with recording the effect of the U.S. Coronavirus Aid, Relief, and Economic Security (“CARES”) Act enacted on  March 27, 2020. The CARES Act makes broad changes to the Internal Revenue Code of 1986, as amended, including, but not limited to, the ability to carry net operating losses generated in tax years 2018, 2019 or 2020 back to the each of the five tax years preceding the tax year of such loss.  The effective income tax rate for the year ended December 31, 2019 was impacted by permanent differences including a true-up of the GILTI provision for the tax year ended December 31, 2018 and goodwill impairment for the year ended December 31, 2019.

 

As of December 31, 2020, the Company does not have a valuation allowance against its U.S. deferred tax assets. The Company analyzed all sources of available income and determined that they are more likely than not to realize the tax benefits of their deferred assets. As of December 31, 2020, the Company has a valuation allowance against deferred taxes in certain foreign jurisdictions with an overall net operating loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.

 

As of December 31, 2020, the Company no longer has U.S. federal net operating losses due to its filing in  August 2020 to carry back $3.6 million of losses generated in the tax year ended  December 31, 2019 to offset taxable income from the tax year ended  December 31, 2016The Company has U.S. state net operating loss carryforwards of $3.5 million that begin expiring in 2039. At December 31, 2020, the Company has foreign net operating loss carryforwards of approximately $2.8 million in various jurisdictions with various expirations.

 

As a result of capital return activities, the Company determined that a portion of its current undistributed foreign earnings is no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. For state income tax purposes, the Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable state corporate income tax rate(s). As of December 31, 2020, the Company has not recorded a state deferred tax liability for earnings that the Company plans to repatriate out of accumulated earnings in future periods because all earnings as of December 31, 2020 have already been repatriated. Due to the U.S. Tax Cuts and Jobs Act in 2017, repatriation from foreign subsidiaries will be offset with a dividends received deduction, resulting in little to no impact on federal tax expense. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of December 31, 2020.

 

The Company and its subsidiaries file tax returns in the United States, California, New Jersey and Texas and various foreign jurisdictions. During the fourth quarter of 2018, the Company was notified that it was selected for audit of the 2016 tax year by the U.S. Internal Revenue Service. The audit was expanded to include the 2017 and 2018 tax years, and a request has been submitted to also include the 2019 tax year. For purposes of this audit, fiscal years since 2007 are open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. No adjustments have been proposed at this time. The Company is no longer subject to state income tax examinations for years prior to 2016.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.4
Note 8 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
 
8.     COMMITMENTS AND CONTINGENCIES

 

On  January 8, 2019, the Company and its two executive officers were named in a putative securities class action filed in the United States District Court for the Central District of California, captioned Kauffman v. Natural Health Trends Corp., Case No. 2:19-cv-00163. On  May 3, 2019, the court issued an order appointing Xia Yang as lead plaintiff and appointing The Rosen Law Firm, P.A. as lead counsel. On  June 3, 2019, lead plaintiff filed an amended complaint. On  January 17, 2020, after briefing and oral argument on the Company’s motion to dismiss, the court issued an order dismissing the entire action with prejudice and ordering that judgment be entered for defendants. On  February 14, 2020, plaintiff filed a notice of appeal to the Ninth Circuit Court of Appeals. On  April 9, 2020, plaintiff filed a stipulated motion for voluntary dismissal of her appeal, concluding this matter.

 

The SEC is conducting a non-public investigation to determine whether there have been violations of the federal securities laws relating to the trading of the Company’s securities and/or its public disclosures. The Company has fully cooperated with the SEC and continues to do so. The amount of time needed to resolve this matter is uncertain, and the Company cannot predict the outcome or whether it will face additional governmental inquiries or other actions.

 

The Company has employment agreements with certain members of its management team that can be terminated by either the employee or the Company upon four weeks’ notice.  The employment agreements entered into with the management team contain provisions that guarantee the payments of specified amounts in the event of a change in control, as defined, or if the employee is terminated without cause, as defined, or terminates employment for good reason, as defined.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block]

9.     STOCKHOLDERS’ EQUITY

 

Authorized Shares

 

The Company is authorized to issue two classes of capital stock consisting of up to 5,000,000 shares of preferred stock, $0.001 par value, and 50,000,000 shares of common stock, $0.001 par value.

 

Dividends

 

The Company declared and paid cash dividends of $0.20 per common share during each quarter of 2020, totaling an aggregate of $9.1 million. The following table summarizes the Company’s cash dividend activity during 2019 (in thousands, except per share data):

 

Declaration Date

 

Per Common Share

  

Amount

 

Payment Date

October 29, 2019 (special)

 $0.40  $4,608 

November 29, 2019

January 27, 2019 (special)

  0.08   912 

March 15, 2019

January 27, 2019

  0.16   1,824 

March 15, 2019

  $0.64  $7,344  

 

Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

Stock Repurchases

 

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

 

On May 16, 2019, the Company’s Board of Directors authorized the Company to proceed with the purchase of up to $8.0 million in shares of common stock under the foregoing stock repurchase program. In connection therewith, the Company was advised that George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding shares of common stock, would participate in the stock repurchase program through The George K. Broady 2012 Irrevocable Trust (the “Broady Trust”) on a basis roughly proportional to his family’s ownership interest in the Company (See Note 10). During May 2019, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market for a total purchase price of $4.7 million. The stock repurchases, which included both open market purchases and the purchase of shares from the Broady Trust, were completed May 31, 2019 and resulted in the Company purchasing a total of 612,729 shares of its common stock for an aggregate purchase price of $6.7 million, plus transaction costs.

 

On August 6, 2019, the Company’s Board of Directors authorized the Company to proceed with additional purchases under the foregoing stock repurchase program in the open market. During August and September 2019, the Company purchased a total of 383,127 shares of common stock in the open market for an aggregate purchase price of $2.9 million, plus transaction costs. During December 2019, the Company purchased a total of 97,785 shares of common stock for an aggregate purchase price of $552,000, plus transaction costs.

 

As of December 31, 2020, $21.9 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

 

Restricted Stock

 

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At December 31, 2020, 1,219,583 shares remained available for issuance under the 2016 Plan.

 

On February 1, 2019, the Company granted 22,603 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interests with those of its stockholders and settling fiscal 2018 performance incentives totaling $377,000. The shares vest on a quarterly basis over the next three years and are subject to forfeiture in the event of an employee’s termination of service to the Company under specified circumstances.

 

On August 9, 2019, the Compensation ‎Committee amended the 2014 Long-Term Incentive Plan (the "LTI Plan") to provide that all then unpaid cash benefits earned by currently employed ‎participants under the LTI Plan with respect to performance periods that concluded on or prior to December 31, 2018 ‎shall be paid in the form of an award of shares of restricted stock under the 2016 ‎Plan. Accordingly, on August 9, 2019, the Company awarded 1,117,485 shares of restricted common stock to ‎certain of its employees (subject to quarterly vesting for the three-year period following the date of award) in lieu of ‎aggregate unpaid cash benefits of $7.9 million earned under the LTI Plan for performance periods ending on or ‎prior to December 31, 2018.

 

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:

 

  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2018

  45,486  $21.61 

Granted

  1,140,088   7.27 

Vested

  (227,892)  9.84 

Nonvested at December 31, 2019

  957,682   7.34 
Vested  (391,410)  7.53 
Nonvested at December 31, 2020  566,272   7.21 

 

Accumulated Other Comprehensive Loss

 

The changes in accumulated other comprehensive loss by component for 2020 were as follows (in thousands):

 

  

Foreign Currency Translation Adjustments

  

Unrealized Gains (Losses) on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2019

 $(1,245) $(19) $(1,264)

Other comprehensive income

  920   8   928 

Balance, December 31, 2020

 $(325) $(11) $(336)

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Related Party Transactions
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

10.     RELATED PARTY TRANSACTIONS

 

The Company is a party to a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called ReStor™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is an indirect owner of BHS. Under this agreement (as amended), the Company agreed to pay BHS a royalty based on a price per unit in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide by or through multi-level marketing or network marketing.  The Company recognized royalties of $83,000 and $96,000 during 2020 and 2019, respectively, under this agreement.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated under certain circumstances with no notice. An amendment to the agreement effective March 20, 2020 extends the term of the agreement for an additional five years to March 31, 2025, after which it shall be automatically renewed for successive one-year terms unless notice is given by either party at least 90 days in advance of the expiration of the then-current term.

 

The Company procured in China and arranged for shipment to The Aberdeen Group, LLC (“Aberdeen”) one order of apparel products in the amount of $7,100 during the first quarter of 2019Aberdeen is owned 40% by Sharng Holdings, which is wholly-owned by the Company’s president, Chris T. Sharng, and his wife, 40% by Mr. Broady, and 20% by an unrelated third party.  Aberdeen promptly paid the Company for the product and shipping cost incurred. Given the Company’s provision of such product sourcing service to Aberdeen, Aberdeen also paid the Company a market-based fee consistent with the provision of such service of $420. The Company analyzed the nature of the transaction with Aberdeen to determine whether it could be construed a violation under the guidelines of Section 402 of the Sarbanes-Oxley Act of 2002. The Company, through advice from its legal counsel, concluded that there is not a reasonable possibility that the transaction with Aberdeen would be deemed a violation of Section 402. This relationship between the Company and Aberdeen ceased following the completion of this transaction.

 

On May 17, 2019, the Company entered into a Stock Repurchase Agreement with The George K. Broady 2012 Irrevocable Trust (“Broady Trust”). Mr. Broady is the trustee and a beneficiary of the Broady Trust. The Stock Repurchase Agreement, which the Company and the Broady Trust entered into in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, provided for the Company’s purchase of common stock from the Broady Trust in off-the-market, private transactions at a rate of 0.4105 times the number of shares purchased by the Company’s broker in the open market as part of the stock repurchase program authorized by the Company’s Board of Directors on May 16, 2019. The Company’s purchases from the Broady Trust concluded on May 31, 2019, were completed at a per share purchase price equal to the weighted average price per share paid by the Company’s broker in its open-market purchases, and resulted in the purchase of 178,324 shares of common stock for an aggregate purchase price of $1.9 million. See Note 9.

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.4
Note 11 - Employee Benefit Plans
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Retirement Benefits [Text Block]

11.     EMPLOYEE BENEFIT PLANS

 

     The Company has a 401(k) defined contribution plan which permits participating employees in the United States to defer up to a maximum of 90% of their compensation, subject to limitations established by the Internal Revenue Service. Employees age 21 and older are eligible to contribute to the plan starting the first day of the month following the date of employment.  Participating employees are eligible to receive discretionary matching contributions and profit sharing, subject to certain conditions, from the Company.  In 2020 and 2019, the Company matched employee deferral contributions up to 4.5% of salary, which vested 100% immediately. No profit sharing has been paid under the plan. The Company recorded compensation expense of $68,000 and $85,000 for 2020 and 2019, respectively, related to its matching contributions to the plan. Certain of the Company’s employees located outside the United States participate in employee benefit plans that are statutory in nature.

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

12.    SEGMENT INFORMATION

 

The Company sells products to a member network that operates in a seamless manner from market to market, except for the China market where it sells to some consumers through an e-commerce retail platform, and the Russia and Kazakhstan market where the Company’s engagement of a third-party service provider results in a different economic structure than its other markets. Otherwise, the Company believes that all of its other operating segments have similar economic characteristics and are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. Therefore, the Company aggregates its other operating segments (including its Hong Kong operating segment) into a single reporting segment (the “Primary Reporting Segment”).

 

The Company reviews its net sales and operating income (loss) by operating segment, and reviews its assets and capital expenditures on a consolidated basis and not by operating segment. As such, net sales and operating income (loss) are presented by reportable segment and assets and capital expenditures by operating segment are not presented. Segment operating income (loss) is adjusted for certain direct costs and commission allocation.

 

The Company’s operating information by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales:

        
Primary Reporting Segment $58,243  $73,693 
China  2,940   2,941 
Russia and Kazakhstan  888   980 

Total net sales

 $62,071  $77,614 
         

Income (loss) from operations:

        
Primary Reporting Segment $9,277  $9,339 
China  330   (1,719)
Russia and Kazakhstan  (96)  (115)

Total income (loss) from operations for reportable segments

  9,511   7,505 
Unallocated corporate expenses  (8,842)  (14,528)
Other income, net  821   1,426 

Income (loss) before income taxes

 $1,490  $(5,597)

 

The Company’s net sales by geographic area are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales from external customers:

        

United States

 $1,573  $2,003 

Canada

  765   1,048 

Peru

  1,453   2,380 

Hong Kong1

  49,169   62,724 

China

  2,940   2,941 

Taiwan

  3,034   3,126 

Russia and Kazakhstan

  888   980 

Europe

  1,050   1,370 

Other foreign countries

  1,199   1,042 

Total net sales

 $62,071  $77,614 

 


1 Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.

 

The Company’s net sales by product and service are as follows (in thousands):

 

  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales by product and service:

        

Product sales

 $55,840  $73,048 

Administrative fees, freight and other

  6,991   6,106 

Less: sales returns

  (760)  (1,540)

Total net sales

 $62,071  $77,614 

 

During June 2020, the Company modified its fee structure associated with certain electronic (eWallet) accounts held by members in Hong Kong, resulting in increased administrative fees recognized as revenue in 2020. Due to system constraints, it is impracticable for the Company to separately disclose sales by product category for the years presented.

 

The Company’s long-lived assets by geographic area are as follows (in thousands):

 

  

December 31,

 
  

2020

  

2019

 

Long-lived assets:

        

United States

 $227  $379 

Hong Kong

  146   135 

China

  47   57 

Other foreign countries

  119   164 

Total long-lived assets

 $539  $735 

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Subsequent Event
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]

13.     SUBSEQUENT EVENT

 

On February 8, 2021, the Board of Directors declared a quarterly cash dividend of $0.20 on each share of common stock outstanding. The dividend will be payable on March 5, 2021 to stockholders of record on February 23, 2021. Declaration and payment of any future dividends on shares of common stock will be at the sole discretion of the Company’s Board of Directors.

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.

 

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassification

 

Certain income taxes payable balances have been reclassified in the prior year consolidated financial statements to conform to current year presentation. No change in total current liabilities occurred.

 

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.

 

The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

 

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

Cash and cash equivalents include the Company’s investments in municipal and corporate debt securities, money market funds, and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Debt securities classified as cash equivalents are required to be accounted for in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at December 31, 2020 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income and expense. Realized gains and losses, as well as interest income, are also included in other income and expense. The fair values of securities are based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs.

 

The Company includes credit card receivables due from certain of its credit card processors in its cash and cash equivalents as the cash proceeds are received within two to five days.

 

The Company maintains certain cash balances at several institutions located in the United States, Hong Kong and elsewhere which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

 

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

 

In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million ($2.9 million at December 31, 2019) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. The Company received a refund of this deposit in  March 2020 in connection with the withdrawal of its application. In November 2019, the Company funded a similar bank deposit account in the amount of VND 10 million ($433,000 and $432,000 at December 31, 2020 and 2019, respectively) for purposes of submitting a direct selling license application in Vietnam.

 

The Company periodically maintains a cash reserve with certain credit card processing companies to provide for potential uncollectible amounts and chargebacks. Those cash reserves held by credit card processing companies located in South Korea are reflected in noncurrent assets since they require the Company to provide 100% collateral before processing transactions, which must be maintained indefinitely.

 

Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three to five years for office equipment, office software and capitalized internal-use software development costs and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the assets. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation and amortization expenses are included in the statement of operations as selling, general and administrative expenses. Such expense totaled $410,000 and $387,000 during 2020 and 2019, respectively.

 

The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of these assets is measured by comparison of its carrying amounts to future undiscounted cash flows the assets are expected to generate. If property and equipment are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair value.

 

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

 

During the fourth quarter of 2019, the Company elected to early adopt the guidance of Accounting Standards Update ("ASU") 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminates Step 2 from the goodwill impairment test. The Company estimated fair value based on market capitalization after considering recent trends in its stock price. Upon comparing such fair value with its carrying amount, the Company recognized an impairment loss of $1.8 million in December 2019.

 

Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized based on the more likely than not recognition criteria. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has evaluated its tax positions and determined that there are no significant uncertain tax positions for the current year or years prior. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided for state income tax purposes on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

 

Amounts Held in Distributor EWallets [Policy Text Block]

Amounts Held in eWallets

 

The Company requires commission payments of certain members in Hong Kong and other markets to be first recorded into an electronic wallet (eWallet) account in lieu of being paid out directly to members. The eWallet functionality allows members to place new product orders utilizing eWallet available balance and/or request commission payout via multiple payment methods. Amounts held in eWallets are reflected on the balance sheet as a current liability.

 

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

 

The functional currency of the Company’s international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into stockholders' equity.

 

Aggregate transaction gains or losses, including gains or losses related to foreign-denominated cash and cash equivalents and the re-measurement of certain inter-company balances, are included in the statement of operations as other income and expense. Loss on foreign exchange totaling $335,000 and $355,000 was recognized during 2020 and 2019, respectively.

 

Commissions, Policy [Policy Text Block]

Commissions Expense

 

Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of the Company’s products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  The Company accrues commissions when earned and as the related revenue is recognized and pays commissions on product sales generally two weeks following the end of the weekly sales period.

 

In some markets, the Company also pays certain bonuses on purchases by up to three generations of personally sponsored members, as well as bonuses on commissions earned by up to seven generations of personally sponsored members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  The Company estimates and accrues all costs associated with the incentives as the members meet the qualification requirements.

 

From time to time the Company makes modifications and enhancements to the Company’s compensation plan to help motivate members, which can have an impact on member commissions. The Company also enters into performance-based agreements for business or market development, which may result in additional compensation to specific members.

 

Earnings Per Share, Policy [Policy Text Block]

Net Income (Loss) Per Common Share

 

Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized, if any, is assumed to be used to repurchase shares.

 

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Certain Risks and Concentrations

 

In late 2019 or early 2020 an outbreak of COVID-19 was first identified in China and subsequently spread around the world. On March 11, 2020 the World Health Organization declared the COVID-19 outbreak a global pandemic. The outbreak caused the Chinese government to implement powerful measures to control the virus, such as requiring businesses to close throughout various areas of China and restricting public gatherings and certain travel within the country.   The Company has significant business in China and in 2020 generated approximately 79% of its revenue in Hong Kong, substantially all of which was derived from the sale of products to members in China.  The Chinese government has recently taken steps to reduce some of the restrictive measures that it imposed to control COVID-19, while the governments of other countries in which the Company operates are working at various stages in their efforts to control the virus. The scope and impact of the pandemic and related control measures are uncertain, but the Company has taken steps to adapt some of its marketing programs, such as relying on certain product promotions and webcast training, to overcome the physical restrictions imposed in response to the pandemic. The Company also canceled both of its major member events planned for 2020, although some relatively small member events were held in the second half of the year. The severity of the impact on the Company of the COVID-19 pandemic will depend on future developments, including the duration and spread of the virus, and related control measures, which the Company is unable to accurately predict. Regardless, these disruptions have materially negatively impacted the Company’s financial results throughout 2020, and the Company expects that its financial results for the near-term may be adversely affected. These disruptions have also adversely impacted the operations of some of the Company’s third-party logistics providers, and it expects that the future operations of these logistics providers and other third parties with whom it works may be adversely affected by these disruptions. The Company will continue to assess the operational and financial impact of the COVID-19 pandemic.

 

In contrast to the Company’s business in other parts of the world, the Company’s China subsidiary has not implemented a direct sales model in China. The Chinese government permits direct selling only by organizations that have a license and has also adopted anti-pyramid selling and multilevel marketing legislation. The Company previously submitted a preliminary application for a direct selling license in China in August 2015, but in 2019 a Chinese governmental authority recommended that the Company withdraw its application. The Company understands that the governmental authorities recommended that other companies with pending direct selling license applications also withdraw their applications. The Company applied to withdraw its application in November 2019, and the governmental authorities approved the withdrawal of its application shortly thereafter. The Company operates an e-commerce direct selling platform in Hong Kong and recognizes the revenue derived from sales to both Hong Kong and Chinese members as being generated in Hong Kong. Products purchased by members in China are delivered to third parties that act as the importers of record under agreements to pay applicable duties. In addition, through a Chinese entity, the Company sells products in China using an e-commerce retail platform. The Chinese entity operates separately from the Hong Kong entity, and a Chinese member may elect to participate separately or in both.

 

The Company continually evaluates its business in China and Hong Kong for compliance with applicable laws and regulations, including seeking the input of outside professionals and certain Chinese authorities. This process can and has resulted in the identification of certain matters of potential noncompliance. The Company works on a continuing basis to satisfactorily address such matters, however there can be no assurance that adequate steps are taken or that applicable laws and regulations are properly interpreted. Should the government authorities determine that the Company’s activities violate applicable laws and regulations, including China’s direct selling, pyramid selling or multilevel marketing laws and regulations, or should new laws or regulations be adopted, there could be a material adverse effect on the Company’s business, financial condition and results of operations.

 

Although the Company attempts to work closely with both national and local Chinese governmental agencies in conducting its business, the Company’s efforts to comply with national and local laws may be harmed by a rapidly evolving regulatory climate, concerns about activities resembling violations of direct selling, pyramid selling or multi-level marketing legislation, subjective interpretations of laws and regulations, and activities by individual members that may violate laws notwithstanding the Company's policies prohibiting such activities. Any determination that the Company’s operations or activities, or the activities of its individual members or employee sales representatives, or importers of record are not in compliance with applicable laws and regulations could result in the imposition of substantial fines, extended interruptions of business, restrictions on the Company’s future ability to obtain business licenses or expand into new locations, changes to its business model, the termination of required licenses to conduct business, or other actions, any of which could materially harm the Company’s business, financial condition and results of operations.

 

No single market other than Hong Kong had net sales greater than 10% of total sales. Sales are made to the Company’s members and no single customer accounted for 10% or more of its net sales. However, the Company’s business model can result in a concentration of sales to several different members and their network of members. Although no single member accounted for 10% or more of net sales, the loss of a key member or that member’s network could have an adverse effect on the Company’s net sales and financial results.

 

The Company’s Premium Noni Juice, Enhanced Essential Probiotics and Triotein™ products each account for at least 10% of the Company’s total revenue. The Company currently sources each such product from a single supplier. If demand decreases significantly, government regulation restricts their sale, the Company is unable to adequately source or deliver the products, or the Company ceases offering the products for any reason without suitable replacements, the Company’s business, financial condition and results of operations could be materially and adversely affected.

 

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

The carrying amounts of the Company’s financial instruments, including cash and accounts payable, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents.

 

Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

 

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis and added Topic 326 to the FASB ASC. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments - Credit Losses.  The amendments to ASU 2019-11 clarify, correct and make improvements to Topic 326.  ASU 2016-13 as well as the updates in ASU 2019-11 are effective for interim and annual periods beginning after December 15, 2022, and early adoption is permitted.  The Company is currently evaluating the impact of this standard on its consolidated financial statements.

 

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This guidance modifies, removes, and adds certain disclosure requirements on fair value measurements. This ASU was effective for interim and annual periods beginning after December 15, 2019, and early adoption was permitted.  The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods.  It also adds guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. This ASU was effective for interim and annual periods beginning after December 15, 2020, and early adoption was permitted.  The Company elected to early adopt the new standard during the first quarter of 2020. Such adoption did not have a material impact on the Company's consolidated financial statements.

 

Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Net Income (Loss) Per Common Share (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 
  

Income

  

Shares

  

Per Share

  

Loss

  

Shares

  

Per Share

 

Basic net income (loss) per common share:

                        

Net income (loss) available to common stockholders

 $843   10,630  $0.08  $(5,611)  10,871  $(0.52)

Effect of dilutive securities:

                        

Non-vested restricted stock

     794               

Diluted net income (loss) per common share:

                        

Net income (loss) available to common stockholders plus assumed conversions

 $843   11,424  $0.07  $(5,611)  10,871  $(0.52)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Additional Balance Sheet Components [Table Text Block]
  

December 31,

 
  

2020

  

2019

 

Cash and cash equivalents:

        
Cash $23,977  $13,720 
Cash equivalents  68,390   82,315 
   92,367   96,035 
Restricted cash  525   3,390 
  $92,892  $99,425 
         

Inventories:

        
Finished goods $3,071  $6,142 
Raw materials  1,047   1,249 
Reserve for obsolescence  (339)  (987)
  $3,779  $6,404 

Property and equipment:

        
Office equipment $449  $578 
Office software  1,001   1,037 
Machinery  30   28 
Furniture and fixtures  254   327 
Leasehold improvements  839   1,001 
Construction in progress  41    

Property and equipment, at cost

  2,614   2,971 
Accumulated depreciation and amortization  (2,075)  (2,236)
  $539  $735 

Other accrued expenses:

        
Sales returns $189  $373 
Employee-related expense  1,149   1,258 
Warehousing, inventory-related and other  584   756 
  $1,922  $2,387 

Deferred revenue:

        
Unshipped product and unredeemed product vouchers $1,005  $2,390 
Auto ship advances  1,977   1,985 
Other  109   131 
  $3,091  $4,506 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Available-for-sale Securities [Table Text Block]
    

December 31, 2020

  

December 31, 2019

 
  

Fair Value Level1

 

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

  

Adjusted Cost

  

Gross Unrealized Losses

  

Fair Value

 

Money market funds

 

Level 1

 $21,042  $  $21,042  $11,659  $  $11,659 

Time deposits

 

Level 2

  5,458      5,458   13,544      13,544 

Municipal debt securities

 

Level 2

  30,280   (5)  30,275   347      347 

Corporate debt securities

 

Level 2

  11,621   (6)  11,615   56,784   (19)  56,765 

Total investments

   $68,401  $(11) $68,390  $82,334  $(19) $82,315 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Leases (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Lease, Cost [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Operating leases

 $1,716  $2,024 

Short-term leases

  299   284 

Total lease cost

 $2,015  $2,308 

Weighted-average remaining lease term (in years)

  5.5 

Weighted-average discount rate

  3.4%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2021

 $1,184 

2022

  1,081 

2023

  583 

2024

  261 

2025

  261 

Thereafter

  990 

Total lease payments

 $4,360 

Less: imputed interest

  (422)

Present value of lease liabilities

 $3,938 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Domestic

 $(1,663) $(4,917)

Foreign

  3,153   (680)

Income (loss) before income taxes

 $1,490  $(5,597)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Current taxes:

        

Federal

 $(512) $399 

State

  1   33 

Foreign

  626   398 

Total current taxes

  115   830 
         
Deferred taxes:        
Federal  346   (381)
State  6   (47)
Foreign  180   (388)
Total deferred taxes  532   (816)

Income tax provision

 $647  $14 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Income tax at federal statutory rate

 $313  $(1,175)

Effect of permanent differences

  121   260 

Global Intangible Low-Taxed Income

  555   364 

Change in valuation allowance

  51   106 

Foreign rate differential

  72   13 

Foreign tax credits

  (98)  10 
Stock-based compensation  164   98 
Net operating loss carryback  (512)   

Goodwill impairment

     375 

Other reconciling items

  (19)  (37)

Income tax provision

 $647  $14 
Income Tax Foreign Rate Differential [Table Text Block]
      

Year Ended December 31,

 
  

Statutory Tax Rate

  

2020

  

2019

 

Cayman Islands

  % $2,589  $(2,746)

Hong Kong

  16.5%  267   3,441 

China

  25.0%  716   (1,644)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

December 31,

 
  

2020

  

2019

 

Deferred tax assets:

        
Net operating losses $628  $1,477 
Stock-based compensation  510   925 
Operating lease liabilities  460   335 
Other  60   73 

Total deferred tax assets

  1,658   2,810 
Valuation allowance  (340)  (289)

Net deferred tax assets

  1,318   2,521 

Deferred tax liabilities:

        
Operating lease assets  (438)  (313)
Foreign deferreds  (216)  (202)
Prepaids  (113)  (109)
Other  (36)  (60)

Total deferred tax liabilities

  (803)  (684)

Net deferred tax assets

 $515  $1,837 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Dividends Payable [Table Text Block]

Declaration Date

 

Per Common Share

  

Amount

 

Payment Date

October 29, 2019 (special)

 $0.40  $4,608 

November 29, 2019

January 27, 2019 (special)

  0.08   912 

March 15, 2019

January 27, 2019

  0.16   1,824 

March 15, 2019

  $0.64  $7,344  
Nonvested Restricted Stock Shares Activity [Table Text Block]
  

Shares

  

Wtd. Avg. Price at Date of Issuance

 

Nonvested at December 31, 2018

  45,486  $21.61 

Granted

  1,140,088   7.27 

Vested

  (227,892)  9.84 

Nonvested at December 31, 2019

  957,682   7.34 
Vested  (391,410)  7.53 
Nonvested at December 31, 2020  566,272   7.21 
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
  

Foreign Currency Translation Adjustments

  

Unrealized Gains (Losses) on Available-For-Sale Investments

  

Total

 

Balance, December 31, 2019

 $(1,245) $(19) $(1,264)

Other comprehensive income

  920   8   928 

Balance, December 31, 2020

 $(325) $(11) $(336)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales:

        
Primary Reporting Segment $58,243  $73,693 
China  2,940   2,941 
Russia and Kazakhstan  888   980 

Total net sales

 $62,071  $77,614 
         

Income (loss) from operations:

        
Primary Reporting Segment $9,277  $9,339 
China  330   (1,719)
Russia and Kazakhstan  (96)  (115)

Total income (loss) from operations for reportable segments

  9,511   7,505 
Unallocated corporate expenses  (8,842)  (14,528)
Other income, net  821   1,426 

Income (loss) before income taxes

 $1,490  $(5,597)
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales from external customers:

        

United States

 $1,573  $2,003 

Canada

  765   1,048 

Peru

  1,453   2,380 

Hong Kong1

  49,169   62,724 

China

  2,940   2,941 

Taiwan

  3,034   3,126 

Russia and Kazakhstan

  888   980 

Europe

  1,050   1,370 

Other foreign countries

  1,199   1,042 

Total net sales

 $62,071  $77,614 
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Year Ended December 31,

 
  

2020

  

2019

 

Net sales by product and service:

        

Product sales

 $55,840  $73,048 

Administrative fees, freight and other

  6,991   6,106 

Less: sales returns

  (760)  (1,540)

Total net sales

 $62,071  $77,614 
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]
  

December 31,

 
  

2020

  

2019

 

Long-lived assets:

        

United States

 $227  $379 

Hong Kong

  146   135 

China

  47   57 

Other foreign countries

  119   164 

Total long-lived assets

 $539  $735 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.4
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)
₫ in Millions, ¥ in Millions
12 Months Ended
Mar. 11, 2020
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
CNY (¥)
Nov. 30, 2019
VND (₫)
Goodwill, Impairment Loss   $ 0 $ 1,764,000    
Foreign Currency Transaction Gain (Loss), Unrealized   (335,000) (355,000)    
Selling, General and Administrative Expenses [Member]          
Depreciation, Depletion and Amortization, Nonproduction, Total   410,000 387,000    
CHINA          
Restricted Cash and Cash Equivalents, Total     2,900,000 ¥ 20  
VIET NAM          
Restricted Cash and Cash Equivalents, Total   $ 433,000 $ 432,000   ₫ 10
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF          
Restricted Cash, Collateral Requirement Percentage   100.00%      
HONG KONG | Revenue from Contract with Customer Benchmark [Member] | Geographic Concentration Risk [Member]          
Concentration Risk, Percentage 79.00%        
Minimum [Member]          
Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day)   2 days      
Minimum [Member] | Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]          
Property, Plant and Equipment, Useful Life (Year)   3 years      
Minimum [Member] | Furniture and Fixtures [Member]          
Property, Plant and Equipment, Useful Life (Year)   5 years      
Maximum [Member]          
Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day)   5 days      
Maximum [Member] | Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]          
Property, Plant and Equipment, Useful Life (Year)   5 years      
Maximum [Member] | Furniture and Fixtures [Member]          
Property, Plant and Equipment, Useful Life (Year)   7 years      
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Note 2 - Revenue (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue from Contract with Customers, Sales Returns, Percent 1.00% 2.00%
Contract with Customer, Liability, Revenue Recognized $ 1.4  
Minimum [Member]    
Revenue from Contract with Customer, Sales Returns Policy Term (Day) 14 days  
Revenue from Contract with Customers, Historical Sales Returns, Percent 1.00%  
Maximum [Member]    
Revenue from Contract with Customer, Sales Returns Policy Term (Day) 1 year  
Revenue from Contract with Customers, Historical Sales Returns, Percent 10.00%  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Net Income (Loss) Per Common Share (Details Textual)
12 Months Ended
Dec. 31, 2019
shares
Restricted Stock [Member]  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 459,654
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.4
Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net income (loss) available to common stockholders $ 843 $ (5,611)
Basic (in shares) 10,630 10,871
Basic (in dollars per share) $ 0.08 $ (0.52)
Non-vested restricted stock $ 0 $ 0
Non-vested restricted stock (in shares) 794 0
Net income (loss) available to common stockholders plus assumed conversions $ 843 $ (5,611)
Diluted (in shares) 11,424 10,871
Diluted (in dollars per share) $ 0.07 $ (0.52)
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Balance Sheet Components (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 92,367 $ 96,035
CHINA    
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 12,500  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.4
Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash and cash equivalents:      
Cash $ 23,977 $ 13,720  
Cash equivalents 68,390 82,315  
Cash and Cash Equivalents, at Carrying Value, Ending Balance 92,367 96,035  
Restricted cash 525 3,390  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance 92,892 99,425 $ 135,651
Inventories:      
Finished goods 3,071 6,142  
Raw materials 1,047 1,249  
Reserve for obsolescence (339) (987)  
Inventory, Net, Total 3,779 6,404  
Property and equipment:      
Office equipment 449 578  
Office software 1,001 1,037  
Machinery 30 28  
Furniture and fixtures 254 327  
Leasehold improvements 839 1,001  
Construction in progress 41 0  
Property and equipment, at cost 2,614 2,971  
Accumulated depreciation and amortization (2,075) (2,236)  
Property, Plant and Equipment, Net, Ending Balance 539 735  
Other accrued expenses:      
Sales returns 189 373  
Employee-related expense 1,149 1,258  
Warehousing, inventory-related and other 584 756  
Accrued Liabilities, Current, Total 1,922 2,387  
Deferred revenue:      
Deferred revenue 3,091 4,506  
Unshipped Product [Member]      
Deferred revenue:      
Deferred revenue 1,005 2,390  
Auto ship advances [Member]      
Deferred revenue:      
Deferred revenue 1,977 1,985  
Product and Service, Other [Member]      
Deferred revenue:      
Deferred revenue $ 109 $ 131  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.4
Note 5 - Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Adjusted cost [1] $ 68,401 $ 82,334
Gross unrealized losses [1] (11) (19)
Fair value [1] 68,390 82,315
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Adjusted cost [1] 21,042 11,659
Gross unrealized losses [1] 0 0
Fair value [1] 21,042 11,659
Bank Time Deposits [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 5,458 13,544
Gross unrealized losses [1] 0 0
Fair value [1] 5,458 13,544
Municipal Bonds [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 30,280 347
Gross unrealized losses [1] (5) 0
Fair value [1] 30,275 347
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Adjusted cost [1] 11,621 56,784
Gross unrealized losses [1] (6) (19)
Fair value [1] $ 11,615 $ 56,765
[1] FASB Topic 820, Fair Value Measurements, establishes a fair value hierarchy that requires the use of observable market data, when available, and prioritizes the inputs to valuation techniques used to measure fair value in the following categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Leases (Details Textual)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
ft²
Dec. 31, 2019
USD ($)
Jun. 30, 2020
Operating Lease, Payments | $ $ 1.6 $ 2.0  
HONG KONG      
Area of Land (Square Foot) 7,300    
Rolling Hills Estates [Member]      
Area of Land (Square Foot) 4,900    
Lessee, Operating Lease, Renewal Term (Year)     5 years
Richmond, British Columbia [Member]      
Area of Land (Square Foot) 1,600    
Metuchen, New Jersey [Member]      
Area of Land (Square Foot) 2,000    
CHINA      
Lessee, Number of Branches 8    
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating leases $ 1,716 $ 2,024
Short-term leases 299 284
Total lease cost $ 2,015 $ 2,308
Weighted-average remaining lease term (in years) (Year) 5 years 6 months  
Weighted-average discount rate 3.40%  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Note 6 - Leases - Maturity of Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
2021 $ 1,184
2022 1,081
2023 583
2024 261
2025 261
Thereafter 990
Total lease payments 4,360
Less: imputed interest (422)
Present value of lease liabilities $ 3,938
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred Tax Assets, Valuation Allowance, Total $ 340 $ 289
Domestic Tax Authority [Member]    
Deferred Tax Assets, Valuation Allowance, Total 0  
Operating Loss Carryforwards, Total 3,600  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards, Total 3,500  
Foreign Tax Authority [Member]    
Operating Loss Carryforwards, Total $ 2,800  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Domestic $ (1,663) $ (4,917)
Foreign 3,153 (680)
Income (loss) before income taxes $ 1,490 $ (5,597)
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Federal $ (512) $ 399
State 1 33
Foreign 626 398
Total current taxes 115 830
Federal 346 (381)
State 6 (47)
Foreign 180 (388)
Total deferred taxes 532 (816)
Income tax provision $ 647 $ 14
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income tax at federal statutory rate $ 313 $ (1,175)
Effect of permanent differences 121 260
Global Intangible Low-Taxed Income 555 364
Change in valuation allowance 51 106
Foreign rate differential 72 13
Foreign tax credits (98) 10
Stock-based compensation 164 98
Net operating loss carryback (512) 0
Goodwill impairment 0 375
Other reconciling items (19) (37)
Income tax provision $ 647 $ 14
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Foreign Rate Differentials (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Foreign $ 3,153 $ (680)
Department for International Tax Cooperation [Member]    
Statutory Tax Rate 0.00%  
Foreign $ 2,589 (2,746)
Inland Revenue, Hong Kong [Member]    
Statutory Tax Rate 16.50%  
Foreign $ 267 3,441
State Administration of Taxation, China [Member]    
Statutory Tax Rate 25.00%  
Foreign $ 716 $ (1,644)
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.4
Note 7 - Income Taxes - Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Deferred tax assets:    
Net operating losses $ 628 $ 1,477
Stock-based compensation 510 925
Operating lease liabilities 460 335
Other 60 73
Total deferred tax assets 1,658 2,810
Valuation allowance (340) (289)
Net deferred tax assets 1,318 2,521
Deferred tax liabilities:    
Operating lease assets 438 313
Foreign deferreds (216) (202)
Prepaids 113 109
Other 36 60
Total deferred tax liabilities (803) (684)
Net deferred tax assets $ 515 $ 1,837
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Aug. 09, 2019
Feb. 01, 2019
Dec. 31, 2019
May 31, 2019
Sep. 30, 2019
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Mar. 20, 2020
May 16, 2019
Jan. 12, 2016
Jul. 28, 2015
Preferred Stock, Shares Authorized (in shares)     5,000,000     5,000,000       5,000,000 5,000,000        
Preferred Stock, Par or Stated Value Per Share (in dollars per share)     $ 0.001     $ 0.001       $ 0.001 $ 0.001        
Common Stock, Shares Authorized (in shares)     50,000,000     50,000,000       50,000,000 50,000,000        
Common Stock, Par or Stated Value Per Share (in dollars per share)     $ 0.001     $ 0.001       $ 0.001 $ 0.001        
Common Stock, Dividends, Per Share, Declared (in dollars per share)           $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.80 $ 0.64        
Dividends, Common Stock, Total                   $ 9,100,000          
Stock Repurchase Program, Authorized Amount                           $ 70,000,000.0 $ 15,000,000.0
Treasury Stock, Shares, Acquired (in shares)     97,785 612,729 383,127                    
Treasury Stock, Value, Acquired, Cost Method     $ 552,000 $ 6,700,000 $ 2,900,000           $ 10,117,000        
Stock Repurchase Program, Remaining Authorized Repurchase Amount           $ 21,900,000       $ 21,900,000          
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)           $ 0.20 $ 0.20 $ 0.20 $ 0.20   $ 0.64        
Equity Incentive Plan 2016 [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)           2,500,000       2,500,000          
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)           1,219,583       1,219,583          
Equity Incentive Plan 2016 [Member] | Restricted Stock [Member]                              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 1,117,485 22,603                 1,140,088        
Stock Issued During Period, Value, Restricted Stock Award, Gross $ 7,900,000 $ 377,000                          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 3 years 3 years                          
Director [Member]                              
Common Stock, Percentage of Beneficial Stock Outstanding                       5.00% 5.00%    
Broady Trust [Member]                              
Stock Repurchase Program, Authorized Amount                         $ 8,000,000.0    
Open Market Purchases [Member]                              
Stock Repurchase Program, Authorized Amount       $ 4,700,000                      
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity - Dividend Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dividends per share (in dollars per share) $ 0.20 $ 0.20 $ 0.20 $ 0.20   $ 0.64
Dividends         $ 9,138 $ 7,344
Special Dividends Declared October 29, 2019 [Member]            
Dividends per share (in dollars per share)           $ 0.40
Dividends           $ 4,608
Special Dividends Declared January 27, 2019 [Member]            
Dividends per share (in dollars per share)           $ 0.08
Dividends           $ 912
Dividends Declared January 27, 2019 [Member]            
Dividends per share (in dollars per share)           $ 0.16
Dividends           $ 1,824
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity - Restricted Stock Activity (Details) - Restricted Stock [Member] - Equity Incentive Plan 2016 [Member] - $ / shares
12 Months Ended
Aug. 09, 2019
Feb. 01, 2019
Dec. 31, 2020
Dec. 31, 2019
Nonvested at December 31, 2018 (in shares)     957,682 45,486
Nonvested balance, wtd. avg. price (in dollars per share)     $ 7.34 $ 21.61
Granted (in shares) 1,117,485 22,603   1,140,088
Granted, wtd. avg. price (in dollars per share)       $ 7.27
Vested (in shares)     (391,410) (227,892)
Vested, wtd. avg. price (in dollars per share)     $ 7.53 $ 9.84
Nonvested at December 31, 2019 (in shares)     566,272 957,682
Nonvested balance, wtd. avg. price (in dollars per share)     $ 7.21 $ 7.34
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
Balance, December 31, 2019 $ 75,064
Balance, December 31, 2020 67,697
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Balance, December 31, 2019 (1,245)
Other comprehensive income 920
Balance, December 31, 2020 (325)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]  
Balance, December 31, 2019 (19)
Other comprehensive income 8
Balance, December 31, 2020 (11)
AOCI Attributable to Parent [Member]  
Balance, December 31, 2019 (1,264)
Other comprehensive income 928
Balance, December 31, 2020 $ (336)
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Note 10 - Related Party Transactions (Details Textual)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Mar. 20, 2020
May 17, 2019
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
May 31, 2019
USD ($)
shares
Sep. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
May 16, 2019
Treasury Stock, Shares, Acquired (in shares) | shares     97,785 612,729 383,127        
Treasury Stock, Value, Acquired, Cost Method     $ 552,000 $ 6,700,000 $ 2,900,000     $ 10,117,000  
Broady Trust [Member]                  
Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction   0.4105              
Treasury Stock, Shares, Acquired (in shares) | shares   178,324              
Treasury Stock, Value, Acquired, Cost Method   $ 1,900,000              
BHS [Member] | Royalty Agreement and License [Member]                  
Royalty Expense             $ 83,000 $ 96,000  
Unrelated Third Party [Member] | Aberdeen [Member]                  
Noncontrolling Interest, Ownership Percentage by Parent             20.00%    
Director [Member]                  
Common Stock, Percentage of Beneficial Stock Outstanding 5.00%               5.00%
Director [Member] | Aberdeen [Member]                  
Noncontrolling Interest, Ownership Percentage by Parent             40.00%    
BHS [Member] | Royalty Agreement and License [Member]                  
Related Party Transaction, Additional Extension Period of Agreement (Year) 5 years                
Related Party Transaction, Automatic Renewal Period of Agreement (Year) 1 year                
Number of Days Termination Notice (Day) 90 days                
Aberdeen [Member]                  
Related Party Transaction, Other Revenues from Transactions with Related Party             $ 420    
Aberdeen [Member] | Shipment of Apparel Products [Member]                  
Number of Product Orders           1      
Related Party Transaction, Amounts of Transaction           $ 7,100      
Sharng Holdings [Member] | Aberdeen [Member]                  
Noncontrolling Interest, Ownership Percentage by Parent             40.00%    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.4
Note 11 - Employee Benefit Plans (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage 90.00%  
Age Requirement For 401K Contributions (Year) 21 years  
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 4.50% 4.50%
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage 100.00% 100.00%
Defined Contribution Plan, Cost $ 68,000 $ 85,000
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information (Details Textual)
12 Months Ended
Dec. 31, 2020
Number of Reportable Segments 1
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information - Operating Information by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net sales $ 62,071 $ 77,614
Income (loss) from operations 669 (7,023)
Other income, net 821 1,426
Income (loss) before income taxes 1,490 (5,597)
Operating Segments [Member]    
Income (loss) from operations 9,511 7,505
Intersegment Eliminations [Member]    
Income (loss) from operations (8,842) (14,528)
CHINA    
Net sales 2,940 2,941
CHINA | Operating Segments [Member]    
Income (loss) from operations 330 (1,719)
Russia and Kazakhstan [Member]    
Net sales 888 980
Russia and Kazakhstan [Member] | Operating Segments [Member]    
Income (loss) from operations (96) (115)
Primary Reporting Segment [Member]    
Net sales 58,243 73,693
Primary Reporting Segment [Member] | Operating Segments [Member]    
Income (loss) from operations $ 9,277 $ 9,339
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information - Net Sales by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net sales $ 62,071 $ 77,614
UNITED STATES    
Net sales 1,573 2,003
CANADA    
Net sales 765 1,048
PERU    
Net sales 1,453 2,380
HONG KONG    
Net sales [1] 49,169 62,724
CHINA    
Net sales 2,940 2,941
TAIWAN, PROVINCE OF CHINA    
Net sales 3,034 3,126
Russia and Kazakhstan [Member]    
Net sales 888 980
Europe [Member]    
Net sales 1,050 1,370
Other Foreign Countries [Member]    
Net sales $ 1,199 $ 1,042
[1] Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. See “Item 1A. Risk Factors”.
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information - Net Sales by Product and Service (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net sales $ 62,071 $ 77,614
Less: sales returns (760) (1,540)
Product [Member]    
Net sales 55,840 73,048
Administrative Fees, Freight and Other [Member]    
Net sales $ 6,991 $ 6,106
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.4
Note 12 - Segment Information - Long-lived Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Total long-lived assets $ 539 $ 735
UNITED STATES    
Total long-lived assets 227 379
UNITED KINGDOM    
Total long-lived assets 146 135
CHINA    
Total long-lived assets 47 57
Other Foreign Countries [Member]    
Total long-lived assets $ 119 $ 164
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Note 13 - Subsequent Event (Details Textual) - $ / shares
3 Months Ended 12 Months Ended
Feb. 08, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Common Stock, Dividends, Per Share, Declared (in dollars per share)   $ 0.20 $ 0.20 $ 0.20 $ 0.20 $ 0.80 $ 0.64
Subsequent Event [Member]              
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 0.20            
EXCEL 69 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M-8?20$3;8T.P6BP^0"X99K>]9!:G<+T]58 MOGCD"#(9G([QA$NAC>U:=.?GR/@"V'A;:JVZ%;4%?G>.F[:GO7%G&]/M27 @_HNZH#/QSD%995+2J\>L4^\YK+ M$EC7N<8#3 G ]&B ;#CE'F1&0&81(6<.POW ,+5D7S>@/R5 VPX;TR MY@.;@F8^)FF8 RNFP\P1,XC>7D3),<6#4=YBEBWB,;^)).*+JKD";/]C-MQ:7CCXD M997DP%K91NQQ%PWKSBU3KG%E.]=<&NX+.J&\DD01BS/+3;.IU7< ]ADD+(5E M4XQ"/B9EEB2&6A+GEAFLNF1A?X:04IY)8W@F<:*9M0L#WUK'>?,2!L644DQZ M8,7,Q$H*;,M=ME66JG73>L6FN/XI11"'4C*5B:&8/F$'Z\:44DP:0S%]P@XQ M*>6D,933)^P0DY)/&D,^OX7-AG.. .:#ST=9)XUAG?^:>R\EI9TTAG;ZW,B& M/B:EG32*=GKB>8A):2>-HIV>M"N8.ADEGBR&>+S$BPVOP7)1&S:'-]OZF)1] MLA@)3F]8SWQ,RC[94>V3^YCD5MI1[1/T)F6?+(9]>C&#WJ3LD\6P3Z\D@]ZD M))3%D) OR6"B![N\E(6R&!;R,']]P7_=6&3V,2D+93$L%&!^<7'>F1(C_;V/ M25DHBV&A]RN/W5_O[YI3%LIC6.@=YLEN \O'I"R4Q[!0'V;@])RR4![#0GLP M'Z%4LA0^)F6A/(:%]F#>*@V8;/J8Y".=8VR[8?$:EJ!U,#8I"^4Q+-2W>@_' M)F6A_)@;<.S$QZ0LE!\S%PJ/-V?Z05EH2*&A7I[TY_I!66A(H:% M>C']F5Z0KQ;$L% O9N%C4A8J8EAH[W9[MS;V,2D+%9V%1KOWG"H,%1*J![R$ MP?J2U^54,_>Q??*:%^Y!R+*MZRNL^RKO%:]VKTWM7OGZ]!-02P,$% @ M"H1:4O,@BWGI 0 $B( !H !X;"]?Z)0A&.14&#YE36 MV/+U7WVRQIZ_I%U;MMTA;[9]GASWNT->-)M2^H<0\G*3]FV^Z?IT.%]9=<.^ M+>?EL Y]NWQOURGH=#H+P\\9S>/\Y\S)ZZE/?YG8K5;;97KJEA_[="B_# Z? MW?">-RF59O+:#NM4%DTX[JZG<[@BN!WHIZ M*X'>.GK9)M!;46\ET%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0 M;R/0VU!O(]#;4&\CT-M&FR4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H; MZFT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^VBSFT!O1[V=0&]'O9U ;T>]G4!O M1[V=0&]'O9U [XAZ1P*](^H="?2.J'$?6. M!'I'U#O^I]ZYG'8I7WN^U_C\_Z2ZG.]-U\=?EM\G1^Q<< [P"\CC%U!+ P04 M " *A%I2LFA)V-4! "_(0 $P %M#;VYT96YT7U1Y<&5S72YX;6S- MVEU/@S 4!N"_LG!K1M>O^1'GC7JK7O@'*IP-,J!-V\WY[RU,331*7&;B>P.! MMN<]M,ESQ>7CBZ,PV;5-%Q99%:.[8"P4%;4FY-91ET:6UK_8LX4:[,B M)F:S.2ML%ZF+T]C7R*XN;VAI-DV[7-8%E;;8M&E)'IPG4X:**+9-OB]Z,IXNI!.S-/A<>]'TJ^>NE2(?*S'/_$C,94^^ONH/^V2RE]FI^U]MGX] MG$=@P^WX/?Y\QA_U#^Q#@/0A0?I0('UHD#[F('V<@O1Q!M+'.4@??(;2"(JH M'(54CF(J1T&5HZC*45CE**YR%%@YBJP"15:!(JM D56@R"I09!4HL@H4606* MK )%5H$BJT215:+(*E%DE2BR2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5 MBJP*15:%(JM"D56AR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU?\IZY.U MZ[_^I:"_YZVIN_=\-ORW&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( J$6E(2 M0E" L@4 #87 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ M"H1:4L[>]WVK @ &0D !@ ("!=A0 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ "H1:4EF"M6VX!0 ?1P M !@ ("!_1X 'AL+W=OLD !X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4NQ";.LH#P AB8 !@ ("! M[BX 'AL+W=O&UL4$L! A0#% @ "H1:4G(H\$NF P #P@ !D M ("!\D0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ "H1:4B$1 W*P! (0H !D ("!WU 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H1: M4A6">6(T!0 &PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4BP1;DY_!0 @T M !D ("!>FL 'AL+W=O&PO=V]R:W-H965TB0(N MFP\ )@O 9 " @8AS !X;"]W;W)K&UL4$L! A0#% @ "H1:4M5&PO=V]R:W-H965T M&UL4$L! A0# M% @ "H1:4F+962/O @ C 8 !D ("!YXT 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4@:E MIFR\! $@P !D ("!5IH 'AL+W=O^1PU4% #G$P &0 M @(%)GP >&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4J&PO M=V]R:W-H965T&UL4$L! A0#% @ "H1:4K\2)KD'!@ .!D !D ("! M.K 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ "H1:4@Y-YGZK @ .P< !D ("!5[\ 'AL+W=O&UL4$L! A0#% @ "H1:4N6]1D]T M @ %@8 !D ("!Q,< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4K>Z3686 P =PD !D M ("!BM$ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ "H1:4KLTP2]. P >PP !D ("!W=X M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M"H1:4K(,&IAP!0 -Q8 !D ("!.>D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4NBXGJ7M P M0P\ !D ("!(O0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "H1:4JS\_RZ@ @ ^@< !D M ("!LO\ 'AL+W=O&PO=V]R:W-H M965T7!E&UL4$L%!@ !! $$ OA$ ,,1 0 $! end XML 70 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 71 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 72 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 161 357 1 true 69 0 false 10 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets- Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations- Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss Consolidated Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity- Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals Consolidated Statements of Stockholders' Equity (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Consolidated Statements of Cash Flows Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows- Consolidated Statements of Cash Flows Statements 8 false false R9.htm 008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies- Note 1 - Nature of Operations and Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 2 - Revenue Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue Note 2 - Revenue Notes 10 false false R11.htm 010 - Disclosure - Note 3 - Net Income (Loss) Per Common Share Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share- Note 3 - Net Income (Loss) Per Common Share Notes 11 false false R12.htm 011 - Disclosure - Note 4 - Balance Sheet Components Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components Note 4 - Balance Sheet Components Notes 12 false false R13.htm 012 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements Note 5 - Fair Value Measurements Notes 13 false false R14.htm 013 - Disclosure - Note 6 - Leases Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases Note 6 - Leases Notes 14 false false R15.htm 014 - Disclosure - Note 7 - Income Taxes Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes Note 7 - Income Taxes Notes 15 false false R16.htm 015 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 16 false false R17.htm 016 - Disclosure - Note 9 - Stockholders' Equity Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity Note 9 - Stockholders' Equity Notes 17 false false R18.htm 017 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Notes 18 false false R19.htm 018 - Disclosure - Note 11 - Employee Benefit Plans Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans- Note 11 - Employee Benefit Plans Notes 19 false false R20.htm 019 - Disclosure - Note 12 - Segment Information Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information Note 12 - Segment Information Notes 20 false false R21.htm 020 - Disclosure - Note 13 - Subsequent Event Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event Note 13 - Subsequent Event Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies- 22 false false R23.htm 022 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables Note 3 - Net Income (Loss) Per Common Share (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share- 23 false false R24.htm 023 - Disclosure - Note 4 - Balance Sheet Components (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables Note 4 - Balance Sheet Components (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components 24 false false R25.htm 024 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements 25 false false R26.htm 025 - Disclosure - Note 6 - Leases (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables Note 6 - Leases (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases 26 false false R27.htm 026 - Disclosure - Note 7 - Income Taxes (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables Note 7 - Income Taxes (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes 27 false false R28.htm 027 - Disclosure - Note 9 - Stockholders' Equity (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables Note 9 - Stockholders' Equity (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity 28 false false R29.htm 028 - Disclosure - Note 12 - Segment Information (Tables) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables Note 12 - Segment Information (Tables) Tables http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information 29 false false R30.htm 029 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual) Details 30 false false R31.htm 030 - Disclosure - Note 2 - Revenue (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual Note 2 - Revenue (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue 31 false false R32.htm 031 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual Note 3 - Net Income (Loss) Per Common Share (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables 32 false false R33.htm 032 - Disclosure - Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables 33 false false R34.htm 033 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual Note 4 - Balance Sheet Components (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables 34 false false R35.htm 034 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details) Details 35 false false R36.htm 035 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details Note 5 - Fair Value Measurements - Investments (Details) Details 36 false false R37.htm 036 - Disclosure - Note 6 - Leases (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual Note 6 - Leases (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables 37 false false R38.htm 037 - Disclosure - Note 6 - Leases - Lease Cost (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details Note 6 - Leases - Lease Cost (Details) Details 38 false false R39.htm 038 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details Note 6 - Leases - Maturity of Lease Liabilities (Details) Details 39 false false R40.htm 039 - Disclosure - Note 7 - Income Taxes (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual Note 7 - Income Taxes (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables 40 false false R41.htm 040 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details) Details 41 false false R42.htm 041 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details) Details 42 false false R43.htm 042 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details) Details 43 false false R44.htm 043 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details Note 7 - Income Taxes - Foreign Rate Differentials (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details Note 7 - Income Taxes - Deferred Income Taxes (Details) Details 45 false false R46.htm 045 - Disclosure - Note 9 - Stockholders' Equity (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual Note 9 - Stockholders' Equity (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables 46 false false R47.htm 046 - Disclosure - Note 9 - Stockholders' Equity - Dividend Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details Note 9 - Stockholders' Equity - Dividend Activity (Details) Details 47 false false R48.htm 047 - Disclosure - Note 9 - Stockholders' Equity - Restricted Stock Activity (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details Note 9 - Stockholders' Equity - Restricted Stock Activity (Details) Details 48 false false R49.htm 048 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details) Details 49 false false R50.htm 049 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions 50 false false R51.htm 050 - Disclosure - Note 11 - Employee Benefit Plans (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual Note 11 - Employee Benefit Plans (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans- 51 false false R52.htm 051 - Disclosure - Note 12 - Segment Information (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual Note 12 - Segment Information (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables 52 false false R53.htm 052 - Disclosure - Note 12 - Segment Information - Operating Information by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details Note 12 - Segment Information - Operating Information by Geographic Area (Details) Details 53 false false R54.htm 053 - Disclosure - Note 12 - Segment Information - Net Sales by Geographic Area (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details Note 12 - Segment Information - Net Sales by Geographic Area (Details) Details 54 false false R55.htm 054 - Disclosure - Note 12 - Segment Information - Net Sales by Product and Service (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details Note 12 - Segment Information - Net Sales by Product and Service (Details) Details 55 false false R56.htm 055 - Disclosure - Note 12 - Segment Information - Long-lived Assets (Details) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details Note 12 - Segment Information - Long-lived Assets (Details) Details 56 false false R57.htm 056 - Disclosure - Note 13 - Subsequent Event (Details Textual) Sheet http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual Note 13 - Subsequent Event (Details Textual) Details http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event 57 false false All Reports Book All Reports nhtc20201231_10k.htm ex_207026.htm ex_207027.htm ex_207028.htm ex_207029.htm nhtc-20201231.xsd nhtc-20201231_cal.xml nhtc-20201231_def.xml nhtc-20201231_lab.xml nhtc-20201231_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 75 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20201231_10k.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 161, "dts": { "calculationLink": { "local": [ "nhtc-20201231_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "nhtc20201231_10k.htm" ] }, "labelLink": { "local": [ "nhtc-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "nhtc-20201231.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 468, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 38, "http://www.naturalhealthtrendscorp.com/20201231": 6, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 50 }, "keyCustom": 33, "keyStandard": 324, "memberCustom": 23, "memberStandard": 42, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 2 - Revenue", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "shortName": "Note 2 - Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 3 - Net Income (Loss) Per Common Share", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "shortName": "Note 3 - Net Income (Loss) Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 4 - Balance Sheet Components", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "shortName": "Note 4 - Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 5 - Fair Value Measurements", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "shortName": "Note 5 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 6 - Leases", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "shortName": "Note 6 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 7 - Income Taxes", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "shortName": "Note 7 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 8 - Commitments and Contingencies", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "shortName": "Note 8 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 9 - Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "shortName": "Note 9 - Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 10 - Related Party Transactions", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "shortName": "Note 10 - Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 11 - Employee Benefit Plans", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "shortName": "Note 11 - Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 12 - Segment Information", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "shortName": "Note 12 - Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 13 - Subsequent Event", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "shortName": "Note 13 - Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "shortName": "Note 3 - Net Income (Loss) Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 4 - Balance Sheet Components (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "shortName": "Note 4 - Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 5 - Fair Value Measurements (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "shortName": "Note 5 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 6 - Leases (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "shortName": "Note 6 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 7 - Income Taxes (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "shortName": "Note 7 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 9 - Stockholders' Equity (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables", "shortName": "Note 9 - Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendsPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 12 - Segment Information (Tables)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "shortName": "Note 12 - Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossUnrealized", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 2 - Revenue (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual", "shortName": "Note 2 - Revenue (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "2", "first": true, "lang": null, "name": "nhtc:RevenueFromContractWithCustomersSalesReturnsPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 3 - Net Income (Loss) Per Common Share (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "shortName": "Note 3 - Net Income (Loss) Per Common Share (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "shortName": "Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 4 - Balance Sheet Components (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "shortName": "Note 4 - Balance Sheet Components (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31_StatementGeographicalAxis-CN", "decimals": "-5", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "shortName": "Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 5 - Fair Value Measurements - Investments (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details", "shortName": "Note 5 - Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 6 - Leases (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual", "shortName": "Note 6 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 6 - Leases - Lease Cost (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details", "shortName": "Note 6 - Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 6 - Leases - Maturity of Lease Liabilities (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "shortName": "Note 6 - Leases - Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 7 - Income Taxes (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual", "shortName": "Note 7 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "shortName": "Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "shortName": "Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "shortName": "Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 7 - Income Taxes - Foreign Rate Differentials (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "shortName": "Note 7 - Income Taxes - Foreign Rate Differentials (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nhtc:IncomeTaxForeignRateDifferentialTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_IncomeTaxAuthorityNameAxis-DepartmentForInternationalTaxCooperationMember", "decimals": "0", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Income Taxes - Deferred Income Taxes (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "shortName": "Note 7 - Income Taxes - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "shortName": "Note 9 - Stockholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:DividendsCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 9 - Stockholders' Equity - Dividend Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details", "shortName": "Note 9 - Stockholders' Equity - Dividend Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDividendsPayableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-01-01_2019-12-31_DividendsAxis-SpecialDividendsDeclaredOctober292019Member", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-EquityIncentivePlan2016Member", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 9 - Stockholders' Equity - Restricted Stock Activity (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details", "shortName": "Note 9 - Stockholders' Equity - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2018-12-31_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-EquityIncentivePlan2016Member", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "shortName": "Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-12-01_2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 10 - Related Party Transactions (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "shortName": "Note 10 - Related Party Transactions (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2019-05-17_2019-05-17_RelatedPartyTransactionAxis-BroadyTrustMember", "decimals": "INF", "lang": null, "name": "nhtc:StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 11 - Employee Benefit Plans (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual", "shortName": "Note 11 - Employee Benefit Plans (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R52": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 12 - Segment Information (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual", "shortName": "Note 12 - Segment Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 12 - Segment Information - Operating Information by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "shortName": "Note 12 - Segment Information - Operating Information by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_ConsolidationItemsAxis-OperatingSegmentsMember", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 12 - Segment Information - Net Sales by Geographic Area (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "shortName": "Note 12 - Segment Information - Net Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 12 - Segment Information - Net Sales by Product and Service (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "shortName": "Note 12 - Segment Information - Net Sales by Product and Service (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "lang": null, "name": "nhtc:ContractWithCustomerRefundLiabilitySalesReturns", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 12 - Segment Information - Long-lived Assets (Details)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "shortName": "Note 12 - Segment Information - Long-lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 13 - Subsequent Event (Details Textual)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "shortName": "Note 13 - Subsequent Event (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2021-02-08_2021-02-08_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "i_2018-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "shortName": "Consolidated Statements of Stockholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 1 - Nature of Operations and Summary of Significant Accounting Policies", "role": "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "shortName": "Note 1 - Nature of Operations and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nhtc20201231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "country_KP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF" } } }, "localname": "KP", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "country_PE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PERU" } } }, "localname": "PE", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_TW": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TAIWAN, PROVINCE OF CHINA" } } }, "localname": "TW", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "country_VN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "VIET NAM" } } }, "localname": "VN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "countryCodeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "nhtc_AberdeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Aberdeen.", "label": "Aberdeen [Member]" } } }, "localname": "AberdeenMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales returns.", "label": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for warehousing and inventory related expense.", "label": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from treasury stock acquired.", "label": "nhtc_AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired", "negatedLabel": "Common stock issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalTreasuryStockAcquired", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "nhtc_AdministrativeFeesFreightAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to administrative fees, freight and other.", "label": "Administrative Fees, Freight and Other [Member]" } } }, "localname": "AdministrativeFeesFreightAndOtherMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "nhtc_AgeRequirementFor401kContributions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents age requirement for 401 K contributions.", "label": "nhtc_AgeRequirementFor401kContributions", "terseLabel": "Age Requirement For 401K Contributions (Year)" } } }, "localname": "AgeRequirementFor401kContributions", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_AmountsHeldInDistributorEwalletsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the policy of amounts held in customer eWallets.", "label": "Amounts Held in Distributor EWallets [Policy Text Block]" } } }, "localname": "AmountsHeldInDistributorEwalletsPolicyTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "nhtc_AutoShipAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to auto ship advances.", "label": "Auto ship advances [Member]" } } }, "localname": "AutoShipAdvancesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_BHSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to BHS.", "label": "BHS [Member]" } } }, "localname": "BHSMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_BroadyTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Broady Trust.", "label": "Broady Trust [Member]" } } }, "localname": "BroadyTrustMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_CapitalizedContractCostsLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount liability recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Amounts held in eWallets" } } }, "localname": "CapitalizedContractCostsLiabilityCurrent", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents period to receive cash proceeds from credit card processors for cash and cash equivalents.", "label": "nhtc_CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors", "terseLabel": "Cash and Cash Equivalents, Period to Receive Cash Proceeds From Credit Card Processors (Day)" } } }, "localname": "CashAndCashEquivalentsPeriodToReceiveCashProceedsFromCreditCardProcessors", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_CommonStockPercentageOfBeneficialStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of beneficial stock outstanding.", "label": "nhtc_CommonStockPercentageOfBeneficialStockOutstanding", "terseLabel": "Common Stock, Percentage of Beneficial Stock Outstanding" } } }, "localname": "CommonStockPercentageOfBeneficialStockOutstanding", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_ContractWithCustomerRefundLiabilitySalesReturns": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents sales returns for refund liability for contract with customer.", "label": "nhtc_ContractWithCustomerRefundLiabilitySalesReturns", "negatedLabel": "Less: sales returns" } } }, "localname": "ContractWithCustomerRefundLiabilitySalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of deferred income tax expense (benefit), excluding effects of foreign exchange.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefitExcludingEffectsOfForeignExchange", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents operating lease liabilities for deferred tax assets.", "label": "nhtc_DeferredTaxAssetsOperatingLeaseLiabilities", "verboseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "nhtc_DepartmentForInternationalTaxCooperationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Department for International Tax Cooperation.", "label": "Department for International Tax Cooperation [Member]" } } }, "localname": "DepartmentForInternationalTaxCooperationMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "nhtc_DividendsDeclaredJanuary272019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents dividends declared January 27, 2019.", "label": "Dividends Declared January 27, 2019 [Member]" } } }, "localname": "DividendsDeclaredJanuary272019Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the net operating loss carryforward.", "label": "Net operating loss carryback" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActGlobalIntangibleLowtaxIncomeGiltiAmount": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Tax Cuts and Jobs Act for Global Intangible Low-tax Income for effective income tax rate reconciliation.", "label": "Global Intangible Low-Taxed Income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActGlobalIntangibleLowtaxIncomeGiltiAmount", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_EquityIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2016 Equity Incentive Plan.", "label": "Equity Incentive Plan 2016 [Member]" } } }, "localname": "EquityIncentivePlan2016Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_IncomeTaxForeignRateDifferentialTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income tax foreign rate differential.", "label": "Income Tax Foreign Rate Differential [Table Text Block]" } } }, "localname": "IncomeTaxForeignRateDifferentialTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_IncomeTaxReconciliationEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effect of permanent differences.", "label": "Effect of permanent differences" } } }, "localname": "IncomeTaxReconciliationEffectOfPermanentDifferences", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInAccruedSalesCommissions": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued sales commissions.", "label": "nhtc_IncreaseDecreaseInAccruedSalesCommissions", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedSalesCommissions", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in capitalized contract cost liability.", "label": "nhtc_IncreaseDecreaseInCapitalizedContractCostLiability", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCapitalizedContractCostLiability", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating lease liabilities.", "label": "nhtc_IncreaseDecreaseInOperatingLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of lessee's noncash lease expense during the period.", "label": "Noncash lease expense" } } }, "localname": "LesseeNoncashLeaseExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "nhtc_LesseeNumberOfBranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the lessees' number of branches.", "label": "nhtc_LesseeNumberOfBranches", "terseLabel": "Lessee, Number of Branches" } } }, "localname": "LesseeNumberOfBranches", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_MetuchenNewJerseyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Metuchen, New Jersey.", "label": "Metuchen, New Jersey [Member]" } } }, "localname": "MetuchenNewJerseyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days for termination notice.", "label": "nhtc_NumberOfDaysTerminationNotice", "terseLabel": "Number of Days Termination Notice (Day)" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_NumberOfProductOrders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of product orders.", "label": "nhtc_NumberOfProductOrders", "terseLabel": "Number of Product Orders" } } }, "localname": "NumberOfProductOrders", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "integerItemType" }, "nhtc_OfficeEquipment": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents other equipment.", "label": "Office equipment" } } }, "localname": "OfficeEquipment", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "nhtc_OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents office equipment, office software and capitalized internal-use software development.", "label": "Office Equipment, Office Software and Capitalized Internal-use Software Development [Member]" } } }, "localname": "OfficeEquipmentOfficeSoftwareAndCapitalizedInternaluseSoftwareDevelopmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_OpenMarketPurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the open market purchases.", "label": "Open Market Purchases [Member]" } } }, "localname": "OpenMarketPurchasesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_OtherForeignCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to other foreign countries.", "label": "Other Foreign Countries [Member]" } } }, "localname": "OtherForeignCountriesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_PrimaryReportingSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the primary reporting segment.", "label": "Primary Reporting Segment [Member]" } } }, "localname": "PrimaryReportingSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the additional extension period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement", "terseLabel": "Related Party Transaction, Additional Extension Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAdditionalExtensionPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the automatic renewal period of the agreement in related party transaction.", "label": "nhtc_RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "terseLabel": "Related Party Transaction, Automatic Renewal Period of Agreement (Year)" } } }, "localname": "RelatedPartyTransactionAutomaticRenewalPeriodOfAgreement", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RestrictedCashCollateralRequirementPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents collateral requirement percentage of restricted cash.", "label": "nhtc_RestrictedCashCollateralRequirementPercentage", "terseLabel": "Restricted Cash, Collateral Requirement Percentage" } } }, "localname": "RestrictedCashCollateralRequirementPercentage", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the sales returns policy term.", "label": "nhtc_RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "terseLabel": "Revenue from Contract with Customer, Sales Returns Policy Term (Day)" } } }, "localname": "RevenueFromContractWithCustomerSalesReturnsPolicyTerm", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "durationItemType" }, "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of historical sales returns.", "label": "nhtc_RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Historical Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersHistoricalSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of sales returns.", "label": "nhtc_RevenueFromContractWithCustomersSalesReturnsPercent", "terseLabel": "Revenue from Contract with Customers, Sales Returns, Percent" } } }, "localname": "RevenueFromContractWithCustomersSalesReturnsPercent", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "percentItemType" }, "nhtc_RichmondBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Richmond, British Columbia.", "label": "Richmond, British Columbia [Member]" } } }, "localname": "RichmondBritishColumbiaMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RollingHillsEstatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Rolling Hills Estates.", "label": "Rolling Hills Estates [Member]" } } }, "localname": "RollingHillsEstatesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyAgreementAndLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Royalty Agreement and License.", "label": "Royalty Agreement and License [Member]" } } }, "localname": "RoyaltyAgreementAndLicenseMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_RussiaAndKazakhstanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Russia and Kazakhstan.", "label": "Russia and Kazakhstan [Member]" } } }, "localname": "RussiaAndKazakhstanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "nhtc_ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of additional balance sheet components.", "label": "Schedule of Additional Balance Sheet Components [Table Text Block]" } } }, "localname": "ScheduleOfAdditionalBalanceSheetComponentsTableTextBlock", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "nhtc_SharngHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Sharng Holdings.", "label": "Sharng Holdings [Member]" } } }, "localname": "SharngHoldingsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_ShipmentOfApparelProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to shipment of apparel products.", "label": "Shipment of Apparel Products [Member]" } } }, "localname": "ShipmentOfApparelProductsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_SpecialDividendsDeclaredJanuary272019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents special dividends declared January 27, 2019.", "label": "Special Dividends Declared January 27, 2019 [Member]" } } }, "localname": "SpecialDividendsDeclaredJanuary272019Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_SpecialDividendsDeclaredOctober292019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents special dividends declared October 29, 2019.", "label": "Special Dividends Declared October 29, 2019 [Member]" } } }, "localname": "SpecialDividendsDeclaredOctober292019Member", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the ratio of number of shares authorized to be repurchased in private transaction.", "label": "nhtc_StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "terseLabel": "Stock Repurchase Program, Ratio of Number of Shares Authorized to be Repurchased in Private Transaction" } } }, "localname": "StockRepurchaseProgramRatioOfNumberOfSharesAuthorizedToBeRepurchasedInPrivateTransaction", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "pureItemType" }, "nhtc_TreasuryStockSharesReissued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of treasury shares reissued.", "label": "Common stock issued (in shares)" } } }, "localname": "TreasuryStockSharesReissued", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "sharesItemType" }, "nhtc_TreasuryStockValueOfSharesReissued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the value of treasury shares reissued.", "label": "Common stock issued" } } }, "localname": "TreasuryStockValueOfSharesReissued", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "nhtc_UnrelatedThirdPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the unrelated third party.", "label": "Unrelated Third Party [Member]" } } }, "localname": "UnrelatedThirdPartyMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "nhtc_UnshippedProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to unshipped product.", "label": "Unshipped Product [Member]" } } }, "localname": "UnshippedProductMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "nhtc_statement-statement-note-12-segment-information-longlived-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Long-lived Assets (Details)" } } }, "localname": "statement-statement-note-12-segment-information-longlived-assets-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-12-segment-information-net-sales-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Net Sales by Geographic Area (Details)" } } }, "localname": "statement-statement-note-12-segment-information-net-sales-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-12-segment-information-net-sales-by-product-and-service-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Net Sales by Product and Service (Details)" } } }, "localname": "statement-statement-note-12-segment-information-net-sales-by-product-and-service-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-12-segment-information-operating-information-by-geographic-area-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information - Operating Information by Geographic Area (Details)" } } }, "localname": "statement-statement-note-12-segment-information-operating-information-by-geographic-area-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-12-segment-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Segment Information" } } }, "localname": "statement-statement-note-12-segment-information-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Net Income (Loss) Per Common Share - Basic and Diluted Net Income (Loss) Per Share (Details)" } } }, "localname": "statement-statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-3-net-income-loss-per-common-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Net Income (Loss) Per Common Share" } } }, "localname": "statement-statement-note-3-net-income-loss-per-common-share-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Summary of Balance Sheet Amounts (Details)" } } }, "localname": "statement-statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-4-balance-sheet-components-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components" } } }, "localname": "statement-statement-note-4-balance-sheet-components-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-fair-value-measurements-investments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements - Investments (Details)" } } }, "localname": "statement-statement-note-5-fair-value-measurements-investments-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-5-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Fair Value Measurements" } } }, "localname": "statement-statement-note-5-fair-value-measurements-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-lease-cost-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Lease Cost (Details)" } } }, "localname": "statement-statement-note-6-leases-lease-cost-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-maturity-of-lease-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases - Maturity of Lease Liabilities (Details)" } } }, "localname": "statement-statement-note-6-leases-maturity-of-lease-liabilities-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-6-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Leases" } } }, "localname": "statement-statement-note-6-leases-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Income (Loss) Before Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Components of Income Tax Provision (Benefit) (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-deferred-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Deferred Income Taxes (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-deferred-income-taxes-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-foreign-rate-differentials-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Foreign Rate Differentials (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-foreign-rate-differentials-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes - Reconciliation of Reported Income Tax Provision (Details)" } } }, "localname": "statement-statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-7-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Income Taxes" } } }, "localname": "statement-statement-note-7-income-taxes-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Changes in Accumulated Other Comprehensive Loss (Details)" } } }, "localname": "statement-statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-dividend-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Dividend Activity (Details)" } } }, "localname": "statement-statement-note-9-stockholders-equity-dividend-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-9-stockholders-equity-restricted-stock-activity-details", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-note-9-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Stockholders' Equity" } } }, "localname": "statement-statement-note-9-stockholders-equity-tables", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "nhtc_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.naturalhealthtrendscorp.com/20201231", "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r96" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r256", "r257", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r420", "r423" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r256", "r257", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r420", "r423" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r177", "r229", "r233", "r374", "r419", "r421" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r177", "r229", "r233", "r374", "r419", "r421" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r236", "r256", "r257", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r420", "r423" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r236", "r256", "r257", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r420", "r423" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r178", "r179", "r229", "r234", "r422", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r178", "r179", "r229", "r234", "r422", "r449", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r11", "r12", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related expense" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r392", "r407" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r20", "r392", "r407" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "us-gaap_AccruedIncomeTaxesNoncurrent", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other accrued expenses:" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r11", "r12", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r202" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r53", "r54", "r55", "r59", "r60" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r57", "r58", "r59", "r409", "r428", "r429" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r60", "r101", "r102", "r103", "r315", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r51", "r59", "r60", "r315", "r332", "r333", "r334", "r335", "r337" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r25", "r272" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r101", "r102", "r103", "r269", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).", "label": "Non-vested restricted stock" } } }, "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "us-gaap_AreaOfLand", "terseLabel": "Area of Land (Square Foot)" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r94", "r159", "r166", "r173", "r189", "r311", "r316", "r324", "r391", "r406" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r48", "r94", "r189", "r311", "r316", "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r186", "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Adjusted cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r185", "r187", "r191", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r260", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r100", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r463" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Office software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r31", "r432", "r433" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r31", "r85" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r86", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r15", "r86", "r92", "r390" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r80", "r85", "r91" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period", "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r80", "r329" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r31" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r92", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions, Policy [Policy Text Block]" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r211", "r396", "r413" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r208", "r209", "r210", "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Dividends per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Dividends declared, per share (in dollars per share)", "terseLabel": "Common Stock, Dividends, Per Share, Declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at December 31, 2020 and 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66", "r70", "r399", "r415" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r140", "r141", "r181", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r140", "r141", "r181", "r322", "r323", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r140", "r141", "r181", "r322", "r323", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r136", "r404" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r140", "r141", "r181", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r140", "r141", "r181", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r92", "r313" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred revenue:" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r218", "r219", "r230" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r237", "r252", "r430" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r74", "r374" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r95", "r292", "r299" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r98", "r292" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r292", "r299", "r301" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r95", "r292", "r299" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.", "label": "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "terseLabel": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r293", "r299" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r293", "r299" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "verboseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r275", "r276" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r95", "r293", "r299", "r300", "r301" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r283", "r393", "r405" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r275", "r276" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r293", "r299" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r284" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r286" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r286" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r290", "r291" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r290", "r291" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "verboseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r290", "r291" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r285" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance", "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r290", "r291" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "verboseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r290", "r291" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "us-gaap_DeferredTaxLiabilitiesOther", "verboseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses", "verboseLabel": "Prepaids" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r290" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings", "negatedLabel": "Foreign deferreds" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.", "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r83", "r200" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "us-gaap_DepreciationAndAmortization", "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r83", "r154" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r214", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "us-gaap_Dividends", "negatedLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r214", "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "us-gaap_DividendsCommonStock", "terseLabel": "Dividends, Common Stock, Total" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r71", "r106", "r107", "r108", "r109", "r110", "r114", "r117", "r123", "r124", "r125", "r129", "r130", "r400", "r416" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net income (loss) per common share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r71", "r106", "r107", "r108", "r109", "r110", "r117", "r123", "r124", "r125", "r129", "r130", "r400", "r416" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r92", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r126", "r127", "r128", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r329" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rates on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r278", "r303" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r101", "r102", "r103", "r105", "r111", "r113", "r133", "r190", "r213", "r214", "r269", "r270", "r271", "r295", "r296", "r331", "r332", "r333", "r334", "r335", "r337", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r252", "r318", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r237", "r239", "r244", "r252", "r318", "r364" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r237", "r239", "r244", "r252", "r318", "r365" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r252", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r92", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r84", "r327", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossUnrealized", "terseLabel": "Foreign Currency Transaction Gain (Loss), Unrealized" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r92", "r339" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r92", "r198" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r83", "r196", "r197", "r199" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill impairment", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r94", "r159", "r165", "r169", "r172", "r175", "r189", "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r97", "r302" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r68", "r159", "r165", "r169", "r172", "r175", "r387", "r397", "r402", "r417" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (loss) before income taxes", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r97", "r302" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r279", "r281", "r288", "r297", "r304", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r112", "r113", "r157", "r277", "r298", "r305", "r418" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r67", "r92", "r273", "r274", "r281", "r282", "r287", "r294", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Foreign rate differential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income tax at federal statutory rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "verboseLabel": "Goodwill impairment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.", "label": "Other reconciling items" } } }, "localname": "IncomeTaxReconciliationOtherReconcilingItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxContingenciesForeign": { "auth_ref": [ "r278" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in foreign income tax contingency.", "label": "Foreign tax credits" } } }, "localname": "IncomeTaxReconciliationTaxContingenciesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid (refunded) for income taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentAssets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r118", "r119", "r120", "r125" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_InlandRevenueHongKongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Hong Kong.", "label": "Inland Revenue, Hong Kong [Member]" } } }, "localname": "InlandRevenueHongKongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r151", "r164", "r165", "r166", "r167", "r169", "r171", "r175" ], "lang": { "en-us": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r43" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r45" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Inventory, Net, Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r46", "r92", "r132", "r192", "r193", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r44" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r45", "r99", "r194" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Reserve for obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r350", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r9", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r351" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r351" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r94", "r167", "r189", "r312", "r316", "r317", "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r94", "r189", "r324", "r394", "r411" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r94", "r189", "r312", "r316", "r317", "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r9", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r80" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r80", "r81", "r84" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r61", "r64", "r69", "r84", "r94", "r104", "r106", "r107", "r108", "r109", "r112", "r113", "r121", "r159", "r165", "r169", "r172", "r175", "r189", "r324", "r398", "r414" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r106", "r107", "r108", "r109", "r114", "r115", "r122", "r125", "r159", "r165", "r169", "r172", "r175" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net income (loss) available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r116", "r122", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net income (loss) available to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "stringItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r159", "r165", "r169", "r172", "r175" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "terseLabel": "Income (loss) from operations", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r344", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r341" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r341" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "us-gaap_OperatingLeaseLiabilityNoncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r342", "r346" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r340" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r349", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r348", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term (in years) (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r164", "r165", "r166", "r167", "r169", "r175" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r52", "r57", "r325", "r326", "r330" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r62", "r65", "r309", "r310", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r53", "r57" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r236", "r238", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r260", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, authorized (in shares)", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment:" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r203" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "us-gaap_PropertyPlantAndEquipmentGross", "totalLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r203", "r412" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Ending Balance" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r92", "r203", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r201" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r165", "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r246", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r356", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r246", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "terseLabel": "Related Party Transaction, Other Revenues from Transactions with Related Party" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r246", "r356", "r358", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r354", "r355", "r357", "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r15", "r85", "r91", "r390", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_RestrictedCashAndCashEquivalents", "terseLabel": "Restricted Cash and Cash Equivalents, Total" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r18", "r91", "r450" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r214", "r272", "r410", "r427", "r429" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r101", "r102", "r103", "r105", "r111", "r113", "r190", "r269", "r270", "r271", "r295", "r296", "r424", "r426" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r150", "r151", "r164", "r170", "r171", "r177", "r178", "r181", "r228", "r229", "r374" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r140", "r181" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r232", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r347", "r352" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "us-gaap_RoyaltyExpense", "terseLabel": "Royalty Expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r76" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r59", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r72", "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r159", "r162", "r168", "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r146", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r175", "r181", "r419" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146", "r148", "r149", "r159", "r163", "r169", "r173", "r174", "r175", "r176", "r177", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Nonvested at December 31, 2019 (in shares)", "periodStartLabel": "Nonvested at December 31, 2018 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Nonvested balance, wtd. avg. price (in dollars per share)", "periodStartLabel": "Nonvested balance, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, wtd. avg. price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r259", "r263" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "BALANCE (in shares)", "periodStartLabel": "BALANCE (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r345", "r352" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAdministrationOfTaxationChinaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of China.", "label": "State Administration of Taxation, China [Member]" } } }, "localname": "StateAdministrationOfTaxationChinaMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r146", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r175", "r181", "r198", "r205", "r206", "r207", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r101", "r102", "r103", "r105", "r111", "r113", "r133", "r190", "r213", "r214", "r269", "r270", "r271", "r295", "r296", "r331", "r332", "r333", "r334", "r335", "r337", "r424", "r425", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r101", "r102", "r103", "r133", "r374" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-comprehensive-income-loss", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-1-nature-of-operations-and-summary-of-significant-accounting-policies-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-11-employee-benefit-plans-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-longlived-assets-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-net-sales-by-product-and-service-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-operating-information-by-geographic-area-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-2-revenue-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-summary-of-balance-sheet-amounts-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-investments-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-lease-cost-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-maturity-of-lease-liabilities-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-loss-before-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-components-of-income-tax-provision-benefit-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-deferred-income-taxes-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-foreign-rate-differentials-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-reconciliation-of-reported-income-tax-provision-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-8-commitments-and-contingencies", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-dividend-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-restricted-stock-activity-details", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r88", "r89", "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of treasury stock for employee awards, net" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-cash-flows-" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r23", "r24", "r213", "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r94", "r184", "r189", "r324" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance, December 31, 2020", "periodStartLabel": "Balance, December 31, 2019", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-changes-in-accumulated-other-comprehensive-loss-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r93", "r214", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r338", "r362" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r338", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r338", "r362" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r361", "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-13-subsequent-event" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-12-segment-information-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-4-balance-sheet-components-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-5-fair-value-measurements-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-6-leases-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-7-income-taxes-tables", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r215" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r215" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r24", "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "us-gaap_TreasuryStockSharesAcquired", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Treasury Stock, Shares, Acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r215", "r216" ], "calculation": { "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, at cost; 1,556,875 shares at December 31, 2020 and 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-balance-sheets-" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r213", "r214", "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "us-gaap_TreasuryStockValueAcquiredCostMethod", "negatedLabel": "Repurchase of common stock", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-10-related-party-transactions-details-textual", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-9-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r134", "r135", "r137", "r138", "r142", "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r116", "r125" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r114", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/20201231/role/statement-consolidated-statements-of-operations-", "http://www.naturalhealthtrendscorp.com/20201231/role/statement-note-3-net-income-loss-per-common-share-basic-and-diluted-net-income-loss-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r363": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41256-110953" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41261-110953" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r464": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r466": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r467": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r468": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r469": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" } }, "version": "2.1" } ZIP 76 0001437749-21-004259-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-004259-xbrl.zip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end